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Abstract 
It has recently been observed that the application of multiple short cycles of reperfusion 
and ischaemia, at the onset of reperfusion, elicits cardioprotection against injury due to 
prior sustained ischaemia. This phenomenon has been termed “postconditioning” (postC) 
and is of special interest due to its clinical applicability. Although much work has been 
done to delineate the mechanism of protection, there is still controversy regarding the 
precise algorithm of postC, the importance of the reperfusion injury salvage kinases 
(RISK), as well as uncertainty about the possible role of p38 MAPK and the protein 
phosphatases in postC cardioprotection. 
 
The aims of this study were therefore: 
I. To develop and characterise a cardioprotective postC protocol in the ex vivo rat 
heart, using both the retrogradely perfused and working heart models. 
II. To characterise the profiles of PKB/Akt, ERK p42/p44 and p38 MAPK associated 
with the postC intervention. 
III. To investigate the possible role of the serine/threonine protein phosphatases type 1 
and type 2A (PP1 and PP2A) in the mechanism of postC. 
 
Hearts from male Wistar rats were perfused in both the retrograde Langendorff (at a 
perfusion pressure of 100 cmH2O and diastolic pressure set between 1 and 10 mmHg) and 
working heart models (preload: 15 cmH20 and afterload: 100 cmH20). Several different 
postC protocols were tested for their cardioprotective effect, as analysed by infarct size 
(IFS; determined by triphenyltetrazolium chloride (TTC) staining) and functional recovery. 
Experimental parameters tested were the number of cycles (3,4 or 6), the duration of the 
cycles (10, 15, 20 or 30 seconds), the method of application (regional or global) and 
temperature during the intervention (36.5 or 37 °C). Different sustained ischaemic insults 
were also utilised: 35 minutes regional (RI) or 20, 25, 30 and 35 minutes global ischaemia 
(GI). 
 
Hearts treated with a cardioprotective postC intervention or standard reperfusion after 
sustained ischaemia, were freeze-clamped at 10 and 30 minutes reperfusion in both 
perfusion models. Tissue samples were then analyzed using Western blotting, probing for 
total and phosphorylated PKB/Akt, ERK p42/p44 and p38 MAPK. The contribution of 
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PKB/Akt and ERK p42/p44 activation to cardioprotection was also investigated by 
administration of inhibitors (A6730 and PD098059 respectively) in the final 5 minutes of 
ischaemia and the first 10 minutes of reperfusion, in the presence and absence of the 
postC intervention. The effect of these inhibitors were analyzed in terms of IFS and kinase 
profiles. 
 
The possible role of the phosphatases in postC was investigated by observing the effect of 
cantharidin (a PP1 and PP2A inhibitor) treatment directly before sustained ischaemia 
(PreCanth) or in reperfusion (PostCanth), in the presence and absence of postC, on IFS 
and kinase profiles. 
 
A postC protocol of 6x10 seconds global reperfusion / ischaemia, at 37°C, was found to 
give the best and most consistent reduction in infarct size in both the Langendorff (IFS in 
NonPostC: 47.99±3.31% vs postC: 27.81±2.49%; p<0.0001) and working heart (IFS in 
NonPostC: 35.81±3.67% vs postC: 17.74±2.73%, p<0.001) models. It could however only 
improve functional recovery in the Langendorff model (after 30 minutes GI: rate pressure 
product (RPP) recovery: NonPostC = 12.27±2.63% vs postC = 24.61±2.53%, p<0.05; and 
after 35 minutes GI: left ventricular developed pressure (LVDP) recovery: NonPostC = 
28.40±7.02% vs postC = 48.49±3.14%, p<0.05). This protection was associated with 
increased PKB/Akt (NonPostC: 0.88±0.26 AU (arbitrary unit) vs postC: 1.65±0.06 AU; 
p<0.05) and ERK p42 (NonPostC: 2.03±0.2 AU vs postC: 3.13±0.19 AU; p<0.05) 
phosphorylation. Inhibition of PKB/Akt activation with A6730 (2.5 µM) abrogated the infarct 
sparing effect of postC.  
 
Administration of cantharidin, either before of after ischaemia, in the absence of postC, 
conferred an infarct sparing effect (IFS in PreCanth: 15.42±1.80%, PostCanth: 
21.60±2.79%; p<0.05) associated with an increase in the phosphorylation of MAPK p38 
(administration before ischaemia: NonCanth: 1.52±0.26 AU vs PreCanth: 2.49±0.17 AU, 
p<0.05; and administration after ischaemia: NonCanth: 5.64±1.17 AU vs PostCanth: 
10.69±1.29 AU, p<0.05) and ERK p42 (when administered in reperfusion; NonCanth: 
2.24±0.21 AU vs PostCanth: 3.34±0.37 AU; p<0.05). Cantharidin treatment combined with 
the postC intervention did not elicit an additive infarct sparing effect (postC: 17.74±2.72%, 
PreCanth-postC: 13.30±3.46% and PostCanth-postC: 15.39±2.67%). 
 
 - 4 -
In conclusion: a postC protocol of 6x10 seconds global ischaemia / reperfusion, at 37°C, 
confers the best infarct sparing effect in both the Langendorff and working rat heart 
models. This protection is associated with ERK p42 and PKB/Akt phosphorylation, 
although only PKB/Akt is necessary for cardioprotection. We could not find evidence for 
PP1 and PP2A involvement in postC, although inhibition of these phosphatases per se 
does elicit an infarct sparing effect. The latter observation suggests that phosphatase 
activation during ischaemia / reperfusion is potentially harmful. 
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Opsomming 
Dit is onlangs waargeneem dat toediening van meervoudige siklusse herperfusie / 
iskemie, met die aanvang van herperfusie, die hart teen iskemie / herperfusie beskadiging 
beskerm. Hierdie verskynsel, bekend as postkondisionering (postC), geniet tans baie 
aandag vanweë die kliniese toepaslikheid van die ingreep. Ten spyte van intensiewe 
navorsing om die betrokke meganisme van beskerming vas te stel, is daar steeds 
kontroversie oor die presiese algoritme van die ingreep, asook die betrokkenheid van die 
sogenaamde iskemie herperfusie oorlewings kinases (RISK). Daar bestaan ook 
onsekerheid oor die rol van die stres-kinase, p38 MAPK, asook die proteïen fosfatases in 
die meganisme van beskerming teen iskemiese besering. 
 
Hierdie studie het dus drie doelstellings gehad: 
I. Ontwikkeling van ‘n postC protokol wat beskerming ontlok in die rothart ex vivo, 
deur gebruik te maak van beide die retrograad geperfuseerde ballon model, asook 
die werkhart model. 
II. Analiese van die profiele van die kinases PKB/Akt, ERK p42/p44 en p38 MAPK 
tydens herperfusie van postC en kontrole (NonPostC) harte. 
III. Ondersoek na die moontlike rol van die serien / treonien proteïen fosfatases tipe 1 
en tipe 2A (PP1 en PP2A) in die meganisme van postC beskerming. 
 
Harte van manlike Wistar rotte is geperfuseer in beide die retrograad geperfuseerde ballon 
(d.i. die Langendorff) model (teen ‘n konstante perfusie druk van 100 cmH20 en ‘n 
diastoliese druk gestel tussen 1 en 10 mmHg), asook die werkhart model (teen ‘n 
voorbelading van 15 cmH20 en ‘n nabelading van 100 cmH20). Verskeie moontlike postC 
protokolle is getoets vir hul vermoë om kardiobeskerming te ontlok, in terme van 
funksionele herstel en infarktgrootte (IFS), soos bepaal deur trifenieltetrazolium chloried 
(TTC) kleuring. Die eksperimentele veranderlikes tydens die postC protokol wat ondersoek 
is, sluit in: die aantal siklusse (3, 4 of 6), die duur van die siklusse (10, 15, 20 of 30 
sekondes), die wyse van postC toediening (streeks of globaal) en laastens die 
temperatuur tydens die ingreep (36.5 of 37 °C). Daar is ook gebruik gemaak van 
verskillende periodes iskemie: 35 minute streeks iskemie (RI), asook 20, 25, 30 en 35 
minute globale iskemie (GI). 
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Na 10 of 30 minute herperfusie is harte wat blootgestel is aan ‘n kardiobeskermende 
postC ingreep of gewone standaard herperfusie na iskemie, in beide perfusie modelle, 
gevriesklamp. Die weefsel proteïen-inhoud is verder geanaliseer deur van die Western blot 
tegniek gebruik te maak vir bepaling van die totale en fosforileerde vlakke van PKB/Akt, 
ERK p42/p44 en p38 MAPK. Die funksionele belang van PKB/Akt en ERK p42/p44 is 
verder ondersoek deur die effek van ‘n geskikte inhibitor (onderskeidelik A6730 en 
PD098059, toegedien tydens die laaste 5 minute van iskemie en die eerste 10 minute van 
herperfusie), in die teenwoordigheid en afwesigheid van die postC ingreep, op 
infarktgrootte en kinase aktiwiteit te monitor. 
 
Die moontlike rol van proteïen fosfatases in postC is ondersoek deur die effek van 
cantharidin (‘n PP1 en PP2A inhibitor) op infarktgrootte en kinase profiele te ondersoek. 
Cantharidin is óf onmiddelik voor iskemie óf tydens herperfusie toegedien, in die aan – en 
afwesigheid van die postC ingreep.  
 
Daar is bevind dat ‘n postC protokol van 6x10 sekondes globale iskemie / herperfusie, 
teen 37°C, die mees effektiewe en konstante verlaging in infarktgrootte teweeg gebring het 
in beide die ballon model (IFS in NonPostC: 47.99±3.31% vs postC: 27.81±2.49%; 
p<0.0001), asook die werkhart (IFS in NonPostC: 35.81±3.67% vs postC: 17.74±2.73%, 
p<0.001). Funksionele herstel kon egter slegs ontlok word in die ballon model (na 30 
minute GI: tempo druk produk (RPP) herstel: NonPostC = 12.27±2.63% vs postC = 
24.61±2.53%, p<0.05; en na 35 minute GI: linker ventrikulêre ontwikkelde druk (LVDP) 
herstel: NonPostC = 28.40±7.02% vs postC = 48.49±3.14%, p<0.05). Die infarkt-
besparende effek van postC was geassosieer met ‘n toename in die fosforilasie van beide 
PKB/Akt (NonPostC: 0.88±0.26 AU (arbitrêre eenhede) vs postC: 1.65±0.06 AU; p<0.05) 
en ERK p42 (NonPostC: 2.03±0.2 AU vs postC: 3.13±0.19 AU; p<0.05). Inhibisie van 
PKB/Akt met A6730 (2.5 µM) het die infarkt-besparende effek van postC opgehef.  
 
Inhibisie van PP1 en PP2A opsigself, deur toediening van cantharidin óf voor óf na 
iskemie (in die afwesigheid van postC), het ‘n infarkt-besparende effek ontlok (IFS in 
PreCanth: 15.42±1.80%, PostCanth: 21.60±2.79%; p<0.05). Hierdie kardiobeskerming 
was geassosieer met ‘n toename in die fosforilasie van beide p38 MAPK (met toediening 
voor iskemie: NonCanth: 1.52±0.26 AU vs PreCanth: 2.49±0.17 AU, p<0.05; en toediening 
na iskemie: NonCanth: 5.64±1.17 AU vs PostCanth: 10.69±1.29 AU, p<0.05), asook ERK 
p42, indien cantharidin toegedien is tydens herperfusie (NonCanth: 2.24±0.21 AU vs 
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PostCanth: 3.34±0.37 AU; p<0.05). Kombinasie van cantharidin behandeling met postC 
toediening kon egter nie ‘n kumulatiewe infarkt-besparende effek uitlok nie (postC: 
17.74±2.72%, PreCanth-postC: 13.30±3.46% en PostCanth-postC: 15.39±2.67%).  
 
In samevatting: ‘n PostC protokol van 6x10 sekondes globale iskemie / herperfusie, teen 
37°C, ontlok die mees effektiewe infarkt-besparende effek in beide die ballon, sowel as die 
werkhart modelle. Alhoewel hierdie beskerming geassosieer is met ‘n toename in die 
fosforilasie van beide PKB/Akt en ERK p42/p44 tydens herperfusie, is dit slegs PKB/Akt 
wat van funksionele belang is in die meganisme van kardiobeskerming. Ons kon geen 
bewyse vind vir die betrokkenheid van PP1 en PP2A in postC beskerming nie, alhoewel 
inhibisie van hierdie fosfatases opsigself infarkt-besparend is. Laasgenoemde waarneming 
toon dat fosfatase aktivering tydens iskemie / herperfusie skadelike gevolge mag hê. 
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cantharidin administration during reperfusion, on the kinase profiles. 
Table 16 : Percentage reduction in infarct size associated with postC and  
NonpostC, in the presence and absence of cantharidin. 
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Inducible NOS      : iNOS 
 - 19 -
Infarct size      : IFS 
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Ischaemia / reperfusion injury   : IRI 
Ischaemic preconditioning    : IPC 
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Lactate dehydrogenase    : LDH 
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Malondialdehyde      : MDA 
MAPK / ERK kinase     : MEK 
MAPK kinase 1     : MAPKK1 
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Mitochondrial permeability transition pore  : mPTP 
Mitogen Activated Protein Kinase p38  : p38 MAPK  
Mitogen Activated Protein Kinase   : MAPK 
Myocardial infarct     : MI 
Myocardial infarction     : MI 
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Nitrcic oxide synthase     : NOS 
Nitric oxide      : NO 
Nitric oxide      : NO 
Okadaic acid      : OA     
Phospatidylinositol 3-kinase    : PI3-kinase 
Phospholamban     : PLB   
Polyvinylidene fluoride    : PVDF 
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Protein kinase C     : PKC 
Protein phospatase type 1     : PP1     
Protein phosphatase type 2A    : PP2A     
Protien kinase B     : PKB/Akt 
Reactive nitrogen species    : RNS 
Reactive oxygen species    : ROS 
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Sarcoplasmic reticulum Ca2+ ATPase  : SERCA      
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Sodium dodecyl sulfate – polyacrylamide gel  : SDS-PAGE 
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Troponin I       : TnI 
Tumour necrosis factor – alpha   : TNF – α 
Voltage – dependent anion channel   : VDAC 
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Chapter 1: Literature overview 
“I praise you because I am fearfully and 
wonderfully made; 
your works are wonderful, 
I know that full well.” 
 
Psalm 139:14 
The Bible 
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Chapter 1: Literature overview 
1.1. Ischaemia and reperfusion: an introduction 
1.1.1. Ischaemic heart disease 
One of the leading causes of death, in especially the developed world, is ischaemic heart 
disease. According to the projections of Murray & Lopez (1997), heart disease is set to 
remain a major contributor to mortality in years to come. This was confirmed by  follow-up 
projections done by Mathers & Loncar, published in 2006. Ischaemic heart disease is 
usually not found in isolation, but is often a single facet of the so-called metabolic 
syndrome (Bonora et al., 2003; Caglayan et al., 2005). The metabolic syndrome is also in 
itself a growing cause of morbidity and mortality in the developed world (Smith, 2007), as 
well as in South Africa (Seedat, 1998; StatsSa, 2005). 
 
Various conditions, especially abdominal obesity and atherosclerosis, are associated with 
the development of coronary heart disease (CHD) and cardiovascular disease (CVD) 
(AACE/ACE, 1998; Kim et al. 2000; Eckel & Krauss, 2007). The basic series of events 
leading to a cardiac ischaemic event originates in the vasculature, and usually involves 
atherogenesis. This is the formation of plaques consisting of calcium crystals, smooth 
muscle cells, macrophages, fatty streaks and inflammatory mediators (Ross, 1999; Guyton 
& Hall, 2000). For reviews on the development and nature of atherosclerosis see Ross 
(1999), Opie (2004) and Scott (2004). In brief: Such a lesion can either be stable or 
unstable. In the case of an unstable plaque, shear stress can lead to the disruption of the 
plaque, leading to the expulsion of pro-thrombotic factors into the blood. Pieces of the 
plaque structure can also enter the circulation. The net effect is the presence of solid 
particles, or thrombi, in the bloodstream that will eventually lodge in a smaller artery, 
capillary or vein. Even if the latter does not happen, the plaque itself can grow in size to 
such an extent that it decreases the vascular lumen diameter. If an occlusion of 
atherosclerotic origin occurs in the coronary arteries, the myocardium “downstream”  of the 
occlusion is left without  sufficient  oxygen supply to meet metabolic demand, leading to 
compromised myocardial viability and function. 
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Oxygen deprivation will lead to several metabolic changes in the cardiomyocytes. 
Primarily, adenosine triphosphate (ATP) levels decrease, leading to a switch from aerobic 
to anaerobic metabolism, and the accumulation of intracellular protons – with a 
corresponding decrease in intracellular pH. The decrease in blood supply also leads to a 
reduction in the rate of removal of metabolic products – leading to the accumulation of 
potentially toxic substances. If the hypoxic condition prevails, ATP levels will become 
insufficient for the maintenance of ion-pump activity, causing a disturbance of normal ion 
homeostasis (Opie, 2004). The combination of these detrimental intracellular changes, 
eventually leads to cell death. It should be mentioned that it has been shown that 
apoptosis also contributes to cell death in myocardial ischaemia. The precise contribution 
of necrosis versus apoptosis to cell death in ischaemia is still controversial. Apoptosis in 
ischaemia and reperfusion will be discussed in more detail later in the text.  
 
It therefore stands to reason that the best treatment for such a state of ischaemia is to re-
establish perfusion of the affected tissue as soon as possible, i.e. transport of nutrients 
and oxygen to the affected tissue and of metabolites away from it. Reperfusion is a clinical 
reality in the setting of thrombolysis, coronary angioplasty, coronary bypass grafting and 
transplantation. The efficacy of reperfusion depends on the duration of ischaemia and the 
degree of tissue injury. In general, the shorter the time of ischaemia, the more tissue can 
be salvaged by reperfusion (Jennings & Reimer, 1983). 
1.1.2. Lethal reperfusion injury 
Unfortunately, reperfusion also has a sinister side, since it can itself induce further injury, 
i.e. reperfusion injury. This refers to reperfusion-associated events that cause the death of 
cells, only reversibly injured at the end of ischaemia (Piper & García-Dorado, 1999; Park & 
Lucchesi, 1999; Yellon & Hausenloy, 2007). This concept is paradoxical, since reperfusion 
is the only way to salvage reversibly damaged tissue. Without reperfusion all the 
ischaemic tissue will eventually be lost. However, ischaemia and reperfusion injury do go 
hand in hand, and in the literature they are often singularly referred to as ischaemia / 
reperfusion injury (IRI).  
 
Some of these possible mechanisms are, briefly, as follows: 
¾ Calcium overload. This is probably one of the most well known causes of tissue 
damage in the setting of ischaemia / reperfusion. In this regard calcium has been 
implicated with the phenomenon of stunning (Kusuoka et al., 1987). This refers to the 
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transient decrease in contractile activity in the first hours of reperfusion (Braunwald & 
Kloner, 1982; Gross et al., 1999). For a review on the alterations in calcium 
homeostasis during reperfusion, see Gross et al. (1999). Obviously various calcium 
transporters have been implicated: In the sarcolemma the L-type calcium channel has 
been implicated in an increase in calcium influx into the cell (Przyklenk et al., 1989). In 
the SR both the Ca2+-ATPase (responsible for calcium uptake) and ryanodine 
receptors (involved in calcium release) could contribute to disturbances in Ca2+ ion 
homeostasis (Smart et al., 1997; Valdivia et al., 1997; Gross et al., 1999). Another 
possibility is that the ischaemia-induced reduction in ATP levels leads to a decrease in 
Na+-K+ -ATPase activity, causing an increase in intracellular sodium. This in turn 
reverses the action of the Na+ / Ca2+ exchanger, causing sodium export in exchange 
for calcium import – eventually leading to excess intracellular calcium levels. In this 
respect, Inserte et al. (2002) found that the administration of a Na+ / Ca2+ exchange 
inhibitor (KB-R7943) during reperfusion or re-energization leads to a decrease in 
intracellular Ca2+ levels, associated with a reduction in hypercontracture and infarct 
size. Calcium overload in itself can also lead to mitochondrial damage (Crompton & 
Costi, 1988).  
 
¾ Free radical generation. A free radical can be defined as an atom, or molecule, with 
an unpaired electron in its outer orbital (Park & Lucchesi, 1999). These chemical 
species are therefore highly reactive, as reflected in a very short half-life, which means 
they can be very harmful in biological systems. Various studies have shown that free 
radicals are generated at the very onset of myocardial reperfusion. These free radicals 
include the reactive oxygen species (ROS), namely superoxide anions, hydrogen 
peroxide and hydroxyl radicals, as well as the reactive nitrogen specie (RNS) 
peroxynitrite (which is formed when nitric oxide (NO) reacts with superoxide) (Zweier & 
Hassan Talukder, 2006). 
 
For a review on the possible sources of free radicals and their effects in the ischaemia-
reperfused myocardium, see Zweier & Hassan Talukder (2006). Free radicals could 
damage the cell by peroxidation of membrane lipids, damaging and denaturating 
proteins (including ion channels and enzymes) and also damaging DNA. Free radicals 
could therefore significantly contribute to cell damage and death via swelling, as well 
as calcium overload due to damaged ion pumps. It is therefore not surprising that ROS 
have been implicated in the phenomenon of stunning (Bolli et al., 1989). Reactive 
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oxygen species could also contribute to mitochondrial dysfunction by contributing to 
the opening of the mitochondrial permeability transition pore (mPTP), which then leads 
to a dysregulation of the mitochondrial membrane potential, compromising ATP 
production in the mitochondria (for a review on the role of the mPTP in reperfusion, see 
Halestrap et al., 2004). In this regard Akao et al. (2003) found that oxidative stress in 
ventricular myocytes was associated with changes in mitochondrial structure, 
eventually leading to the opening of the mPTP, which in turn initiated cell death. Free 
radical generation could also be important in the human heart, as illustrated by Ferrari 
et al. (1990). They found that there is an increase in oxidative stress in human 
myocardium at reperfusion, which, in turn, is dependent on the duration of ischaemia. 
 
It should however be mentioned that the importance of free radical generation in 
reperfusion injury is not universally accepted, especially in the light of the failure of 
administered free radical scavengers to prevent reperfusion-associated injury in some 
studies (Richard et al., 1988; Piper & Garciá-Dorado, 1999; Park & Luchessi, 1999).  
 
¾ Inflammatory processes. Since ischaemia and reperfusion causes tissue damage, it 
is not surprising that inflammatory processes are also involved in ischaemia / 
reperfusion. These inflammatory processes can be detrimental through various 
mechanisms. Neutrophils are recruited to the area of damage in the myocardium – as 
would be the case in any damaged tissue. Dreyer et al. (1999) for example found that, 
in canine hearts, there was an increase in neutrophile accumulation during reperfusion, 
especially in the subendocardium. In the heart neutrophils potentially contribute to 
damage by generating free radicals and / or various cytotoxic agents. Various studies 
have also shown that inhibition or depletion of neutrophils lead to a decrease in tissue 
injury associated with ischaemia / reperfusion (Romson et al., 1983; Kin et al., 2006). 
The increase in neutrophils in the coronary system can also lead to the formation of 
“plugs” in the coronary capillaries. These plugs then contribute to the phenomenon of 
no-reflow (Engler et al., 1983). This is a form of reperfusion injury in which the opening 
of  a blocked coronary artery does not lead to the perfusion of the tissue distal to the 
initial blockage (Rezkalla & Kloner, 2002). For an extensive review on the possible role 
of neutrophils in ischaemia-reperfusion injury, see Jordan et al. (1999). 
 
The complement system has also been implicated in ischaemia / reperfusion (for a 
short review see Park & Luchessi, 1999). The complement system is a complicated 
 - 26 -
extracellular system of up to thirty proteins, that can interact via a classical (beginning 
with protein C1) -, or a alternative pathway (initiated with protein C3). After activation 
various proteins bind to each other in a sequential manner, in the process contributing 
to chemotaxis, opsonization and eventually severe cell damage and death via the 
formation of the C5b-9 membrane attack complex (MAC) (Guyton & Hall, 2000). In 
fact, Hill & Ward (1971) already found C3-cleavage fragments in myocardial tissue 
due to coronary ligation in 1970. They also implicated these fragments in the 
chemotaxis of neutrophils to the injured area. More recently, Yasojima et al. (1998) 
found that components of the classical complement pathway are expressed in injured 
heart tissue and could contribute to myocardial injury after the initiation of reperfusion. 
Buerke et al. (2006) did a proteomic study of complement in the setting of ischaemia-
reperfusion, in the presence of a specific C1s inhibitor. They found that inhibition of 
C1s was associated with a decrease in both tissue damage, as well as C5b-9 
deposition in myocardial tissue. It therefore seems that the complement system is 
activated during ischaemia (as evident by an increase in the presence of MAC 
complexes on myocardial tissue), and its activity is increased by reperfusion (Mathey 
et al., 1994; Parks & Lucchesi, 1999).  
 
¾ Sudden wash-out of metabolites. Anaerobic metabolism, occuring during ischaemia, 
leads to the accumulation of both carbon dioxide (CO2) and hydrogen ions (H+), with an 
associated reduction in pH (Opie, 2004). On reperfusion, the H+ concentration in the 
interstitial space could normalize, before normalization of intracellular pH. The resulting 
H+ concentration gradient drives a speedy decrease in intracellular H+ concentration, 
which could be detrimental for two reasons: 1.) Slight, transient acidosis could be 
protective against Ca2+-dependent contracture (Eisner et al., 1989). During reperfusion, 
this protective factor is however quickly removed. 2.) The transport of H+ out of the cell 
occurs, amongst others, via a Na+ / H+ exchanger. This causes an increase in 
intracellular Na+, which in turn drives the Na+ / Ca2+ exchanger in a direction that leads 
to Ca2+ overload. In this context, Inserte et al. (1997) found that reoxygenation-oedema 
was decreased in the presence of a  Na+ / H+ exchange inhibitor (HOE642), as well as 
when bicarbonate (HCO3-)-dependent Na+ transport  into the cell was prevented. Wang 
et al. (2007) also found that combined treatment with a Na+ / H+ exchange inhibitor 
(cariporide) and a β-blocker, prior to ischaemia, improved mitochondrial function and 
decreased infarct size in reperfusion. They speculate that the protection of 
 - 27 -
mitochondrial function is attributable to stabilisation of the mPTP, which then prevents 
calcium overload of the mitochondria. 
 
Other osmotic active metabolites also accumulate during ischaemia. Just as in the case 
of the H+ ions, interstitial metabolites could be washed out of the extracellular space 
before the accumulated intracellular metabolites. This leads to the generation of an 
osmotic gradient, driving an influx of fluid into the cells (Tranum-Jensen et al., 1981). 
This influx then contributes to cell stress, and combined with other reperfusion 
stressors, could lead to the disruption of the cell membrane. In this regard Ruiz-Meana 
et al. (1995) found that hypercontracture, together with osmotic cellular swelling, in 
mechanically fragile myocardiocytes (due to metabolic inhibition), lead to sarcolemmal 
disruption. Askenasy et al. (2001) however found that the osmotic-gradient across the 
membrane decreases after ischaemia / reperfusion. They speculate that this could be 
due to the free movement of osmolytes out of the cells, since they also showed that 
membrane permeability increases with the duration of ischaemia. This increase of 
sarcolemmal permeability due to ischaemia, or ischaemia with reperfusion, was also 
observed by Koba et al. (1995). 
 
1.1.3. Necrosis and apoptosis in ischaemia / reperfusion 
Both necrosis, as well as apoptosis, have been implicated in ischaemia / reperfusion 
injury. Initially it was thought that necrosis was the only form of cell death due to ischaemia 
/ reperfusion. Freude  et al. (2000) reported that after 90 minutes global ischaemia, up to 
92% of cell death was due to necrosis. Necrosis refers to cell-death due to loss of ATP, 
which then leads to loss of cell membrane integrity and spillage of the cellular content 
(including lactate dehydrogenase (LDH), which can be measured to assess necrotic death) 
into the interstitial space.   
 
It has however been reported that a degree of cell death in the injured myocardium can be 
attributed to apoptosis. In contrast to the above, Anversa et al. (1998) observed that up to 
86% of cell death in a large infarct, following coronary occlusion, could be attributed to 
apoptosis. Apoptosis is an energy dependent, and ordered phenomenon in which a cell 
dies without comprimising membrane integrity. Instead the cell is ‘divided’ into small 
membrane vesicles, after enzymatic digestion of its chromosomal DNA into 
internucleosomal fragments. Apoptosis can be identified by microscopic identification of 
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the apoptotic bodies, the identification of DNA fragments that form a ‘DNA ladder’ in an 
agarose gel, or quantification of the presence of proteases typical of the apoptotic process, 
such as caspase-3 (Edinger & Thompson, 2004; Eefting et al., 2004).  
 
The relative contribution of necrosis and apoptosis to cell death in ischaemia / reperfusion 
is however still very much a matter of debate.  
 
The precise timing of apoptosis in the injury-process is also controversial. In one study 
(Fliss & Gattinger, 1996) it was found that apoptosis was initiated and executed during 
ischaemia, while Gottlieb et al. (1994) reported that apoptotic death only occurs during 
reperfusion. Others (Freude et al., 2000) proposed that apoptosis could be initiated during 
ischaemia, but only executed during reperfusion. This is indeed a possibility, since 
apoptosis is an ATP-dependent process. Otani et al. (2006) found that mechanical stress 
early in reperfusion could also influence the mode of death. Specifically, an increase in 
mechanical stress favours oncosis (necrosis due to oedema), even if the cells initially 
seem to be heading for apoptosis.  
 
Differences in the distribution of apoptosis have also been reported in whole tissue. 
Scarabelli et al. (2001) found that apoptosis in reperfusion (as measured by DNA damage, 
using the TUNEL method) initially occurs in the endothelial cells of small bloodvessels, 
followed by the endothelium of larger coronary vessels after 5-60 minutes of reperfusion. 
This process then expands concentrically from these vessels to neighbouring 
cardiomyocytes.  
 
For  a brief review on apoptosis, necrosis and programmed necrosis see Edinger & 
Thompson (2004). For a review on apoptosis, specifically in reperfusion, see Eefting et al. 
(2004). 
1.1.4. Summary 
In summary, suffice it to say that: ischaemia in heart tissue leads to progressive cellular 
damage and death, especially necrotic death. Early reperfusion is necessary to limit cell 
death and salvage reversibly damaged tissue. The process of reperfusion itself however, 
also damages cells through necrosis and apoptosis. It is therefore of clinical importance to 
find methods of reperfusion that can limit reperfusion injury, and in that way limit the 
overall extent of damage due to an ischaemia / reperfusion-incident. 
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1.2. Clinical reality 
In the clinical setting, there are primarily four situations in which ischaemia / reperfusion 
injury (IRI) is a complicating factor: 
¾ Myocardial infarction (MI). 
¾ Coronary artery bypass grafting (CABG). 
¾ Cardiac surgery, necessitating cardiopulmonary bypass. 
¾ Heart transplant. 
 
In this text MI will be used as an example to briefly describe the clinical setting and 
treatment of IRI.  
1.2.1. Currently accepted treatment of myocardial infarction 
When a patient presents with a myocardial infarction, treatment simply entails the rapid 
revasculerization of the affected tissue. Currently, the emphasis is on keeping the time of 
ischaemia as short as possible, by instituting rapid reperfusion (Cannon, 2001). In 1983 
Jennings et al. already demonstrated that the period of ischaemia is the most important 
factor determining the measure of myocardial damage.  
 
There are two ways to reperfuse ischaemic tissue: 
1. Thrombolytic treatment. The use of thrombolytic drugs to lyse the obstructing blood 
clot in the coronary circulation ushered in the era of reperfusion. 
2. Percutaneous coronary intervention (PCI). PCI refers to coronary angioplasty, i.e. 
the use of an inflatable balloon or a stent, delivered by a catheter to the blocked 
coronary artery. Since this intervention requires a hospital with a catherization 
laboratory, the application thereof is limited. 
For a brief review on the guidelines for the application of these two methods see Ting 
(2006). 
 
Together with these reperfusion interventions, it is also standard practice to administer 
certain drugs, especially to help maintain reperfusion: 
¾ Glycoprotein IIb/IIIa receptor blockers, such as eptifibatide and abciximab. These 
drugs are only used in the setting of PCI, since they increase the risk of bleeding 
when used alongside thrombolysis therapy (Ting, 2006).  
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¾ Aspirin (Amin, 2005). Ting (2006) reports that apirin must be used, if possible, 
together with thrombolytic therapy. The antiplatelet function of aspirin is necessary 
to counter platelet activation due to thrombolytic treatment.  
¾ Heparin (Amin, 2005). 
¾ Beta-blockers (ß-blockers): Advantageous effects associated with ß-blocker 
treatment could possibly be attributed to its anti-arrythmic and anti-tachyarrythmic 
effects, as well as a decrease  in oxygen demand (by decreasing heart rate and 
contractility) (Amin, 2005; Kloner & Rezkalla, 2004). 
1.3. Natural infarct-sparing mechanisms  
In the laboratory two major natural phenomena have been described that can significantly 
lessen infarct-related injury. They can be described as “natural” in that both were initially 
described without the use of any drugs. These phenomena are: 
¾ Ischaemic preconditioning (IPC) 
¾ Postconditioning (postC). 
1.3.1. Ischaemic Preconditioning: an overview 
In 1986, Murry and colleagues made the surprising discovery that multiple brief episodes 
of ischaemia applied before a sustained ischaemic insult, did not contribute to ischaemic 
injury, but rather induced an increased tolerance against ischaemia. They termed this 
phenomenon ischaemic preconditioning (IPC) and the observation catapulted ischaemia / 
reperfusion research in a new direction. Experimentally, the stimulus for cardioprotection is 
elicited by one or more brief ischaemic episodes, which is then followed by a brief period 
of reperfusion before the sustained ischaemic insult (against which it protects). This period 
between stimulus and actual protection implies the presence of myocardial ‘memory’, one 
of the most unique attributes of IPC (Yellon & Downey, 2003; Bolli, 2007).  
 
Initial research focussed on elucidating the optimal protocol to elicit IPC protection. Some 
researchers found that a single brief ischaemic episode elicited the same degree of 
protection as multiple cycles (Li et al., 1990; Iliodromitis et al., 1997) – implying that there 
is a threshold ischaemic stimulus required for protection (Crisostomo et al., 2006). Once 
this threshold is reached, protection is then elicited in an all-or-nothing manner. The 
degree of protection is then set, whereafter a further ischaemic stimulus could itself even 
become detrimental (Iliodromitis et al., 1997). The opposite has however also been 
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reported: that IPC protection is graded, and an increase in the ischaemic stimulus (such as 
number of cycles) augment cardioprotection (Volovsek et al., 1992; Lawson et al., 1993; 
Schulz et al., 1998). This protection will however also reach a plateau. These variable 
observations might reflect differences in species and experimental setup. It should be 
noted that IPC has been shown in all species tested, even man (Yellon et al., 1993). Its 
cardioprotective efficacy has been illustrated in the context of infarct size reduction (Murry 
et al., 1986), functional recovery improvement (Cave & Hearse, 1992) and in some cases, 
reduction in reperfusion arrythmias (Shiki & Hearse, 1987). 
 
In an attempt to understand the mechanisms behind IPC cardioprotection, its mechanism 
has been conceptualised as a “trigger” – “mediator” – “end-effector” pathway, in which the 
trigger occurs during the IPC stimulus before sustained ischaemia, while the mediators 
and end-effectors come into play after the onset of sustained ischaemia (Yellon & Downey, 
2003). Various possible molecular role-players have been implicated in this framework, 
although it is not always clear where these molecules exert their effect. It is outside the 
scope of this text to elaborate on the precise role of the different molecules, let it therefore 
suffice to say that the most prominent role-players that have been identified are:  
¾ Adenosine, which probably acts as a ligand trigger for IPC (Liu et al., 1991; 
Crisostomo, et al. 2006). 
¾ Protein kinase C, as well as protein kinase A, both of which probably act as 
mediators during sustained ischaemia (Yang, et al. 1997; Yellon & Downey, 2003). 
¾ Free radicals and reactive oxygen species (Tritto, et al. 1997). 
¾ The mitochondrial ATP-dependent potassium channel (mK+ATP – channel), although 
its precise role is still to be determined (Pain et al., 2000; Yellon & Downey, 2003). 
¾ Signalling kinases, such as the mitogen activated protein kinases (MAPKs) and 
protein kinase B (PKB/Akt) (Hausenloy & Yellon, 2006) . 
¾ The mitochondrial permeability transition pore has increasingly been implicated 
(Halestrap et al., 2007; Hausenloy & Yellon, 2007). 
 
It is especially the latter two role-players that have complicated the framework of the IPC 
mechanism, since they exert some of their effects in reperfusion. Both the MAPK, 
extracellular signal-regulated kinase p42/p44 (ERK p42/p44) (Fryer et al., 2001), and 
phospatidylinositol 3-kinase (PI3-kinase) – PKB/Akt (Tong et al., 2000; Uchiyama et al., 
2004) have been implicated as important triggers during the IPC protocol itself (prior to 
sustained ischaemia), but recently activation of these kinases in reperfusion has also been 
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shown to be important in IPC cardioproptection (Hausenloy et al., 2005). Hausenloy et al. 
(2004) also demonstrated “cross-talk” between these two survival kinase pathways (PI3-
kinase – PKB/Akt and Raf – MEK1/2 (MAPK/ERK kinase) – ERK p42/p44). They found 
that inhibition of the one pathway led to an increase in the activation of the other, 
suggesting that they could compensate for each other. However, activation of both 
pathways is necessary to elicit optimal IPC protection.  
 
The mitochondrial permeability transition pore (mPTP) also seems to play a role both 
before and after sustained ischaemia. Hausenloy et al. (2004) found that transient, low-
conductance opening of the pore during the IPC protocol is necessary to mediate 
cardioprotection (although this conclusion has been challenged by Halestrap et al., 2007). 
On the other side of ischaemia, Javadov and coworkers (2003) showed that IPC inhibits 
the opening of the mPTP during reperfusion, through indirect mechanisms (i.e. possibly by 
changing the intracellular milieu so that it does not favour mPTP opening, for example by 
decreasing calcium load and / or reactive oxygen species production). 
 
It is also important to note that IPC can induce an acute protected state (lasting for 1-2 
hours), as well as a “second window” of protection approximately 24 hours after the initial 
IPC stimulus and lasting for 2 to 3 days (Kuzuya et al., 1993; Yellon & Downey, 2003; 
Bolli, 2007). This late phase of protection probably utilises the same signal transduction 
components as the early phase, but with different end-effectors. The early phase of 
protection recruits posttranslational changes in cellular molecules, while the late phase 
utilises synthesis of new proteins to exert its effect. Two such proteins that have received a 
lot of attention is NOS (nitric oxide synthase) and COX (cyclooxygenase) – 2, although 
other proteins such as heat shock and anti-oxidant proteins are probably also involved 
(Yellon & Downey, 2003; Bolli, 2007). 
 
As mentioned earlier, even human myocardium has been preconditioned – which opens 
the door for the possibility of applying IPC in the clinical setting. Small scale studies have 
already been done in the settings of: 
¾ Percutaneous coronary intervention (PTCI); although it could be argued that this 
study, by Deutsch and colleagues (1990), did not really investigate IPC in a true 
clinical situation. 
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¾ Coronary artery bypass grafting (CABG). In the studies done by Yellon et al. (1993) 
and Teoh et al. (2002) two cycles of 3 minutes ischaemia and 2 minutes 
reperfusion were applied after the institution of cardiopulmonary bypass. 
¾ Studies also showed that IPC can be used as a safe and advantageous adjunct to 
cold blood cardioplegia (Illes & Swoyer, 1998; Li et al., 1999). 
 
The successful translation of IPC to the clinical setting has however not met expectations. 
It seems this could be due to the risks of applying repetitive ischaemia – specifically the 
risk of particulate emboli being dislodged by the process (Vaage  et al., 2000). It could also 
be that IPC is already induced in patients – either due to the inherent inflammatory 
response in sick patients, or possibly the cardiopulmonary bypass process in itself (in the 
setting of cardiac surgery), which might induce preconditioning (Valen & Vaage, 2005), or 
angina prior to a cardiovascular incident (Kloner et al., 1995). There are also questions 
about the ability of IPC to confer cardioprotection in patients who have other pathologies, 
such as diabetes (Ishihara et al., 2001), or in aged patients (Wu et al., 2001; Pasupathy & 
Homer-Vanniasinkam, 2005). 
 
Despite these clinical limitations, there is still a large amount of research being done on 
IPC. The primary goal is to elucidate the mechanism of protection and identify possible 
pharmacological interventions that could be used safely and easily as adjunct to current 
ischaemia / reperfusion therapies. Some of the pharmacological agents that have shown 
potential are: 
¾ ß-adrenergic stimulation. Schwarz et al (1999) reports that although ß-adrenergic 
stimulation shows experimental promise, it could also lead to a increase in oxygen 
demand – which could have adverse effects in ischaemia / reperfusion injury (IRI). 
¾ Adenosine. Clinical evidence that adenosine limits cell death, is conflicting (Kloner 
& Rezkalla, 2004).  
¾ Adenosine triphosphate-sensitive potassium channel (KATP-channel) openers. 
Although these drugs show good potential, Schwarz et al. (1999) report that their 
side-effects could also be problematic.  
¾ Nitroglycerin (a nitric oxide (NO) donor) has shown benefit in the setting of delayed 
preconditioning (Leesar et al., 2001). 
¾ Volatile anesthetics. Research has shown cardioprotective effects for these 
anesthetics (for a review see Kloner & Rezkalla, 2006). A possible explanation is 
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that these drugs generate small amounts of free radicals, which in turn act to 
trigger IPC. 
 
Another major drawback of IPC is the fact that it must be applied before ischaemia, which 
is impossible in the setting of MI. A truly clinical relevant cardioprotective intervention 
would be one that is applicable at the onset of reperfusion. 
1.3.2. Postconditioning: an introduction 
In 2003, Zhao and coworkers demonstrated the cardioprotective effects of very brief cycles 
of reperfusion and ischaemia at the very onset of reperfusion, after sustained ischaemia, in 
the canine heart. This intervention became known as postconditioning (Crisostomo et al. 
2006, Tsang et al. 2005, Vinten-Johansen et al. 2005). In fact, it has been reported that 
postconditioning is just as effective in reducing infarct size as IPC. (Zhao et al., 2003). 
 
As is the case with IPC, the application of repetitive episodes of ischaemia and reperfusion 
seems risky in the ischaemic heart disease patient. The focus of research is therefore on 
deciphering the mechanisms behind postC, with the goal of identifying possible 
pharmacological mimetics of postC. 
 
The concept of applying an intervention during reperfusion, in an attempt to minimise 
myocardial injury is not a new one. The existence of reperfusion interventions that can 
minimise damage is also argued to be proof of the existence of reperfusion injury. 
Examples of reperfusion interventions are: pressure-controlled initial reperfusion 
(Selimoglu et al., 2007), initial hypoxic reperfusion (Serviddio et al., 2005), altering the 
content of the reperfusate and initial low flow reperfusion (Hori et al. 1991; Sato et al., 
1997; and Schlensak et al., 1999). A large amount of research has also been done on 
postconditioning. For a review on the possible clinical implications of postC, see Kloner & 
Rezkalla (2006). Some of the drugs that have shown potential as postC mimetics, are as 
follows: 
¾ Adenosine. Involvement of adenosine has been suggested by the finding that 
adenosine receptor antagonists can inhibit the protective effects of postC (Kin et 
al., 2005). Jin and coworkers (2007) also demonstrated the effective utilisation of 
adenosine administration in reperfusion, as an adjunct to cold-blood cardioplegia. 
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¾ KATP-channel openers. It has been reported that blocking the KATP-channel 
abolishes postC cardioprotection (Yang et al.; 2004), implying a role for these 
channels in the mechanism of postC.  
¾ Volatile anesthetics, such as isoflurane, have also been implicated as postC-
mimetics (Chiari et al., 2005). 
 
Although various mechanisms have been implicated in postC (to be discussed later in this 
text), it seems that pharmacological reperfusion-based treatment is still lacking. 
1.4. Postconditioning 
As already mentioned, a large body of research points to the possibility of actually 
intervening in ischaemia / reperfusion injury at the very onset of reperfusion. Reperfusion 
is also clinically the most realistic window of treatment opportunity. Despite evidence for 
the possible advantages of reperfusion-intervention, the very existence of reperfusion 
injury, and hence the value of reperfusion-intervention, has for a long time been 
controversial (Schaper & Schaper, 1997; Tsang et al. 2005).  
 
Nevertheless, Zhao and colleagues (2003), inspired by the potent cardioprotective effects 
of ischaemic preconditioning and motivated by the clinical relevance of a reperfusion-
intervention, combined the two concepts. Using an open-chest canine model of coronary 
occlusion and reperfusion, they showed that three cycles of 30 seconds reperfusion and 
30 seconds ischaemia, at the onset of reperfusion, could confer cardioprotection 
comparable to the protection associated with ischaemic preconditioning. This intervention 
became known as postconditioning. Postconditioning can therefore be defined as the 
application of multiple brief cycles of reperfusion / ischaemia at the very onset of 
reperfusion, after sustained ischaemia (Zhao & Vinten-Johansen, 2006). Since the first 
report of the possibility of conditioning a heart after the ischaemic period, many research 
efforts – spanning from basic laboratory science to clinical research – have been directed 
at this phenomenon.   
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1.4.1. Postconditioning in the laboratory 
1.4.1.1. The postconditioning algorithm 
When considering the precise algorithm that should be employed to elicit postconditioning-
mediated cardioprotection, there are three variables that have been reported to be of 
importance. 
1. The time lapse between the onset of reperfusion and the initiation of the 
postconditioning cycles. Several workers reported a loss of cardioprotection when 
administration of the postC intervention was delayed by one minute (Kin et al. 
(2004) using a rat model and Downey & Cohen (2005) in a rabbit model). In 
contrast, Bopassa et al. (2006) employed a protocol in which they allowed one 
minute reflow before initiating postconditioning. Despite this delay their postC 
protocol elicited functional recovery. Yang et al. (2004) even found that postC only 
lost its protective effect when delayed for as much as 10 minutes in the rabbit 
heart. In general most studies apply the postconditioning protocol at the very onset 
of reperfusion, without any significant delay.  
2. The number of cycles applied.  
3. The duration of each cycle. 
 
The latter two factors seem to be species-related. Vinten-Johansen et al. (2005) reported 
in their review that, in general, the smaller the species the shorter the periods of 
reperfusion and ischaemia should be. It also appears that the efficacy of the protocol is 
dependent on the duration of the cycles, but less sensitive to the number of cycles 
(although this was not observed in all experimental setups). The precise optimal 
algorithm for postC is still a subject of investigation, but it seems to be species-
dependent. Some of these species-dependent variations and findings concerning postC 
will be discussed in the following section. 
 
1.4.1.2. Postconditioning: success, limitations and experimental 
variations 
The canine heart 
Postconditioning was first described in the in vivo canine heart, with an infarct sparing 
effect comparable to IPC (Zhao et al., 2003). In this model a postC protocol, of 3 cycles of 
30 seconds (3 x 30 sec) reperfusion and ischaemia, was also associated with a decrease 
in neutrophil accumulation in the area at risk (AAR), preserved coronary endothelial 
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function and a reduction in reactive oxygen species generation and oxidative damage. 
Although the precise interaction between these observations (cause vs effect) is still 
unknown, this early study clearly demonstrated the advantageous effects of postC. These 
positive results were confirmed by a follow-up study (Halkos et al., 2004) which 
investigated the possibility that postC and IPC, if administered together, could have 
additive cardioprotective effects in the same in vivo canine model. Just as in the first study, 
they found that the cardioprotective effects of postC is associated with a decrease in 
superoxide anion generation and free radical-mediated damage (as indicated by 
malondialdehyde (MDA) levels, a marker of lipid peroxidation). The degree of protection 
elicited by postC was, however not potentiated by co-administration of a IPC protocol. The 
cardioprotective potential of postC was further tested by Couvreur and colleagues (2006), 
who investigated the ability of postC to protect against stunning (after only 10 minutes 
regional ischaemia) in conscious dogs. Various protocols (4 x 15, 30 or 60 second 
reperfusion / ischaemia) could however not protect against stunning. Mykytenko et al. 
(2007), following the same postC protocol as Zhao et al. (2003) and Halkos et al. (2004), 
found that postC cardioprotection in the canine heart (as measured by IFS and plasma 
creatine kinase (CK) levels) persisted after 24 hours of reperfusion (compared to control 
hearts, in which they observed continual injury development as reperfusion continued). 
Fujita et al. (2007), also using the in vivo canine heart model, followed a completely 
different protocol to investigate the association between transient acidosis and postC in 
reperfusion: They applied a 90 minute period of regional ischaemia (contrary to the 60 
minutes used by others), followed by a postC protocol of 4 x 60 seconds reperfusion / 
ischaemia. Despite these differences they could also illustrate a postC-mediated decrease 
in infarct size. In view of all these studies, it seems that the canine heart can readily be 
protected against infarct development by applying a postC protocol. 
 
The rabbit heart 
The next species to be postconditioned was the rabbit. The positive outcomes found in the 
initial canine-study of Zhao et al. (2003) could also be replicated in the in vivo rabbit heart. 
Yang et al. (2004) reported a 43% decrease in infarct size, comparable to the infarct 
sparing effects of IPC, with a postC protocol of either 4 or 6 cycles of 30 seconds 
reperfusion / ischaemia. Interestingly, they  demonstrated an additive effect when both IPC 
and postC was applied – in contrast to the findings of Halkos et al. (2004) in the canine 
heart. The same group went on to demonstrate postconditioning in the isolated rabbit heart 
(Yang et al., 2005). This illustrated that, at least a measure of the observed protection was 
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due to intrinsic mechanisms of the heart – independent of blood borne factors. Interesting 
to note, they found that a postC protocol of 6 x 10 seconds reperfusion / ischaemia 
protected the isolated heart model much better than 4 x 30 seconds reperfusion / 
ischaemia – which was sufficient in the in vivo model. Another group also managed to 
postcondition the isolated rabbit heart model (Darling  et al., 2005), applying a 4 x 30 
seconds postC protocol. In their model postC had an infarct sparing effect, although it 
could not elicit a significant improvement in function. 
 
Differences in the postC protocol between in vivo an ex vivo models are to be expected 
(Yang et al., 2005; discussed above), but further studies in the in vivo rabbit model 
illustrated slight differences in the optimal protocol. Iliodromitis et al. (2006) tried both 4 x 
30 sec, as well as 6 x 10 sec protocols. In their model only the 6 x 10 sec protocol 
conferred cardioprotection comparable to an IPC intervention. Chiari et al. (2005)  found 
that a 3 x 20 sec postC protocol could elicit an infarct sparing effect, whereas 3 x 10 sec 
reperfusion / ischaemia could not. Couvreur and colleagues (2006), as well as Philipp et 
al. (2006), succesfully applied a 4 x 30 second reperfusion / ischaemia postC protocol. 
Argaud et al. (2005) however, could elicit a longterm (72 hours reperfusion) postC-
mediated infarct sparing effect with a 4 x 60 second protocol. Despite these slight 
differences in protocols applied by the different researchers, it seems that generally in the 
in vivo rabbit heart, a protocol of 4 cycles of 30 seconds reperfusion / ischaemia should 
confer cardioprotection. 
 
The murine heart 
The phenomenon of postC has also been investigated in probably the most used 
laboratory animals, namely rats and mice.  
 
It seems that most of the studies done in mice employed the same postC protocol of 3 x 
10 seconds reperfusion / ischaemia to induce a reduction in IFS (Heusch et al., 2006; Lim 
et al., 2007; Boengler et al., 2007). Interesting to note that Lim and colleagues (2007) 
found the 3 x 10 second reperfusion / ischaemia protocol more efficient in decreasing 
infarct size, than a 6 x 10 second algorithm (although both decreased IFS significantly in 
comparison to controls). It is therefore interesting that Kin et al. (2005) reported that a 6 x 
10 second protocol was associated with an improved post-ischemic systolic and diastolic 
function, in the first minutes of reperfusion, while a 3 x 10 second protocol was ineffective. 
They therefore concluded that this protocol could protect against myocardial stunning 
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(contrary to the findings of Couvreur et al. (2006) in the canine and rabbit heart). 
Confirming these results, Morrison et al. (2007) also applied a 6 x 10 sec protocol in their 
ex vivo preparation, which also elicited an increase in functional recovery, as well as a 
reduction in cardiac troponin I (TnI; a marker of cell damage) release. 
 
The murine model of postC however, does not escape the variability of the phenomenon: 
Gomez et al. (2007) applied a 3 times 60 second postC protocol after 60 minutes of 
coronary ligation (other studies employed between 20 and 30 minutes of ischaemia), 
which conferred an infarct sparing effect 24 hours into reperfusion. Tsutsumi and 
coworkers (2007) demonstrated an infarct sparing effect elicited by a postC protocol of 3 x 
20 sec reperfusion / ischaemia, while Yang and colleagues (2006), using an in vivo balloon 
occlusion model, successfully postconditioned their mice with a 3 cycles of only 5 second 
occlusion / reperfusion protocol. 
 
The rat heart 
The rat has been extensively used in postC research, despite variable outcomes reported. 
The first researchers to attempt postconditioning the rat heart were Kin and coworkers 
(2004), who found in an in vivo model that a postC protocol of 3 or 6 x 10 seconds applied 
immediately at the onset of reperfusion, led to a decrease in infarct size, creatine kinase 
(CK) activity, neutrophil accumulation in the AAR, as well as a decrease in oxidative-
related damage (as measured by plasma MDA activity), and superoxide anion generation. 
It is interesting to note that the authors mentioned that the postC-related infarct sparing 
effects observed were not as robust as in the dog or rabbit, and it was also notably weaker 
than the infarct sparing effect of IPC in the rat heart. The authors speculated that these 
differences could be due to species-related differences in xanthine oxidase activity and 
anti-oxidative mechanisms. Since this initial study by Kin and colleagues, other 
researchers have also illustrated the cardioprotective effect of  this postC protocol. Wang 
et al. (2007) recently reported that a 6 x 10 second protocol, imparted functional recovery 
in their isolated rat heart model. In the ex vivo isolated rat heart, Penna et al. (2006) 
employed a basic, what they termed “classical”, postC protocol of 5 times 10 second 
reperfusion / ischaemia. They also used a modified protocol in which the reperfusion 
periods became progressively longer (15, 20, 25 and 30 seconds), while the ischaemic 
episodes were shortened (20, 15, 10 and 5 seconds). They found that both protocols 
imparted the same measure of infarct sparing effect. Tang et al. (2006) did a interesting 
study in which they used an implanted balloon occluder to investigate postC and IPC in 
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conscious rats. Applying a 6 x 30 sec protocol, they could not demonstrate any 
cardioprotection. They did however find that both 6 x 10 sec and 20 x 10 sec protocols 
were infarct sparing after 30 minutes of coronary occlusion, but not after 45 minutes of 
ischaemia. Increasing the number of cycles (60 x 10 seconds) however reversed the 
protective effect of postC. It is noteworthy that they noted that IPC (12 x 2 minutes 
occlusion / reperfusion) could also protect against infarct development after 45 minutes of 
ischaemia, while late IPC (applied 24 hours before occlusion) even protected after 60 
minutes ischaemia. These observations confirm those of Kin et al. (2004) that in the rat, 
postC does not seem to be as robust in its cardioprotective effect as IPC. 
 
Application of longer reperfusion / ischaemia cycles (30 seconds) may also be effective in 
eliciting protection, contrary to the observations of Tang et al. (2006). Manintveld et al. 
(2007) found that 3 x 30 second cycles reperfusion / ischaemia applied after 45 or 60 
minutes coronary occlusion, in an in vivo model, reduced infarct size. In their study postC ( 
3 x 30 second, 3 x 5 second and 3 x 15 second cycles of reperfusion / ischaemia) could 
not confer cardioprotection after 90 or 120 minutes ischaemia, and surprisingly, 
significantly aggravated infarct size when applied after 30 or 15 minutes of ischaemia. 
These latter observations are contrary to expectation, but (as the authors argue) it does 
illustrate that the duration of sustained ischaemia could also determine the efficacy of a 
postC protocol.  Intriguingly, Tillack et al. (2006) successfully employed a 3 x 30 sec 
protocol to decrease infarct size after 30 minutes regional ischaemia, in their in vivo model. 
This difference in outcome, between these two similar experimental setups, still remain to 
be explained. A 3 x 30 second postC protocol was also applied by Bopassa et al. (2006), 
after an initial one minute period of reperfusion, following 30 minutes global ischaemia. In 
their ex vivo model this protocol was associated with an increase in functional recovery 
after 60 minutes of reperfusion. Although they did not measure infarct size, their postC 
protocol decreased the levels of markers of myocardial necrosis (lactate dehydrogenase 
(LDH), creatine kinase and TnI) in the coronary effluent, during 60 minutes reperfusion.  
 
One of the most unique postC protocols was applied in one of the first papers on the 
phenomenon. Galagudza et al. (2004) applied a postC intervention of two minutes global 
ischaemia after 15 minutes of reperfusion, in hearts that developed persistent ventricular 
fibrillation. This was done in an isolated heart model, with a 30 minute regional ischaemic 
insult. They found that this protocol possessed strong antiarrythmic effects. It could 
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however, be argued that their protocol was per definition, not a true postconditioning 
protocol. 
 
In light of the above discussion, it is clear that postconditioning of the rat heart is not as 
straight forward or reproducible as seems to be the case in some of the other animal 
species. This is especially highlighted by two recent studies. Dow & Kloner (2007) 
attempted to postcondition the in vivo rat heart after either 30 or 45 minutes of regional 
ischaemia. They applied various protocols: 4 x 10 second, 4 x 20 second, 8 x 30 second 
and 20 x 10 second cycles of reperfusion / ischaemia. None of these protocols could 
reduce infarct size. This is despite the successful application of IPC, as well as previous 
findings in their lab that postC does reduce ventricular arrythmias. One possible 
explanation for these findings may lie in the fact that they used female rats. Crisostoma et 
al. (2006) found that although the female rat heart can be postconditioned (postC protocol: 
6 x 10 second cycles), this protection is dependent on the degree of ischemic injury. In 
their ex vivo model, male hearts were postconditioned after 20 and 25 minutes of global 
ischaemia, while female hearts could only be protected after 20 minutes and not 25 
minutes of ischaemia. It should however be noted that Crisostoma and colleagues used 
functional recovery as end-point, while the effect of gender on infarct size and 
postconditioning has not yet been investigated. Kaljusta et al. (2007) also experienced 
problems postconditioning the rat heart. In their study they investigated both rats and mice, 
both in vivo and ex vivo, with the goal of developing a robust postC protocol. Although they 
could illustrate cardioprotection in mice, only in one laboratory (of two) could they elicit 
cardioprotection in the in vivo rat model (with a protocol of 3 x 10 second reperfusion / 
ischaemia after 30 minutes of regional ischaemia). In the isolated rat heart they 
investigated various protocols: 3 x 10 second, 3 x 30 second or 2 x 60 second cycles of 
reperfusion / ischaemia following 30 minutes of global ischaemia; while after 40 minutes 
regional ischaemia they applied a 3 x 10 second, as well as a 6 x 10 second cycle 
protocol. They could however, not induce an infarct sparing effect with any of these 
protocols. 
 
It is clear from the above that some researchers experience problems in obtaining 
cardioprotection with postconditioning. Up until the present time, we do not yet have an 
explanation for these variable outcomes. 
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The porcine heart 
Despite the irregular results found in the rat heart, the postC experiments in the pig heart 
seemed to cause the most concern. The first paper published on postC in the swine heart 
did not report success: Schwartz & Lagranha (2005) applied a protocol of 3 x 30 second 
reperfusion / ischaemia in their in vivo pig heart model of regional ischaemia (30 minutes 
of coronary occlusion). This protocol could however not limit infarct size, although IPC 
could confer cardioprotection in this model. Interestingly, both interventions of IPC and 
ineffectual postC were associated with an increased phosphorylation of the survival 
kinases: ERK p42/p44  and PKB/Akt. These findings opened the door for the possibility 
that the ability to be postconditioned might in fact really be very species dependent. 
Iliodromitis et al. (2006) subsequently evaluated the efficacy of the protocol applied by 
Schwartz & Lagranha (2005). They compared a 4 x 30 second cycle with a 8 x 30 second 
cycle protocol, applied after 60 minutes of coronary ligation in the in vivo model. The latter 
protocol (8 x 30 sec) elicited an infarct sparing effect. The authors speculated that the total 
time of postC intervention (four minutes vs eight minutes) might explain these differences 
in protocol efficacy. According to this explanation, in the longer protocol the heart is 
exposed for a more substantial time to the postC protective trigger(s). However, these 
findings are in contrast to the protocol of 3 x 30 second cycles that Jiang et al. (2005) 
applied in closed-chest pigs (they induced and manipulated the ischaemic episodes using 
an angioplasty balloon), which did elict an infarct sparing effect.  
 
Two recently published research projects also reported successful postconditioning of the 
swine heart, despite application of different protocols. Skyschally et al. (2007) found that a 
postC protocol of 6 x 20 seconds (total time: four minutes) significantly decreased infarct 
size, following 90 minutes of regional low-flow ischaemia. Zhao et al. (2007) applied a 
postC protocol of 6 x 10 second (total time: two minutes) cycles of reperfusion / ischaemia 
after 3 hours of regional ischaemia. They found that this protocol reduced infarct size, as 
well as the area of so-called no-reflow, combined with an increase in coronary flow and 
ventricular function. Unfortunately these studies did not reveal the reason why in the initial 
study the swine heart failed to show successful postconditioning. The fact that both studies 
utilised a shorter total time of intervention than the 8 minutes reported by Iliodromitis et al. 
(2005), raises doubt about the explanation proposed by these workers. If the findings 
made by Manintveld et al. (2007), concerning the possibility that a too short ischaemic 
duration could render postC non-cardioprotective, can be extrapolated to pigs, it might also 
be that Schwartz & Lagranha (2006) applied a suboptimal period of regional ischaemia 
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(i.e. too short) to successfully elicit postC protection. It should be noted that all the studies 
that have shown cardioprotective postC in swine, applied a longer index ischaemia  period 
than Schwartz & Lagranha (2006), in the first study on this species.  
 
In summary 
Despite the problems experienced and the differences in protocols, these studies done in 
the different animal models clearly confirm the existence of the cardioprotective 
postconditioning phenomenon. It is however also clear that postconditioning is difficult to 
induce, primarily because of the variability and seeming unreproducibility in the efficacy of 
the reported protocols. There are five variables that may influence the efficacy of 
postconditioning: 1) The animal species being studied; 2) the time lapse between the end 
of sustained ischaemia and the onset of postconditioning; 3) duration of the reperfusion / 
ischaemia cycles; 4) the number of cycles might be important as well (the latter two 
determine the total time of postC intervention), contrary to the initial observations made by 
Vinten-Johansen et al. (2005); and 5) the duration of sustained ischaemia. This variable 
might not be as straightforward as one might think, as illustrated by the research done by 
Manintveld et al. (2007). 
 
In a recent review, Vincent-Johansen et al. (2007) speculate that the observed species 
differences may be due to differences in the rate and degree of ischaemia / reperfusion 
injury development in different animal species. These parameters are determined by 
factors such as myocardial metabolism, endogenous anti-oxidant defences and the role of 
inflammatory cells during reperfusion. 
 
In cell culture 
It is worthy to note that a successful postC protocol has also been developed for cell 
cultures. This was first described in neonatal rat cardiomyocytes by Sun et al. (2005), and 
entailed a postC protocol of 3 cycles of 5 minutes alternating normoxia and hypoxia at the 
onset of a 6 hour reoxygenation period, after a 3 hour hypoxic period. This protocol was 
associated with decreases in superoxide production,  tumour necrosis factor-alpha (TNF-
α) release, as well as cellular markers of apoptosis (such as caspases and DNA 
fragmentation). Exactly the same protocol was also applied in H9c2 cardiac muscle cells 
(Zhao et al., 2006), the only difference being that the hypoxic episode was longer (8 hours 
vs 3 hours) and the reoxygenation period was shorter (3 hours vs 6 hours). These authors 
also reported a postC associated reduction in apoptosis, as well as an increase in 
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mitochondrial preservation. A different protocol was applied by Wang and colleagues 
(2006) in an isolated adult rat cardiomyocyte model. Following a hypoxic episode of 2 
hours, at the onset of 3 hours reoxygenation, they exposed the cells to 2 x 5 minutes 
normoxia / hypoxia. Similiarly to the other studies on postC in cell culture, Wang et al. 
(2006) reported a postC-associated reduction in apoptosis, increase in cell viability and a 
decrease in free radical (specifically peroxynitrite (ONOO-)) generation.  
 
The application of postC in cell culture introduces an ideal model for research into the 
cellular and molecular changes associated with postC. 
 
However, the ultimate goal of postconditioning is to apply it in humans, in the clinical 
setting. Surprisingly, despite the difficulties experienced in eliciting postconditioning in 
animal models, a considerable amount of research has already been done in humans, as 
will be described in the next section. 
 
1.4.1.3. Postconditioning the human heart 
In 2005 Laskey published a pilot study in which he investigated the effects of a 
“preconditioning-like” intervention in reperfusion. This study focused on patients presenting 
with an acute myocardial infarct (AMI), receiving percutaneous coronary intervention (PCI). 
The conditioning intervention entailed two 90 second balloon inflations in the stenotic 
artery, divided by 3 to 5 minutes of reperfusion. In the control group only a single 90 
second inflation was performed at the same time as the second inflation in the conditioned 
group. It should be noted that flow greater than TIMI grade 0–1 was established by 
minimum intervention in the infarct-related artery before the intervention. All patients 
experienced relief of angina, a decrease in stenosis to less than 10 % and coronary flow 
greater than TIMI grade 2. In this study Laskey (2005) found that the preconditioning-like 
stimulus was associated with favourable changes in electrocardiographic and coronary 
hemodynamic markers. Although it is questionable if this study really applied a true postC 
intervention, it certainly illustrated the potential for postconditioning in humans. This 
potential for postC protection was also illustrated by a retrospective analysis of patients 
who had received angioplasty after presenting with myocardial infarction (Darling et al., 
2007). It was found that 4 or more balloon inflations at reperfusion were associated with 
less peak creatine kinase release, than when between 1 and 3 inflations were applied. 
Oddly enough, despite this positive finding, patients receiving 4 or more balloon inflations 
had a longer sojourn in hospital. 
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 Two studies done on human tissue also suggested that human tissue could be 
postconditioned. Loukogeorgakis et al. (2006) investigated human endothelium in vivo by 
applying a 20 minute ischemic insult on the forearm of test subjects. In their model this 
insult confers a transient  decrease in flow-mediated dilation of the brachial artery (which is 
the reversible injury end-point monitored). Two postC protocols were applied on the 
ischemic arm: a 3 x 10 second cycle and a 3 x 30 second cycle protocol, in the absence 
and presence of a minute delay before the postC intervention. They found that both 
protocols protected the endothelium, provided they were applied within the first minute of 
postC. Due to the model used, this study could however not adress the efficacy of postC in 
a more rigorous ischaemia scenario – such as myocardial infarction, in which prolonged 
ischaemia leads to irreversible cell damage and death. A study by Sivaraman et al. (2007) 
applied a more potent ischaemic insult of 90 minutes hypoxia (paced at 3 Hz) on isolated 
human atrial trabeculae. After 120 minutes simulated reperfusion (exposure to oxygenated 
buffer while paced at 1 Hz) residual contractile function was measured as end-point. They 
investigated both a 4 x 30 second cycle, as well as a 4 x 60 second cycle postC protocol. 
Only the latter (4 x 60 sec) protocol conferred protection, comparable to a preconditioning 
stimulus (4 minutes hypoxia at a pacing rate of 3 Hz, followed by 16 minutes of simulated 
reperfusion at 1 Hz pacing). 
 
Three studies have been reported that purposefully investigated postC in humans in the 
clinical setting. Staat et al. (2005) applied a postC protocol of 4 cycles of 1 minute 
reperfusion / ischaemia at the onset of reflow, after angioplasty. This was achieved by 
inflating and deflating the angioplasty balloon upstream of the implanted stent (to avoid 
damaging the stent, as well as to prevent thrombi embolization). This intervention 
decreased infarct size (as measured by the area under the creatine kinase curve) after 72 
hours of reperfusion, illustrating the feasibility and cardioprotective ability of postC in the 
human heart. The question whether postC permanently protects tissue, or just delays 
damage, was answered by Yang et al. (2006). They applied a postC protocol of 3 x 30 
seconds reperfusion / ischaemia by deflating and inflating the angioplasty balloon. They 
confirmed the reduction in infarct size observed by Staat et al. (2005), but by using nuclear 
imaging they also observed a sustained decrease in infarct size after 7 days of 
reperfusion. Applying a similar protocol as Yang et al. (2006), of 3 x 30 seconds 
angioplasty balloon deflation and inflation, Ma and coworkers (2006) found that postC was 
associated with a decrease in blood levels of MDA and CK – illustrating a decrease in free 
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radical mediated cell injury. They also reported an increase in microcirculation reperfusion, 
peripheral artery endothelial function (using a technique similar to the one used by 
Loukogeorgakis et al. (2006)) and left ventricular wall motion (measured 8 weeks after 
PCI). 
 
It therefore seems that postconditioning does indeed have potential as a reperfusion 
intervention in human ischaemia / reperfusion, such as coronary angioplasty following a 
myocardial infarct. 
1.4.2. Possible mechanisms of postconditioning 
When postconditioning was initially described by Zhao et al. (2003) they speculated that it 
was unlikely that the mechanisms (and timing of these mechanisms) recruited by postC 
are the same, as those at work in IPC. This made sense, due to the radical differences in 
the timing of application of these interventions (IPC before sustained ischaemia and postC 
after sustained ischaemia). Since then there have been studies supporting this line of 
thought. For example Schwartz & Lagranha (2006) found a similar activation of the 
salvage kinases in both postC and IPC, although only IPC conferred protection. Heusch et 
al. (2006) also demonstrated that postC is independent of connexin 43, a molecule that is 
known to be important for IPC cardioprotection. There have however, also been several 
studies showing common mechanisms for postC and IPC.  For a review on the common 
signalling pathway recruited by both postC and IPC in reperfusion, see Hausenloy and 
Yellon (2007). This section will briefly focus on some of the possible mechanisms that 
have been implicated in postconditioned cardioprotection. 
 
1.4.2.1. Attenuation of the inflammatory response 
PostC was first described in an in vivo setting, and Zhao et al. (2003) also initially 
explained this phenomenon in this context. They observed that postC was associated with 
a decrease in tissue edema, and neutrophil accumulation in the area at risk, as well as a 
preserved coronary artery endothelial function. The latter two observations could explain 
the postC-related decrease in no-reflow area, seen by Zhao et al. (2007) in mini-swine, 
since neutrophil capillary plugging and edema can contribute to the “no-reflow” 
phenomenon (Rezkalla & Kloner, 2002).  Interesting to note that postC protection against 
“no-reflow” was lost in hypercholesterolemic conditions (Zhao et al., 2007). Halkos et al. 
(2004) confirmed that postC was associated with a decrease in tissue edema in the 
ischemic epicardium. In the open chest rat model Kin et al. (2004) also reported a 
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decrease in neutrophil accumulation in the area at risk, associated with postC. Mykytenko 
et al. (2007) found in the in vivo canine model, that this reduction in neutrophil 
accumulation (together with a decrease in IFS) was maintained in postC hearts, even after 
24 hours of reperfusion (compared to control hearts). There was however still an increase 
in IFS and neutrophil accumulation between 3 and 24 hours of reperfusion, even in the 
postC hearts. This illustrates that postC does not seem to have an effect on reperfusion / 
injury events that occur later in reperfusion. Associated with this theme of reduced 
inflammation, Sun and colleagues (2006) reported a decrease in TNF-α associated with 
postC, in neonatal cardiomyocyte lysates. 
 
1.4.2.2. Free radical generation 
As previously mentioned, reperfusion is associated with a burst of free radicals that can be 
harmful to the myocardial tissue (Zweier & Hassan Talukder, 2006). Interestingly,  reactive 
oxygen species (ROS) have been implicated in the triggering and mediation of both IPC 
(Baines et al., 1997 & Vanden Hoek et al., 1998) and postC. In this regard; Penna et al. 
(2006) found that the administration of a ROS scavenger during the postC protocol in the 
isolated rat heart, abrogated the infarct sparing effect of postC – implicating a trigger role 
for ROS in postC. This triggering role of ROS in postC was also more recently confirmed in 
an in vivo murine model, in which administration of a ROS scavenger just before (but not 
after) a postC intervention blocked its infarct sparing effect (Tsutsumi et al., 2007). 
 
It is however, generally accepted that large amounts of free radicals contribute to cell 
damage and death in ischaemia / reperfusion (Zweier & Hassan Talukder, 2006 & Valko et 
al., 2007). It is therefore not surprising that in vivo studies (Zhao et al., 2003; Kin et al., 
2004) have found that postC is related to a reduction in both ROS (specifically the 
superoxide anion) and plasma MDA (a marker of free radical mediated membrane lipid 
peroxidation). Mykytenko et al. (2007), in their study on the longterm effects of postC, also 
found that postC was associated with a decrease in superoxide generation after 24 hours 
of reperfusion. Interestingly, Halkos et al. (2004) found that both IPC and postC is 
associated with a reduction in ROS generation during reperfusion. In their study on the 
association between the duration of sustained ischaemia, postC and IFS, Manintveld et al. 
(2007) found that postC reduction in infarct size (after 60 minutes of regional ischaemia) 
was associated with a reduction in superoxide generation. Unsuccessful postC 
implimentation (after 15 minutes ischaemia) was however associated with increased 
infarct size development and superoxide production (compared to control).  
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 Studies in cell culture have also shown an important role for ROS  reduction, associated 
with postC. In this regard Sun et al. (2005), found that in neonatal rat cardiomyocytes, 
postC was associated with a decrease in cell death, reduction in ROS generation, lipid 
peroxidation and cytosolic, as well as mitochondrial Ca2+-levels. They speculate that these 
phenomena are linked. The same researchers confirmed these early results by finding a 
decrease in superoxide generation in a postconditioned cell preparation (Sun et al., 2006).  
Reactive oxygen species could contribute to an increased influx of Ca2+ into the cell via 
three routes: 1) increased Ca2+ influx through damaged cell membranes (Bagchi et al., 
1997); 2) increased Na+ / H+-exchanger activity, which in turn drives the Na+ / Ca2+-
exchanger to pump Ca2+-ions into the cell (Rothstein et al., 2002) and; 3) inactivation of 
the sarcoplasmic reticulum Ca2+ - transporting ATPase (Lounsbury et al., 2000), which 
then leads to inhibition of sarcoplasmic reticulum Ca2+ uptake.  
 
These studies in cell preparations, isolated hearts and in vivo models demonstrate the 
significance of free radical activity in the phenomenon of postC. It seems probable that, as 
is the case with IPC, postC protects the heart against deleteriously high levels of reactive 
species, although itself is triggered by a slight exposure to these same reactive molecules.  
 
It is noteworthy that many of these studies were conducted in the absence of blood borne 
agents and cells. The fact that both in vivo, as well as blood-free preparations, show postC 
cardioprotection illustrates that postC functions through mechanisms both intrinsic and 
extrinsic to cardiomyocytes. 
 
1.4.2.3. Triggering postconditioning – the delayed washout of 
metabolites 
Convincing evidence has been produced for a role for the so-called Reperfusion Injury 
Salvage Kinase (RISK) pathway in postC. The fundamental question is though: How are 
these signalling pathways activated? The delayed washout of triggering metabolites could 
be prominent in this regard. 
Penna and coworkers (2007) found that postC protection is dependent on the availability 
of the bradykinin B2 receptor, since they could mimick postC-protection by the intermittent 
(5 cycles of 10 seconds) administration of bradykinin to the isolated rat heart preparation. 
Just as with postC, ROS scavengers administered during the bradykinin-cycles, inhibited 
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this protective effect. The beneficial effect of bradykinin in reperfusion was also shown by 
Yang et al. (2004) and Lim et al. (2007). 
Besides bradykinin, opioids have also been implicated in postC. The administration of non-
selective opioid antagonists in reperfusion abrogated the infarct sparing effect of postC, in 
an open-chest rat model (Kin et al., 2005). Wang and coworkers (2007) specifically 
identified the κ-opioid receptor as being involved in the mechanism of postC. Stimulation of 
the δ-opioid receptor in the first minutes of reperfusion  (as a pharmacological postC 
intervention) has also been shown to elict cardioprotection in the in vivo murine model 
(Tsutsumi et al., 2007), suggesting a possible role for this receptor in postC as well. 
 
It is however especially endogenous adenosine which has received the most attention as 
possible trigger for the cellular postC-related signalling cascade. In one of many studies on 
the protective effects of adenosine per se in reperfusion (for a review see Donato & Gelpi, 
2003), Yang et al. (2004) suggested a role for adenosine, when they found 
cardioprotection associated with the administration of NECA (5’-(N-ethylcarboxamido) 
adenosine), a A1/A2 receptor agonist, in reperfusion. Similarly, AMP 579, another A2-
receptor agonist, also elicited cardioprotection when given during reperfusion (Xu et al., 
2001).  
 
In 2005 Yang et al. made the connection between postC and adenosine receptor 
stimulation, when they found that blockade of this receptor (using a nonselective 
adenosine receptor blocker, 8-p-(sulfophenyl) theophylline (SPT)) impaired the ability of 
postC to limit infarct size. It appears that an increase in the retention time of extracellular 
adenosine during the postC protocol, early in reperfusion, may be of significance (Kin et 
al., 2005). They also found that the stimulation of both the A2A and A3A receptors are 
necessary for postC cardioprotection. Using the same pharmacological inhibitor approach 
as Kin et al. (2005), Philipp et al. (2006) also demonstrated the importance of adenosine 
receptor stimulation in postC, with the difference that they found the A2b receptor to be 
involved (and not A2A). Two recent studies, using  a knock-out mouse model, however 
favour the A2A receptor as being the important one in the mechanism of postconditioning 
(Yang et al., 2006; Morrison et al., 2007). It is therefore clear that the cardioprotection 
elicited by postC is dependent on the binding of endogenous adenosine to adenosine 
receptors (specifically the A2A receptors) in reperfusion. 
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1.4.2.4. The role of protein kinase C 
Penna et al. (2006) found that the inhibition of protein kinase C (PKC) during reperfusion 
(even after the postC protocol itself) was associated with a loss in postC-related 
cardioprotection. Utilising pharmacological inhibition, Philipp et al. (2006) made the 
interesting observation that blockade of the adenosine A2A-receptor (by administering an 
A2A antagonist just before reperfusion) also abrogated the cardioprotective effects of a 
PKC activator (administered in reperfusion), indicating that PKC is upstream from 
adenosine stimulation in the signalling pathway, and participates in the activation of 
adenosine-mediated protective mechanisms. Fantinelli & Mosca (2006) linked PKC with 
the free radical reduction associated with postC, since they observed a loss in postC 
cardioprotection (in terms of functional recovery and reduced lipid peroxidation), when 
PKC was inhibited in their isolated spontaneously hypertensive rat heart model. 
 
1.4.2.5. Nitric oxide and guanylyl cyclase activity 
Nitric oxide synthase (NOS) activity has also been implicated in postconditioning (Yang et 
al., 2004 & Manintveld et al., 2007). It seems that NOS is of importance in the protective 
pathways activated by adenosine and bradykinin, during reperfusion (Yang et al., 2004). 
Zhao et al. (2007) measured constitutive NOS (cNOS) and inducible NOS (iNOS) activity 
in swine myocardial tissue after 2 hours of reperfusion and found that postC was 
associated with an increase in cNOS and a decrease in iNOS activity. The authors linked 
this profile to protected endothelial function. In their hypercholesterolemic animals this 
profile, as well as postC protection was lost. This absence of difference in NOS activity 
between control and postC hearts, under conditions of hypercholesterolemia, might be due 
to advanced endothelial injury in these animals – to such an extent that the postC 
intervention can not induce favourable changes in metabolism. 
 
The dependence of postC-related cardioprotection on the activity of guanylyl cyclase (GC) 
has been demonstrated by both Yang et al. (2005) and Penna et al. (2006). Both studies 
used 1H-[1,2,4]oxadiazole[4,3-a]quinoxalin-1-one (ODQ) to inhibit GC activity, which in 
turn abrogated postC protection. Penna and colleagues (2006) went further by showing an 
increase in cyclic guanosine-monophosphate (cGMP)-levels in reperfusion, following 
postC. This observed GC-cGMP activity however seems to be partially dissociated from 
nitric oxide (NO), since they also found that NOS inhibition resulted in only a partial 
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reduction in postC cardioprotection, as well as a decrease in cGMP levels (later in 
reperfusion).  
 
It could be that the NO-cGMP pathway contributes to postC cardioprotection through: 1) 
the anti-oxidant activity of NO (Wallace, 2005); 2) the abilibilty of cGMP to open the 
mitochondrial ATP-dependent potassium channel (mK+ATP-channel) (Qin et al., 2004); and 
3) reduced intracellular Ca2+ overload and hypercontracture (for a brief review on 
hypercontracture in reperfusion see Piper et al., 2004). 
 
1.4.2.6. Postconditioning and the mitochondria 
The mitochondrial K+ ATP- dependent channel 
One of the first studies on postconditioning demontrated the importance of the mK+ATP-
channel in this form of cardioprotection (Yang et al., 2004). It seems that opening of the  
mK+ATP-channel is associated with the activation of the survival kinases (to be discussed 
later), since blocking it also diminished the levels of phosphorylated protien kinase B 
(PKB/Akt) and extracellular signal-regulated kinase (ERK) in the mitochondria (Zhao, et 
al., 2006). This same study ruled out the possible role of the sarcolemmal K+ATP-channels, 
since blocking them had no effect on postC in cardiac muscle cells. The significance of the 
mK+ATP-channels was further underscored by the finding that administration of a mK+ATP-
channel blocker in reperfusion (including and excluding the postC protocol) leads to 
blockade of the infarct sparing effect of postC (Penna et al., 2006). 
 
The mitochondrial permeability transition pore 
Currently the mitochondrial permeability transition pore (mPTP) is receiving much attention 
as a / the possible end-effector in both postC, as well as IPC. The concept of a permeable 
pore in the mitochondrial membrane, the opening of which precedes cell death, is not a 
new concept. In 1988 Crompton & Costi published evidence for a mitochondrial pore which 
can be opened by Ca2+, inorganic phosphates (Pi) and oxidative stress. A recent study 
(Kim et al., 2006) has however shown that it is ROS and the sudden normalisation of pH 
(in the ischaemia / reperfusion setting) that open the channel. In this scenario, Ca2+ 
overload is a consequence of mPTP opening, and not a stimulus. Three main molecules 
have been implicated in the structure of this pore: the voltage-dependent anion channel 
(VDAC) located in the outer mitochondrial membrane, the adenine nucleotide translocase 
(ANT) in the inner membrane and cyclophilin-D (CypD) in the mitochondrial matrix. It is 
thought that these molecules form a complex which is “deformed” by stressors, such as 
 - 52 -
oxidants, to form an open pore through which relatively large molecules can pass freely. 
The end-result is a loss in mitochondrial membrane potential, uncoupling of oxidative 
phosphorylation and a loss of ATP, which, in turn leads to dysregulation of ion 
homeostasis and necrotic cell death. Rupture of the outer membrane could also result in 
leakage of pro-apoptotic molecules (such as cytochrome c) into the cytosol, mediating an 
apoptotic mode of cell death (for a review on this topic see Crompton, 2000).  
 
The importance of the mPTP in ischaemia / reperfusion injury has repeatedly been 
demonstrated. Hausenloy et al. (2003) showed that this pore is especially critical in the 
reperfusion phase, since inhibiting it right at the onset of reperfusion conferred 
cardioprotection. It is therefore not surprising that Argaud and colleagues (2005) found that 
postC was associated with a delay in Ca2+-induced mPTP opening. They speculate that 
this could be due to the decrease in ROS associated with postC. Bopassa et al. (2006) 
also demonstrated a role for the preservation of the mPTP in its closed conformation, in 
the cardioprotection elicited by both postC and low pressure reperfusion, in the isolated rat 
heart. The inhibition of the mPTP elicited by these interventions was however lost with 
inhibition of phospatidylinositol 3-kinase (PI3-kinase), implicating a connection between 
mPTP and PI3-kinase. Zhao et al. (2006) also report a link between postC-
cardioprotection, mK+ATP-channel activity, the increase in phosphorylated survival kinases 
(PKB and ERK) in the mitochondria and mPTP activity. 
 
Cyclophilin-D (and per implication the CypD-dependent mPTP) has been shown to be 
involved in Ca2+ and ROS mediated cell death, especially necrosis (Nakagawa et al. 2005 
& Baines et al. 2005). The importance of this molecule in postC has also been 
demonstrated by Lim et al. (2007). They found that CypD-deficient mice could not be 
cardioprotected by IPC, postC or pharmacological mimetics of these mechanical 
interventions, since these hearts were already “protected”. Control IFS-values were 
already in the same range as the reduced IFS-values associated with cardioprotection in 
the wild-type mice.  
 
Juhaszova et al. (2004) suggested a model in which numerous cellular pathways 
associated with survival  (such as PKC and PI3-kinase) converge on one “master-switch”, 
which then regulates the common end-effector of these pathways – namely the mPTP. 
Their study suggested that this “master-switch” could be glycogen synthase kinase-3β 
(GSK-3β). Phosphorylation of this kinase inactivates it, leading to cell survival. These 
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interactions could also be of importance in postC. Tillack et al. (2006) reported that a 
postC protocol increased the phosphorylation of GSK-3β. Using GSK-S9A transgenic mice 
(in which GSK-3β can not be inactivated), Gomez et al. (2007) found that postC could not 
reduce infarct size. Only administration of the mPTP inhibitor cyclosporin-A could 
decrease infarct size, also suggesting that GSK-3β is upstream of mPTP. For a review on 
the mPTP in postconditioning see Gateau-Roesch et al. (2006). 
 
1.4.2.7. The protein kinases in postconditioning 
Both mitogen activated protein kinase p38 (p38 MAPK), as well as c-Jun NHP2 terminal 
kinase (JNK) have been implicated in cell death and apoptosis. Cicconi et al. (2003) found 
that although both these kinases are involved in ROS-mediated apoptosis, they seem to 
be exerting opposite effects, with p38 MAPK being pro-apoptotic and JNK possibly 
involved as part of a scavenger pathway.  This is contrary to the observation that inhibition 
of JNK in reperfusion was associated with cardioprotection (Ferrandi et al., 2004). The 
precise role and functions of these kinases, as well as their roles in IPC, are therefore still 
quite uncertain (for a review on the kinases in pre- and postconditioning see Hausenloy & 
Yellon (2006)). Not much is known about their significance in postC either. In neonatal 
cardiomyocytes Sun and colleagues (2006) found that postC cardioprotection was 
associated with a reduction in the activity of both p38 MAPK and JNK, indicating that a 
part of the cardioprotection conferred by postC, might be due to the down regulation of 
these kinases. However, Feng et al. (2006) applying an isoflurane postC protocol (which 
refers to the administration of isoflurane for the first 15 minutes of reperfusion), found no 
alterations in the phosphorylation of p38 MAPK in infarct-remodeled myocardium. 
 
The Reperfusion Injury Salvage Kinases 
The Reperfusion Injury Salvage Kinases (RISK) refer to the pro-survival kinase pathway 
duo of PI3-kinase – PKB/Akt  and MAPK/ERK kinases (MEK) 1/2 – ERK p42/p44. For a 
review on the RISK pathway within the setting of reperfusion and ischaemia see 
Hausenloy & Yellon (2004). These kinases appear to play a role in the salvage of tissue 
from ischaemia / reperfusion injury, exerting their effects in reperfusion. This is illustrated 
by Yang et al. (2004) who found that the cardioprotection associated with both NECA and 
bradykinin, given in reperfusion, is dependent on the activity / phosphorylation of both PI3-
kinase and ERK p42/p44. Bopassa et al. (2006) also found that PI3-kinase activity is of 
importance in the cardioprotection conferred by low-pressure reperfusion.  
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Despite their action in reperfusion, they have also been implicated in the mechanism of 
IPC (Hausenloy et al., 2005). It is therefore no surprise that a large amount of research 
has already been done on their role in the phenomenon of postconditioning. 
 
The PI3-kinase – PKB/Akt pathway 
Most studies that have investigated the importance of PI3-kinase in postC, by using 
pharmacological inhibitors (Wortmannin and LY-294002), have found it to be an essential 
feature of the postC cardioprotective mechanism (Yang et al., 2004; Tillack et al., 2006; 
Fujita et al., 2007).  It is therefore not surprising that PKB/Akt, a downstream effector of 
PI3-kinase, has also been implicated in postconditioning (by analysis of the activity of 
PKB/Akt (Zhu et al., 2006), or Western blot quantification of phosphorylation (Morrison et 
al., 2007)). Darling et al. (2005) however, found that although ERK p42/p44 is involved in 
their isolated rabbit heart model, they could not show a role for PI3-kinase (using the 
inhibitor LY-294002). Together with this inhibitor data, they did not find significant 
differences in the degree of phosphorylation of PKB/Akt in postC vs control hearts. 
 
Philipp et al. (2006) found PI3-kinase to be downstream of both adenosine receptor 
stimulation and PKC activity. Some of the possible ways in which the PI3-kinase – 
PKB/Akt pathway exerts its effects, is by stimulating NO production and inhibiting the 
opening of the mPTP. Manintveld et al. (2007) illustrated that together with PI3-kinase, 
NOS activity is also critical for postC protection. Tsang et al. (2004) and Zhu et al. (2006) 
found that the phosphorylation of endothelial NOS (eNOS) is dependent on the activity of 
PI3-kinase, indicating that NO production is downstream of PI3-kinase. Zhu et al. (2006) 
found that GSK-3ß (which links with the mPTP) seems to be downstream of PI3-kinase – 
PKB/Akt. Similarly, Tillack et al. (2006) demonstrated that the increased phosphorylation of 
GSK-3ß, associated with postC, is dependent on PI3-kinase activity. This link between 
PI3-kinase and the mPTP is nicely illustrated by Bopassa et al. (2006), who found that PI3-
kinase activity is not only necessary for postC protection, but it is also important in the 
postC-linked inhibition of the mPTP (as measured by analyzing the mPTP’s response to 
Ca2+ loading).  
 
The MEK1/2 – ERK p42/p44 pathway 
A number of studies have demonstrated a role for the ERK p42/p44 pathway in postC 
cardioprotection (Yang et al., 2004; Darling et al., 2005; Fujita et al., 2007; Morrison et al., 
2007), although results are not as straight forward as with the PI3-kinase – PKB/Akt 
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pathway. Just as is the case with PI3-kinase – PKB/Akt, all studies done on ERK p42/p44 
utilised either the MEK1/2 inhibitors PD-98059 or UO126, or measurement of 
phosphorylation or activity. Zhu et al. (2006) reported an elevation in ERK p42/p44 
phosphorylation, associated with postC, but interestingly they did not find increased in vitro  
ERK p42/p44 activity. Taken together with the increased activity of PKB/Akt and the 
dependence of postC cardioprotection on PI3-kinase, the authors concluded that only  PI3-
kinase – PKB/Akt is the dominant protective pathway in postC. 
 
Interestingly, Feng et al. (2006) and Chiari et al. (2005) found that isoflurane 
postconditioning is dependent on PI3-kinase – PKB/Akt activity, although Feng and 
colleagues (2006) did not observe any relationship between isoflurane postC and ERK 
p42/p44 phosphorylation. 
 
More interesting facts on the role of the RISK pathway in postC 
In H9c2 cardiac muscle cells Zhao et al. (2006) report that blockade of the mK+ATP-channel 
lead to a loss of postC protection, as well as a decrease in the levels of mitochondrial 
phosphorylated PKB/Akt and ERK p42/p44. This means that the mK+ATP-channel is 
upstream of the survival kinases, and might stimulate their translocation from the cytosol to 
the mitochondria. These observations, combined with an observed decrease in Bax and 
upregulation of Bcl-2 in the mitochondria, associated with postC, suggest that the RISK 
kinases act in the mitochondria to inhibit apoptosis. 
 
There is only one study showing the significance of the RISK pathway in human tissue: 
Sivaraman et al. (2007) found that postC protection of isolated human atrial tissue was lost 
with the inhibition of PI3-kinase and MEK 1/2 - ERK p42/p44.  
 
Schwartz & Lagranha (2006) investigated the role of the RISK kinases, in postC, in the 
porcine heart. They observed an increased phosphorylation of both ERK p42/p44 and 
PKB/Akt, associated with postC, which however, was not associated with a reduction in 
IFS. This anomaly implies that the activity of the RISK pathways, although important, might 
not be the single most critical component of postC protection in the in vivo setting.  
 
It therefore seems reasonable to conclude that the RISK pathway is indeed recruited in 
postconditioning, as a central pathway mediating protection. There are however studies 
which did not show the involvement of both, or even any, of the PI3-kinase – PKB/Akt or 
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MEK1/2 – ERK p42/p44 pathways. An explanation for these contradictory observations is 
not readily available, but it seems as if the RISK pathway might not be the only and most 
critical component of postconditioning. 
 
1.4.2.8. The role of pH 
The knowledge that transient acidosis confers a degree of protection is not new. Kitakaze 
et al. published  a paper in 1988 in which they report that reperfusion with an acidic 
perfusate (pH 6.6 or 7.0) after 15 minutes of ischaemia protected the isolated ferret heart 
against stunning. They attributed this protection to the blunting of the effect of Ca2+ 
overload, under acidic conditions. Hori et al. (1991) linked acidosis with staged 
reperfusion. In their model they found that staged increase in perfusion pressure over the 
first 10 minutes of reperfusion, conferred protection against stunning. They found this 
protection to be closely related to pH, with a decrease in pH eliciting protection and an 
increase in pH inhibiting staged reperfusion protection. Recently two research groups 
reported links between postC and transient acidosis. Fujita and colleagues (2007) found 
that postC was associated with prolonged transient acidosis (as measured in the coronary 
venous blood), as well as the phosphorylation / activation of the RISK kinases PKB/Akt 
and ERK p42/p44. Interestingly, they found that increasing the pH (by infusing sodium 
bicarbonate (NaHCO3)) abrogated the cardioprotective effect of postC, as well as blocked 
the phosporylation of RISK. Cohen et al. (2007) also investigated the link between postC 
and acidosis by comparing postC with two different protocols of acidotic reperfusion. They 
found that both decreased infarct size, provided that the total time of intervention is 2 
minutes and the intervention is applied immediately at reperfusion. The authors 
hypothesize that postC protects through two equally important mechanisms: at initial 
reperfusion the prolonged acidosis keeps the mPTP closed (a link between acidosis and 
mPTP inhibition has been shown (Petronilli et al. (1993)), while gradual reperfusion is still 
occurring which can then activate a redox sensitive survival pathway – which then 
permanently inhibits opening of the mPTP. 
 
1.4.2.9. Other possible role-players in postC 
There are also other molecules that have been identified as possibly involved in postC, 
although they have not received as much attention.  
 
Boengler et al. (2007) report that postC protection is lost in STAT3 (signal transducer and 
activator of transcription 3)-deficient mice, implicating a role for STAT3. They link this to 
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the loss of postC protection which they observed in old wild-type mice, since they found 
that older mice also present with decreased levels of STAT3.  
 
Jiang et al. (2005) found that postC was associated with a decrease in the expression of 
tissue factor (TF) and the inhibition of thrombin activity in the area at risk. This means that 
postC could also exert its protective effect by inhibiting the TF-thrombin pathway. 
 
It is also interesting to note that postC does not  confer cardioprotection in old (Boengler et 
al., 2007), hypercholesterolemic (Zhao et al., 2007) or metabolic syndrome hearts 
(Reubner et al., 2006). This is similar to reports concerning the effects of aging and 
hyperlipidemia in IPC protection (Juhaszova et al., 2005; and Ferdinandy 2003). It seems 
these conditions attenuate the cardioprotective potential of endogenous protection 
mechanisms. Interestingly, Reubner et al. (2006) found that postC in a rat strain with 
metabolic syndrome (Wistar-Ottawa-Karlsburg-W-rats (WOKW)) could not elicit an 
increase in the phosphorylation of GSK-3β, suggesting that metabolic syndrome blocks 
postC cardioprotection by inhibiting its signal transduction pathway. These findings could 
limit the clinical application of postC, or postC mimetics.  
1.5. Phosphatases in ischaemia / reperfusion 
In all cells there is a balance between the levels of phosphorylated and unphosphorylated 
proteins. This balance is controlled by two broad classes of enzymes: kinases (which 
phosphorylate proteins) and phosphatases (which dephosphorylate proteins). This balance 
is of importance, since in many cases the phosphorylation state of a protein determines 
the activity of that protein. As illustrated in the previous section, research has largely 
focussed on the role and importance of kinases in the setting of ischaemia / reperfusion. 
However, the role of the phosphatases in this setting has received much less attention. 
This section will primarily focus on the serine / threonine phosphatases type 1 and type 2A 
(PP1 and PP2A). For a review on the serine / threonine phosphatases, including types 2B 
and 2C see Wera & Hemmings (1995). A more recent review by Gallego & Virshup (2005) 
focusses on the regulation of specifically PP1, PP2A and PP5.  
 
An example of the importance of the phosphatases in cardiac physiology is illustrated by 
Carr et al. (2002). They found that a shift in the kinase / phosphatase balance (by 
overexpressing PP1 in murine hearts) was associated with a reduction in cardiac function, 
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dilated cardiomyopathy and premature mortality. They speculate that changes in PP1 
activity could also be involved in the pathology of heart failure in humans, and that these 
changes might be due to dysfunctional regulation of  PP1 – which is itself also dependent 
on phosphorylation / dephosphorylation reactions. 
1.5.1. Phosphatases and protection 
It seems that phosphatase inhibition is generally associated with an improvement in the 
outcome of ischaemia / reperfusion (Xiuhua et al., 1997; Weinbrenner et al., 1998 and 
1998; Armstrong et al., 1998; Barancik et al., 1999). This is illustrated by the study of 
Isotani et al. (2002), who reported that the phosphatase inhibitor okadaic acid (OA) 
protected rat kidneys against  ischaemia / reperfusion injury, when administered early 
(within the first few minutes) in reperfusion. However, contradictory observations have 
been made. For example, Hausenloy et al. (2002) utilised cyclosporin A (CsA) to 
investigate the role of the mPTP in ischaemic preconditioning. CsA is an inhibitor of mPTP 
activity and associated with cardioprotection, but also inhibits the phosphatase calcineurin 
(also known as PP2B). To determine whether calcineurin inhibition was responsible for 
CsA-induced cardioprotection, FK506 was administered, which also inhibits calcineurin, 
without acting on the mPTP. Their results indicated that FK506 did not induce a decrease 
in infarct size, when given in reperfusion (5 minutes before the onset of reperfusion, for the 
duration of 20 minutes), clearly excluding calcineurin inhibition as a protective intervention 
during reperfusion. However, Weinbrenner et al. (1998) found that FK506 exerted a potent 
infarct sparing effect, when administered from 15 minutes before 30 minutes ischaemia 
until the end of ischaemia. It seems that the timing and / or duration of phosphatase 
inhibition might be determining factors in the eventual effect of an inhibitor.  
 
Ladilov et al. (2002) found that PP1 and PP2A has contrasting effects on tissue damage 
and cell survival. They found that inhibition of PP2A only (by administration of a low dose, 
5 nmol/L, of okadaic acid before sustained ischaemia) increased the protective effets of a 
hypoxic preconditioning (HP) protocol. When both PP1 and PP2A were inhibited (with 
cantharidin administered before ischaemia, in the presence or absence of HP), all 
protection against functional deterioration or intracellular Ca2+ loading (in isolated 
cardiomyocytes) was lost. The authors concluded that PP1 could be a mediator of HP-
protection, in contrast to PP2A activity, which exerts a detrimental effect on HP-protection.  
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1.5.2. Phosphatase activity and ischaemia / reperfusion 
It is possible that protection against ischaemia / reperfusion damage by inhibition of 
phosphatases, is mediated by an increase in the phosphorylation states of various pro-
survival proteins in the cell. Conversely, phosphatase activity per se could be protective if 
it mediates inactivation (through dephosphorylation) of pro-death effectors. The big 
question is which proteins are involved. 
 
Calcium (Ca2+) homeostasis 
In the study by Carr and colleagues (2002) mentioned earlier, they demonstrated that it is 
possible that overexpressed PP1 exerts its effects on the level of the sarcoplasmic 
reticulum (SR), by decreasing the level of phosphorylation of phospholamban (PLB), and 
in doing so contributing to a dysregulation of Ca2+ transport. Phosphorylation of 
phospholamban regulates the activity of the sarcoplasmic reticulum Ca2+-ATPase 
(SERCA) by alleviating its inhibition of SERCA (Kim et al., 1990; Brittsan, et al., 2000), 
with a resulting increase in Ca2+ movement out of the cytosol into the SR. 
 
This interaction between phosphatase activity and Ca2+ regulation was also noted by 
Neumann and coworkers.  In 1993 they found that okadaic acid (OA; a PP2A inhibitor) 
exerted a postive inotropic effect on isolated guinea-pig papillary muscles, associated with 
an increase in the phosphorylation of, amongst other proteins, PLB, troponin inhibitor (TnI) 
and myosin light chains (MLC). Similar effects were also reported to be elicited by 
cantharidin (Neumann et al., 1995; Boknik et al. 2002).  
 
Schaffer & Punna (1993) made the observation that the rat heart sarcolemma has a high 
activity of both PP1 and PP2A, which contributes to the regulation of Ca2+ pump activity. In 
corroboration of this, Neumann and colleagues found that (besides PLB modulation) both 
OA and cantharidin increased the sarcolemmal Ca2+ channel current (Neumann et al, 
1993; and 1995), although canthadirin exerted only a weak modulatory effect on the L-type 
Ca2+ channel (Neumann et al., 1995). It should be kept in mind that the effects associated 
with an inhibitor is also potentially determined by the cell system being studied. In this 
regard, Knapp et al. (1998) found that cantharidin did not increase intracellular Ca2+ levels 
in arterial smooth muscle cells, contrary to the observations reported in cardiomyocytes 
(Neumann et al., 1995). 
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It could also be speculated that phosphatases influence Ca2+ homeostasis through other 
ion-channels and transporters. In this regard Chen et al. (1995) found that phosphatases 
similiar to PP2A and calcineurin dephosphosphorylates sodium  (Na+) channels in the rat 
brain, which then leads to an increase in current through these channels. It is noteworthy 
that Ladilov (2002) speculated that the protection conferred by HP might be via regulation 
of Na+ overload. 
 
Structural maintenance 
Another possible explanation for the protection induced by phosphatase inhibition is via its 
effects on structural integrity. During anoxia there is a progressive reduction in protein 
phosphorylation, probably due to the decrease in substrate (ATP) levels, as well as a 
reduction in kinase activity, while the phosphatases remain active (Kobryn & Mandel; 
1994). Preservation of cytoskeletal phosphorylation, through inhibition of phosphatases, 
may therefore increase a cell’s resistance against ischaemic injury. 
 
Fernandez et al. (1990) illustrated that PP1 is involved in regulation of actomyosin 
filaments. In their model PP1 inhibition (by OA) protected nonmuscle cells against A-
kinase induced actin reorganization. Armstrong et al. (1997 & 1998) found that the 
administration of phosphatase inhibitors (such as OA, calyculin A and fostriecin) 
immediately before, or during, an anoxic insult, could protect isolated cardiomyocytes, 
suggesting that this could be due to a decrease in the dephosphorylation of structural, or 
cytoskeletal, proteins during anoxia. In support of Armstrong et al.’s speculation, 
Loktionova & Kabakov (1993) found that both OA and cantharidin increased the stability of 
ATP-depleted endothelial cells’ cytoskeleton, prevented F-actin degradation and preserved 
cell morphology. The authors attributed these observations to the arrest of HSP27 (heat 
shock protein 27; a protein associated with actin resistance against various stressors) 
dephosphorylation. 
 
Preservation of the activity of pro-survival proteins and kinases 
Weinbrenner et al. (1998) found fostriecin (used at a concentration to inhibit PP2A) to be 
protective (as demonstrated by a decrease in IFS in the isolated rabbit heart), even when 
administered during ischaemia. They suggest that this protection could be due to an 
increase in the phosphorylation state of a substrate in a protective signal transduction 
pathway, possibly PKC-specific substrate. Intriguingly, Armstrong and colleagues (1998) 
however found that fostriecin protection was independent of PKC activation. Xiuhua et al. 
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(1997) also speculated that OA protection could be mediated through an increased 
phosphorylation of PKC.  
 
Protection through an increase in the phosphorylation of proteins, recruited in survival 
kinase pathways, could therefore also contribute to protection. In this regard, Armstrong et 
al. (1997) found that blockade of the mitochondrial K+ATP-channel (by 5-hydroxydecanoate) 
attenuated fostriecin-mediated protection in pig cardiomyocytes (this dependence on the 
mK+ATP-channel could however not be demonstrated in rabbit myocytes).  
 
Calyculin A (an inhibitor of PP1 and PP2A) administration before or during anoxia, has 
been implicated in both myocardial cell protection, as well as an increase in 
phosphorylation of p38 MAPK and HSP27 (Armstrong et al, 1998; and 1999).  This 
protection was lost with the administration of a p38 MAPK inhibitor (SB203580). The role 
of p38 MAPK phosphorylation in protection is however controversial. Mackay & Mochly-
Rosen (2000) found that inducing increased phosphorylation of p38 MAPK during anoxia, 
using the tyrosine phosphatase inhibitor vanadate, increased cardiomyocyte susceptibility 
to ischaemic injury. In the setting of IPC, it has been found that, a decrease in p38 MAPK 
phosphorylation during ischaemia and reperfusion is in fact associated with 
cardioprotection (Marais et al., 2005; and Moolman et al., 2006). Barancik et al. (1999) 
found that administration of OA, before a regional ischaemic insult in an in vivo swine 
model, conferred an infarct sparing effect, associated with an increase in the 
phosphorylation and activity of JNK. The inhibitor, however had no effect on the 
phosphorylation and activity of either p38 MAPK or ERK p42/p44. It is clear that a great 
deal of confusion and uncertainty still prevails regarding the role of p38 MAPK in the 
setting of ischaemia / reperfusion. 
 
1.5.3. Phosphatases in ischaemic preconditioning 
In light of the above discussed, it is logical that many studies (including some already 
mentioned) have focussed on the possibility that phosphatases are somehow involved in 
preconditioning. Weinbrenner et al. (1998) however found that although PP2A inhibition 
per se had an infarct sparing effect comparable to IPC, neither PP1 nor PP2A was 
inhibited in preconditioned hearts. Despite these findings, it is conceivable that 
phosphatase activity could modulate IPC. This was demonstrated by Fenton and 
colleagues (2005). By applying OA (at a concentration to inhibit both PP1 and PP2A) 
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during the preconditioning stimulus, the effectiveness of the IPC protocol was restored in 
old rat hearts. It is noteworthy that OA (on its own) could only confer cardioprotection in 
the old hearts when administered both before and after ischaemia. In young hearts 
however, OA in reperfusion alone was sufficient. This indicates the existence of a 
protection threshold, which must be overcome before an intervention (such as 
phosphatase modulation) can successfully elicit cardioprotection. 
 
Except for the possible modulation of the phosphorylation status of proteins already 
mentioned, Cai & Semenza (2005) also investigated PKB/Akt activity in preconditioning. It 
should be noted that PKB/Akt activity is largely regulated by PI3-kinase / PTEN 
(phosphatase and tensin homologue deleted from chromosome 10). Cai and Semenza 
(2005) found that IPC induces down regulation of PTEN during sustained ischaemia. This 
then (together with the oxidative inactivation of residual PTEN in reperfusion) favoures the 
activation of PKB/Akt – which mediates cardioprotection. Besides the role of PTEN, PP2A 
has also been implicated as a regulator of PKB/Akt activity (Andjelkovíc et al., 1996). 
 
1.5.4. Conclusion 
Most studies on the subject have found that the inhibition of phosphatase activity during, or 
just before, ischaemia / reperfusion confers cardioprotection – suggesting a deleterious 
role for PP1 and PP2A in this setting. Mechanisms for this observed protection probably 
involves the preservation of, or increase in, the phosphorylation levels of certain proteins 
involved in cell survival. Modulation of the activity of these proteins could have an effect on 
structural stability, ion homeostasis, and the activation of pro-survival pathways. 
Unfortunately the lack of suitably specific phosphatase inhibitors has hampered efforts to 
identify the roles of specific phosphatases and proteins. Therefore, the precise role of the 
phosphatases in cell survival in ischaemia / reperfusion, as well as their importance in the 
mechanisms of known cardioprotective interventions such as IPC and postC, is still a topic 
of ongoing investigation. 
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1.6. Motivation and aims of this study 
Since it was described in 2003, a large amount of research has been done on the 
phenomenon of postconditioning. As discussed in the preceding literature review, PostC 
cardioprotection has been demonstrated in all species tested and in various experimental 
setups. There are however, still discrepancies concerning the precise algorithms 
associated with cardioprotection. Although the retrogradely perfused (Langendorff) 
isolated rat heart has been widely used in postC research, investigations in the setting of 
the isolated working heart model is lacking, with only one reported study (Sasaki et al., 
2007). 
 
Concerning the mechanisms by which postC protects, most reasearch has been aimed at 
the pro-survival mechanisms known to be active in IPC, such as adenosine, PKC, the 
mK+ATP-channel, etc. Despite the focus on the roles of pro-survival kinases in postC, much 
less has been published on the involvement of other kinases and no work has been done 
on the possible role of the phosphatases. In fact, relatively little research has been done 
on the phosphatases in ischaemia / reperfusion per se.  
 
The aim of this study was therefore to contribute to some of these outstanding issues by: 
1. Development of an effective cardioprotective postC protocol in the isolated rat 
heart, using both the Langendorff and working heart models. End-points 
investigated were infarct size and functional recovery.  Comparing postC in these 
two models could shed light on the factors that determine the efficacy of postC 
under different conditions. 
2. Characterization of the signalling kinase profiles associated with postC, at different 
time points in reperfusion, in the two perfusion models. We focused our 
investigation on the widely publicized RISK pathway (i.e. PKB/Akt and ERK 
p42/p44), as well as the less investigated (in the setting of postC) p38 MAPK.  
3. Investigation of the possible role of the phosphatases, PP1 and PP2A, in 
postconditioning and ischaemia / reperfusion per se. This was done by 
investigating the effect of co-administration of the PP1 and PP2A inhibitor, 
cantharidin, on postC-induced cardioprotection, using infarct size and activation of 
PKB/Akt, ERK p42/p44 and MAPK p38 as end-points. 
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Chapter 2: Material and Methods 
 
“The heart is deceitful above all things 
and beyond cure. 
Who can understand it?” 
 
Jeremiah 17:9 
The Bible 
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Chapter 2: Material and methods 
This study can be divided into three sections. The methods used in each section will be 
descibed separately. They are: 
1. The development of a cardioprotective postconditioning protocol. 
2. Analysis of the involvement of the reperfusion injury salvage kinase (RISK)-
pathway in the setting of postconditioning. 
3. The effect of a phosphatase inhibitor in the setting of postconditioning and 
reperfusion. 
2.1. Animals 
Male Wistar rats, weighing between 210 and 350 g, were used. Animals were given free 
access to food  and water until the time of experimentation. All rats were anaesthetized by 
administration of an intra-peritoneal injection of pentobarbital, at a dose of approximately 
80 mg / rat.  
 
All experiments were done in accordance to the “Guide for the care and use of laboratory 
animals” published by the US National Institutes of Health (NIH publication no 85–23, 
revised 1985). The project was also approved by the Ethics committee of the University of 
Stellenbosch (Faculty of Health Sciences). 
2.2. Perfusion technique of the isolated rat heart 
Following proper sedation, hearts were rapidly excised and arrested in ice-cold Krebs 
solution. Immediately thereafter, the aortas were cannulated and in all instances the hearts 
were perfused with Krebs-Henseleit bicarbonate buffer, containing (in mM): NaCl 119; 
NaHCO3 24.9; KCI 4.74; KH2PO4 1.19; MgSO4 0.6; Na2SO4 0.59; CaCl2 1.25 and glucose 
10.  The buffer was continuously gassed with a 95 % O2 / 5% CO2 combination in order to 
ensure adequate oxygenation of the buffer and also to maintain a pH of 7.4. The 
temperature of the heart was monitored by inserting a temperature probe into the coronary 
sinus. Two different modes of perfusion were employed, namely retrograde Langendorff 
perfusion (the balloon model) and the working heart model. In both models a basic 
protocol of 30 minutes stabilisation, variable time periods of ischaemia and a total of 30 
minutes reperfusion, was followed.  
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2.2.1. Retrograde Langendorff perfusion (Balloon model) 
In this model the aorta was cannulated and hearts retrogradely perfused with Krebs-
Henseleit bicarbonate buffer at a pressure of 100 cmH20. Temperature was maintained at 
approximately 37 °C during stabilisation, ischaemia and reperfusion.  
 
A water filled cling-film balloon, connected to a pressure transducer (Viggo Spectromed), 
was inserted into the left ventricle, via the left atrium. By setting the pressure in this 
balloon, the end-diastolic pressure was maintained between 0 and 10 mmHg. Myocardial 
function was quantified in terms of heart rate (HR) and left ventricular developed pressure 
(LVDP). The LVDP can be defined as the difference between the measured systolic 
pressure and the set diastolic pressure. These functional parameters were recorded on a 
computerized system throughout the duration of the experiment. Another important 
functional parameter that was used, is the rate pressure product (RPP, i.e. LVDP x HR).  
2.2.2. The working heart model 
After mounting the aorta onto the aortic cannula, the pulmonary vein of the heart was also 
cannulated. The heart could then be perfused either retrogradely or in the working heart 
mode. The term “work” refers to the heart functioning against a set afterload of 100 cmH20 
and a preload of 15 cmH2O (applied through the pulmonary vein cannula). Hearts were not 
electrically paced.  
 
Functional parameters monitored in this model were the intra-aortic pressure and heart 
rate, as well as the coronary and aortic flow rates. The intra-aortic pressure and heart rate 
were measured with a pressure transducer (Viggo Spectromed) inserted into the aortic 
cannula. Data were recorded on a computerized system and left ventricular work 
performance calculated using the formula described by Kannengieser et al. (1979): 
 
  0.002222 (PAO – 11.25)(CO) 
  where, PAO = aortic pressure 
   CO  =  cardiac output (aortic output + coronary flow rate) 
 
Coronary and aortic flow rates were manually measured by timed collection of the 
perfusate passing through the coronary system and the aorta (during work mode).  
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The temperature of the hearts was monitored to ensure that it did not rise above 37 °C 
during work. Temperature was maintained at approximately 36.5 °C during the ischemic 
period and elevated to 37 °C during reperfusion. 
2.3. Application of ischaemia 
As will be expanded on later in this chapter, different protocols required different modes of 
ischaemia. These different modes of ischaemia are as follows: 
¾ Global ischaemia (GI) This refers to total cessation of coronary perfusion to the heart. 
This was achieved by perfusion of the heart in the Langendorff mode and closure of 
the aortic cannula.  
¾ Regional ischaemia (RI) In this form of ischaemia, only the left coronary artery was 
ligated. This was done by ensnaring the proximal part of the left coronary artery using 
a silk suture, in such a way that it could be loosened again to reperfuse the affected 
tissue. This was done by tightening the snare using two pieces of interlocking tubing. 
Occlusion of the artery was confirmed by measuring the resultant reduction in the 
coronary flow. This form of ischaemia is used for the determination of infarct size.  
2.4. Determination of infarct size 
At the end of the RI experiments the left coronary artery, which at this stage was open to 
allow reperfusion, was securely ligated again. This was followed by the slow infusion of 
Evans Blue suspension (0.5 %) into the heart, via the cannulated aorta. By doing this the 
Evans Blue solution is forced through the coronary arteries that are still open and 
unaffected by the occlusion. Care was taken to ensure that a sufficient volume of Evans 
Blue (between 0.5 and 1.0 ml) was infused to clearly delineate the area affected by the 
closed suture from the rest of the ventricular tissue. The heart was then removed from the 
system and frozen overnight, before being sliced into thin slices of equal thickness (about 
2 mm). These slices were then stained by incubation in 1% w/v triphenyltetrazolium 
chloride (TTC) in phosphate buffer (pH 7.4) for 15 minutes, at room temperature. Pitts et 
al. (2007) describes this as a staining reaction in which the TTC reacts with active 
dehydrogenases in the viable tissue to form a brick-red precipitate. The slices were then 
removed from the TTC-buffer solution and fixed in a 10% v/v formaldehyde solution. This 
was done in order to enhance the contrast between the stained and unstained areas. At 
this point the damage to each slice of tissue becomes visible: the blue area showed viable 
and undamaged tissue, the white, unstained area was dead, infarcted tissue and, together 
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with the surrounding brick-red area, indicated the area at risk. Quantification of the 
different surface areas was done by using planimetry. The areas of the tissue slices were 
then summated to determine the infarct size (IFS) and area at risk (AR) for the whole left 
ventricle. Infarct size was expressed as a percentage of the area at risk. Planimetry was 
done using the UTHSCSA ImageTool program (developed at the University of Texas 
Health Science Center at San Antonio, Texas), which is available from the internet at 
http://ddsdx.uthscsa.edu/dig/itdesc.html. 
 
2.5. Western blot analysis 
As will be described in more detail later in the text, hearts were freeze–clamped at different 
time points in reperfusion using precooled Wollenberger tongs, whereafter the tissue 
samples were plunged into and stored in liquid nitrogen. These collected tissue samples 
were then used for protein identification and quantification analysis as follows: 
 
Protein extraction:  Frozen tissue samples were initially pulverized in a stainless steel 
mortar under liquid nitrogen cooled conditions, whereafter further homogenization was 
done (using a Polytron homogenizer) in lysis buffer. The lysis buffer contained (in mM): 
Tris-HCL (pH 7.5) 200; EGTA 10; EDTA 100; sodium chloride (NaCl) 1000; β-
glycerophosphate 1; tetrasodiumpyrophospate 2.5; sodium vanadate (Na3VO4) 10; 
phenylmethylsulphonylfluoride (PMSF) 100; leupeptin 10 μg/ml; aprotonin 10 μg/ml; Triton 
X-100 1%. Following homogenization, samples were centrifuged at 1000 g for 10 minutes. 
The supernatant was then separated from the pellet and used for further experimentation. 
 
The amount of proteins extracted was quantified using the Bradford technique (Bradford; 
1976). The lysis samples were then diluted in Laemmli sample buffer to a final protein 
concentration of 2.2 μg/μl. The final samples were then boiled for 5 minutes and stored at 
–20 ºC. 
 
Protein separation: Proteins were separated according to their molecular weight using a 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) setup. After brief 
boiling (see above) and centrifugation (to ensure all the samples were at the bottom of the 
eppendorff tubes) of the samples, 20 μg of protein from each sample was loaded in a 4 % 
stacking polyacrylamide gel and separated on either a 12 % (for p38 MAPK and ERK 
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p42/p44) or a 10 % (for PKB/Akt) polyacrylamide gel, using the standard Bio-RAD Mini-
PROTEAN II System.  
 
Western blotting: After separation, proteins were transferred from the gel to a 
polyvinylidene fluoride (PVDF) membrane (ImmobilonTM P, Millipore) in a tank 
electrotransfer setup. In this setup the membrane-gel stack is immersed in transfer buffer, 
through which electrical current is applied. The transfer buffer contained (in mM): Tris 25; 
glycine 192; methanol 20%. After transfer, membranes were regularly stained with 
Ponceau red (which is a reversible protein stain) to confirm that adequate transfer had 
taken place. 
 
Blocking of the membrane: Following transfer, the non-specific protein binding sites on 
the membrane were blocked by incubating the membrane in a 5% fat-free milk in Tris-
buffered saline (TBS)-0.1 % Tween 20 solution for at least one hour.  
 
Incubation with antibodies: In all experiments p38 MAPK, ERK p44/p42 and PKB/Akt 
were investigated. Membranes were therefore probed with primary antibodies directed 
against: total p38 MAPK and dual phospho-p38 MAPK (Thr180/Tyr182); total ERK 
p44/p42 and phospho-ERK p44/p42 (Thr202/Tyr204); total PKB/Akt and phospho-PKB/Akt 
(Ser473). All antibodies used were from Cell Signalling Technology. Primary antibodies 
were diluted in TBS-Tween solution (1:1000) and incubated with the membranes for at 
least 5 hours. 
 
Following primary antibody-binding, membranes were incubated for 1 hour in an ECL anti-
rabbit immunoglobulin G, Horseradish peroxidase-linked (from donkey) secondary 
antibody (Amersham), diluted in TBS-Tween solution (1:4000). This conjugated antibody 
then bound to the already bound primary antibody. 
 
Membranes were briefly rinsed with 3 changes of TBS-Tween, followed by at least 4 x 5 
minutes washing with large volumes of TBS-Tween solution after blocking, between 
antibody incubations, and before final visualisation.  
 
Visualisation: After incubation with the secondary antibody, membranes were covered 
with ECLTM detection reagents for 1 minute, and then exposed to an autoradiography film 
(Hyperfilm ECL, RPN 2103). The detection reagents react with the Horseradish peroxidase 
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(linked to the secondary antibody) in a luminescence reaction and the resulting light 
emmision is “captured” on the radiography film.  
 
Films were then densitometrically analysed (UN-SCAN-ITTM version 5.1, Silkscience). For 
comparison purposes, samples from negative control hearts (exposed to only 30 minutes 
perfusion) were included in each blot and used for normalization of the unknown samples 
(i.e. calculation of the ratio between the sample and negative control). Normalized data 
was expressed in arbitrary units (AU). 
2.6. Statistical analysis 
All results are given as mean ± standard error of the mean (SEM). Where only two 
parameters were compared, comparisons were done with an unpaired T-test. For 
comparison of multiple parameters, one-way analysis of variance (ANOVA) was applied, 
followed by the Bonferroni correction as post hoc test. P values of < 0.05 was considered 
significant.  
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Chapter 3: Development of a cardio-protective 
protocol 
 
 J Appl Physiol 2007; 103:1441–1448. 
 
Vinten-Johansen J, Zhao Z-Q, Jiang R, Zatta AJ, Dobson GP. 
“The entire question of the optimal algorithm and 
durations of reperfusion and ischemic segments of 
the PoC (postconditioning) stimulus is open." 
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 Chapter 3: Development of a cardioprotective protocol 
3.1. Background and motivation 
A relatively large number of studies have already been done on postconditioning of the rat 
heart. Most of these studies have also shown that postconditioning can confer 
cardioprotection in the rat heart, both ex vivo, as well as in vivo. It is however, also clear 
from the studies reported, that some groups experienced difficulties in eliciting protection, 
suggesting that the rat heart may be sensitive to the postC protocol employed. A general 
overview of postconditioning work that has been done in specifically the rat heart is 
summarised in table 1. 
 
The first phase of this project therefore logically entailed the development of a 
postconditioning protocol in the ex vivo rat heart, capable of eliciting a significant degree of 
cardioprotection. Up to date all studies published on postconditioning in the isolated rat 
heart, except one, utilised a retrogradely perfused Langendorff setup. Sasaki and 
coworkers (2007) utilised a working heart setup to investigate a unique postconditioning 
protocol of 1 minute reperfusion and 5 minutes ischaemia. Although this protocol protected 
against reperfusion arrythmias, they could not demonstrate increased functional recovery 
or a reduction in cell damage (as measured by CK release). Therefore, since research on 
postconditioning in the working ex vivo heart is lacking, we foucussed our investigation on 
postconditioning in our working heart setup. A number of different postC protocols were 
applied and their efficacy evaluated in terms of functional recovery during reperfusion and 
infarct size. The protocol that showed the most potential in the working heart, was also 
evaluated in the retrograde perfusion (Langendorff) model. 
 
During the course of our study, we realised that there were three different variables that 
had to be considered in the establishment of a postconditioning protocol. These variables 
and our experimental approaches are summarized in table 2. 
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Table 1: Summary of studies done on postconditioning in the rat heart. Although most of 
these could demonstrate a cardioprotective role for postconditioning, there are still 
discrepancies in the literature.For a more detailed discussion, see chapter 1. 
 
Authors Model 
used 
End-point  PostC protocol Success 
Kin et al., 2004 In vivo Infarct size 3 or 6 x 10 sec Yes 
Wang et al., 2007 Ex vivo 
Functional 
recovery 6 x 10 sec Yes 
5 x 10 sec Yes 
Penna et al., 
2006 Ex vivo Infarct size 
Reperfusion:15, 
20, 25, 30 sec 
Ischaemia: 20, 15, 
10, 5 sec 
Yes 
6 x 10 sec Yes 
20 x 10 sec Yes Tang et al., 2006 In vivo Infarct size 
60 x 10 sec No 
Manintveld et al., 
2007 In vivo Infarct size 3 x 30 sec Yes 
Bopasse et al., 
2006 Ex vivo 
Markers of 
necrosis 3 x 30 sec Yes 
Galagudza et al., 
2004 Ex vivo Fibrillation 
2 minutes 
ischaemia after 15 
minutes 
reperfusion 
Yes 
4 x 10 sec No 
4 x 20 sec No 
8 x 30 sec No 
Dow & Kloner, 
2007 In vivo Infarct size 
20 x 10 sec No 
Crisostoma et al., 
2006 Ex vivo 
Functional 
recovery 6 x 10 sec Yes 
In vivo Infarct size 3 x 10 sec 
Yes in one 
of two 
laboratories
3 x 10 sec No 
3 x 30 sec No 
2 x 60 sec No 
Kaljusta et al., 
2007 
Ex vivo Infarct size 
6 x 10 sec No 
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Table 2: The different variables that were taken into consideration in the development of a 
cardioprotective postC protocol in the ex vivo rat heart, in our laboratory. 
 
Variable Options 
35 minutes of regional ischaemia induced 
by coronary ligation. 
Time and mode of ischaemia 
20 or 25 minutes of global no-flow 
ischaemia. 
36.0 – 36.5 °C.   Temperature during ischaemia and initial reperfusion (first 10 minutes) 
36.5 – 37.0  °C. 
6 × 10 seconds applied regionally, i.e via 
the suture ligating the coronary artery 
6 × 10 seconds applied globally, i.e via 
manipulation of global flow to the heart. 
3 × 30 seconds applied regionally or 
globally. 
3 × 20 seconds applied regionally. 
Postconditioning cycles 
4 × 15 seconds applied globally. 
 
3.2. Materials and methods 
As previously described: male Wistar rats between 210 and 350 g were sacrificed, the 
hearts rapidly excised and aortas cannulated. Hearts were perfused with Krebs-Henseleit 
buffer for the duration of the experiment, except for periods of global no-flow ischaemia.  
 
Both infarct size, as well as functional recovery, were investigated as end-points. The 
basic perfusion protocol that was applied consisted of a 30 minute stabilisation period 
before an ischaemic insult, which was followed by 30 minutes of reperfusion. All 
postconditioning protocols were applied at the very onset of reperfusion, without any delay. 
To facilitate the interpretation of the data, the relevant protocols are described in the 
“Results” section. 
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3.3. Results 
3.3.1. The working heart model 
3.3.1.2. Global ischaemia 
Initially we focused our investigation on developing a postC protocol that could elicit an 
increase in functional recovery of the working rat heart. To do this we applied either a 25 
or a 20 minute period of no-flow global ischaemia (temperature 36.5 °C), followed by either 
uninterrupted reperfusion (i.e. non-postconditioned; NonPostC), or 6 x 10 seconds 
reperfusion / ischaemia applied by manipulating the global coronary flow with the aortic 
cannula (postC). We chose this postC protocol since, it has been reported in various 
studies to confer cardioprotection.  
 
In this model two different sets of experiments were conducted: a 20 minute GI postC 
group, with its NonPostC control group, as well as a 25 minute GI postC group, with its 
corresponding NonPostC group (Fig. 1).  
25 minutes global ischaemia 
35 minutes regional ischaemia 
30 minutes reperfusion30 minutes 
stabilisation 
In the working heart model 
6 x 10 
PostC 
28 minutes reperfusion
PostC 
Control 
(NonPostC) 
30 minutes 
stabilisation 
30 minutes reperfusion25 or 20 minutes global 
ischaemia 
30 minutes 
stabilisation 
General perfusion protocol 
15 min 
20 min
20 min
25 or 20 minutes global 
ischaemia
Figure 1: Experimental protocol to investigate the ability of postC to increase post-ischaemic 
functional recovery in the working heart model, following a global ischaemic insult. 
Working heart 
perfusion 
15 min 
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It was decided to simplify data presentation by omitting coronary flow  (CF) data, except in 
instances in which a significant difference in functional parameters was present which 
might be influenced by the coronary flow rate. Both the postC (n=10), as well as NonPostC 
(n=9) groups, in the 25 minute GI study, generated acceptable aortic – and cardiac outputs 
before the onset of ischaemia (NonPostC group: AO = 38.56 ± 1.91ml/min, CO = 53.50 ± 
2.19 ml/min; postC group: AO = 41.70 ± 1.90 ml/min, CO = 56.95 ± 2.19 ml/min). The 
percentage recoveries of both of these parameters are shown in figure 2. NonPostC hearts 
recovered to an AO of 1.78 ± 1.35 ml/min and a CO of 9.56 ± 1.92 ml/min. This level of 
recovery was comparable to that observed in the PostC group (AO = 0.0 ml/min and CO = 
8.85 ± 0.8 ml/min).  
PostC 
Figure 2: Recoveries of aortic 
output (AO) and cardiac output 
(CO) associated with postC, after 
25 minutes of global ischaemia, in 
the working heart model. 
NonPostC 
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The recoveries in aortic output and cardiac output associated with postC after 20 minutes 
GI followed the same pattern (figure 3). The 20 minute GI postC group (n = 4), had a mean 
aortic output of 37.25 ± 2.056 ml/min, together with a cardiac output of 52.25 ± 3.62 ml/min 
at the end of stabilisation. The aortic output measured in the NonPostC group (n=4)  was 
47.25 ± 3.198 ml/min, with a cardiac output of 64.13 ± 3.25 ml/min. There were no 
significant differences in recovery between the NonPostC and PostC groups. In fact, in the 
NonPostC hearts AO recovered to 8.0 ± 6.06 ml/min, compared to a strikingly low post-
ischaemic AO in the PostC group of 1.5 ± 1.5 ml/min. Post-ischaemic CO in the NonPostC 
and PostC groups were 18.38 ± 6.63 ml/min and 10.50 ± 2.53 ml/min respectively.  
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The postC intervention we applied was disappointingly ineffectual at eliciting functional 
recovery after both 20 and 25 minutes of global ischaemia. This could be due to either a 
suboptimal postC algorythm, or the inherent inability of postC to protect against functional 
decline. To study postC in the working heart further we therefore decided to  investigate a 
slightly different ischaemic model. 
 
3.3.1.3. Regional ischaemia 
In view of our failure to elicit postconditioning in the globally ischaemic working rat heart, it 
was decided to switch from global ischaemia to regional ischaemia, using both functional 
recovery and infarct size as end-points. In all experiments where infarct size was used as 
end-point, 35 minutes of regional ischaemia was applied (by using a suture to occlude the 
coronary artery). Hearts were broadly divided into one of two groups: Either control hearts, 
which received uninterrupted full reperfusion after ischaemia (NonPostC), or 
postconditioned  hearts (postC). In this latter group a number of different postC protocols 
were applied at reperfusion (fig. 4).  
 
In addition to testing different postC algorythms, the best method of applying the postC 
reperfusion / ischaemia cycles also had to be determined. In this regard two possiblities 
were investigated: either manipulating the flow of perfusate to the heart as a whole, or 
manipulating the flow to only the tissue exposed to ischaemia. Manipulating the flow to the 
whole heart would technically be the easiest option, and it would mean that both the 
ischaemic and non-ischaemic myocardium would be exposed to the postC intervention. 
On the other hand, opening and closing the occluder would be more challenging, 
especially since it would impede effective thermal regulation during the postC intervention. 
0
10 Figure 3: Recoveries of aortic 
output (AO) and cardiac output 
(CO) in the presence and absence 
of postC, after 20 minutes of global, 
no-flow ischaemia. 
NonPostC PostC
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The advantage however, is that it would target only the tissue exposed to the ischaemic 
insult.  
25 minutes global ischaemia 
35 minutes regional ischaemia 
30 minutes reperfusion 30 minutes 
stabilisation 
Working heart 
perfusion 
20 min
Control 
(NonPostC) 30 minutes reperfusion35 minutes regional ischaemia Stabilisation 
PostC 
28 minutes reperfusion
PostC 
35 minutes regional ischaemia Stabilisation 
 Where postC:  
• 6 x 10 second R/I, either globally or on regional level. Either with, or without, thermal 
regulation. 
• 3 x 30 second R/I, either globally or regionally. 
• 3 x 20 second R/I, regionally applied. 
• 4 x 15 second R/I, on a global level. 
General perfusion protocol 
15 min 
20 min
In the working heart model 
Figure 4: Experimental protocol for the investigation of postC in the setting of regional ischaemia. 
All hearts underwent a 30 minute period of stabilisation, 35 minutes of regional ischaemia and a 
total of 30 minutes reperfusion. Different postC protocols were tested for their cardioprotective 
ability, as evaluated by infarct size and functional recovery. Protocols differed  in terms of number 
of cycles, duration of cycles and thermal regulation. 
15 min 
 
The following protocols were applied: 
¾ 6 x 10 second cycles of reperfusion and ischaemia, applied by opening and closing the 
snare around the coronary artery (i.e. on a regional level). Technically this required 
that, for the 2 minute duration of the postC protocol, the hearts were exposed to the 
cooler ambient room temperature. To correct for a possible thermal effect, two sets of 
controls were therefore perfused: one set with a temperature maintained at 
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approximately 36.5 °C, while the other set was also exposed to the ambient room 
temperature for the first 2 minutes of reperfusion. 
¾ 6 x 10 second cycles of reperfusion and ischaemia, applied by manipulating the total 
flow of buffer to the heart as a whole (i.e. on a global level). This protocol had the 
advantage that the hearts’ temperature could be maintained throughout the postC 
intervention (as the hearts remained in the waterbath-warmed environment after 
opening the suture). However, no rigorous temperature control was done at this stage. 
¾ 3 x 30 second cycles of reperfusion and ischaemia, applied either on a regional or a 
global level.  
¾ 3 x 20 second cycles of reperfusion and ischaemia, applied by directly manipulating the 
snare around the coronary artery (i.e. on a regional level). 
¾ 4 x 15 second cycles of reperfusion and ischaemia, applied by manipulating global flow 
to the heart. 
 
In all the above mentioned protocols temperature was maintained at an ischaemic 
temperature of approximately 36.5 °C, there was however no rigorous thermal control 
during reperfusion. 
 
¾ 6 x 10 second cycles of reperfusion and ischaemia, applied on a global level. This 
protocol differed from the above mentioned protocol in terms of its thermal control. In 
these hearts, the temperature during the postC protocol was maintained between 
approximately 36.5 °C and 37.3 °C. This was higher than the temperature during 
ischaemia (36.5 – 36.7 °C). It should be mentioned that  the temperature fluctuates 
significantly during the postC protocol, necessitating active regulation to maintain the 
temperature within certain limits. Control hearts (without postC intervention) were also 
maintained at elevated temperatures during especially the first two minutes of 
reperfusion. 
 
Initial results for the 6 x 10 second postC intervention, by opening and closing the coronary 
suture, are shown in figure 5. Two NonPostC groups were included: The first (NonPostC1) 
did not take possible temperature fluctuations during the postC intervention into 
consideration (n=4; AO before ischaemia: 32.50 ± 0.5 ml/min; CO before ischaemia: 48.00 
± 0.00 ml/min). Although the second NonPostC (NonPostC2) group (n = 7; AO = 36.57 ± 
1.50 ml/min; CO = 51.29 ± 1.94 ml/min) underwent the exact same procedure during 
reperfusion as the postC hearts (i.e.  exposed to ambient room temperature for the first 2 
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minutes of reperfusion), this did not lead to significant changes in infarct size (NonPostC1: 
26.46 ± 6.02% compared to NonPostC2: 33.61 ± 3.80%). Both NonPostC groups had 
similar area at risk values (NonPostC1: 42.70 ± 4.0% and NonPostC2: 53.19 ± 3.25%). 
The functional parameters in the postC group also fell within acceptable limits (n = 11; AO 
= 38.45 ± 1.63 ml/min; CO = 53.68 ± 1.80 ml/min).  
Figure 5: Infarct sizes when 6 x 
10 second postC cycles are 
applied on a regional level. 
NonPostC1 does not take 
temperature fluctuations during 
the initial reperfusion into 
account, while NonPostC2 
does. 
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Since no significant differences in infarct size were present, both of the NonPostC groups 
were combined as a single control group (n = 11; AO = 35.09 ± 1.12 ml/min; CO = 50.09 ± 
1.30 ml/min) for the other experiments where postC was applied on  a regional level.  
 
Two other regional postC protocols were tested: a 3 x 20 second protocol (n = 4; AO = 
37.00 ± 2.08 ml/min; CO = 54.35 ± 2.65 ml/min) and a 3 x 30 second intervention (n = 6; 
AO = 36.00 ± 1.37 ml/min; CO = 53.42 ± 1.28 ml/min). Infarct sizes for these protocols are 
shown in figure 6.  
 
NonPostC1 PostC NonPostC2 
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Figure 6: Infarct sizes 
associated with 3 x 20 
second and 3 x 30 second 
postC protocols, applied 
by manipulating the 
coronary artery occluder. 
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None of the three regional postC protocols were associated with a significant decrease in 
infarct size (figures 5 and 6: NonPostC: 31.01 ± 3.26%; 6 x 10 sec: 24.12 ± 5.22%; 3 x 20 
sec: 40.01 ± 6.27%; 3 x 30 sec: 25.31 ± 3.66%). Area at risk size was comparable between 
the four different groups (NonPostC: 49.37 ± 2.88%; 6 x 10 sec: 51.47 ± 4.35%; 3 x 20 sec: 
46.79 ± 4.88%; 3 x 30 sec: 47.69 ± 3.25%). These protocols conformed to the general 
protocol described in the literature (see chapter 1). We however found that none of these 
postC interventions could exert an infarct-sparing effect. From the three postC protocols 
tested it seems that the 6 x 10 sec protocol showed the most promise, since more than 
50% of the hearts subjected to this protocol presented with infarct sizes lower than 20%. 
 
In all postC protocols applied regionally, no significant differences in functional recovery 
were observed between postC and NonPostC hearts (i.e. recovery in aortic output and 
cardiac output). Functional data is shown in table 3.  
 
As with infarct size reduction, although  no significant differences were observed, the postC 
6 x 10 sec protocol showed the most potential to increase functional recovery (6 x 10 sec: 
AO recovery = 46.58 ± 9.27%, CO recovery = 60.45 ± 7.80%; compared to NonPostC: AO 
= 34.47 ± 7.02%, CO = 52.94 ± 5.44%; 3 x 20 sec: AO = 20.88 ± 5.68%, CO = 44.60 ± 
3.66%; and 3 x 30 sec: AO = 21.17 ± 6.31%, CO = 43.78 ± 5.69%). 
 
3 x 30 sec 
PostC 
NonPostC 
PostC 
3 x 20 sec 
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Table 3: Functional data before and after sustained ischaemia in the presence of different 
postC interventions, applied regionally. No significant differences were present between 
the groups. AO: aortic output; CO: cardiac output.  
 
Protocol 
Baseline AO 
(ml/min) 
Post-ischaemic 
AO (ml/min) 
Baseline CO 
(ml/min) 
Post-ischaemic 
CO (ml/min) 
NonPostC 35.09 ± 1.12 12.18 ±2.64 50.09 ± 1.30 26.59 ± 2.95 
6 x 10 sec 38.45 ± 1.63 17.75 ± 3.73 53.68 ± 1.80 32.38 ± 4.27 
3 x 20 sec 37.00 ± 2.08 7.8 ± 2.40 54.35 ±2.65 24.30 ± 2.63 
3 x 30 sec 36.00 ± 1.37 7.92 ± 2.51 53.42 ± 1.28 23 ± 3.27 
 
It is therefore however clear that none of the postC protocols applied by manipulating 
regional flow (i.e. 6 x 10 sec, 3 x 20 sec and 3 x 30 sec) could confer cardioprotection, as 
measured by infarct size and functional recovery. It might be that this lack of benefit is due 
to the method of postC application (i.e. regional).  
 
In order to investigate the efficacy of globally applied postC (by manipulating the flow of 
perfusate to the whole heart), three different postC protocols were tested: 6 x 10 sec, 3 x 
30 sec and 4 x 15 sec. Although these protocols were not  a precise repeat of the 
regionally applied postC protocols (the very unsuccessful  3 x 20 second regional postC 
was replaced by a 4 x 15 second protocol), this gave us the opportunity to investigate more 
postC algorithms. 
 
The baseline values for these series’ are shown in table 4. All of the hearts’ basic 
functional measurements fell within acceptable limits. 
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Table 4: Baseline functional parameters of hearts that underwent postC applied globally. 
As was the case in the regionally applied intervention,there is a single series of control 
hearts (NonPostC)  that were exposed to the same procedure as the experimental groups. 
 
PostC protocol N – value Aortic output 
(ml/min) 
Cardiac output 
(ml/min) 
NonPostC 22  37.23 ± 0.89 52.50 ± 1.17 
6 x 10 seconds 26 38.15 ± 1.16 53.85 ± 1.57 
4 x 15 seconds 10 34.70 ± 1.90 49.75 ± 1.59 
3 x 30 seconds 3 39.33 ± 3.71 55.33 ± 4.41 
 
There was no significant recovery in aortic output or cardiac output in the 6 x 10 second 
and 4 x 15 second protocols (table 5).  
 
Table 5: Post-ischaemic function, as well as functional recovery in hearts treated with 6 x 
10 sec, 4 x 15 sec and 3 x 30 sec postC algorythms, applied by manipulating global flow to 
the hearts. AO: aortic output; CO: cardiac output. * P < 0.05 vs NonPostC. 
 
Protocol 
Post-ischaemic 
AO (ml/min) 
AO recovery (%) 
Post-ischaemic 
CO (ml/min) 
CO recovery (%) 
NonPostC 6.34 ± 1.03 16.62 ± 2.71 19.05 ± 1.49 36.13 ± 2.59 
6 x 10 sec 6.52 ± 0.91 16.95 ± 2.19 20.42 ± 1.37 37.80 ± 2.17 
4 x 15 sec 7.80 ± 1.91 22.52 ± 5.44 20.34 ± 2.05 40.99 ± 4.14 
3 x 30 sec 13.07 ± 3.73 32.47 ± 7.70 36.40 ± 4.57 65.30 ± 3.18* 
 
There was however a significant increase in cardiac output in the 3 x 30 second postC 
hearts (NonPostC = 36.13 ± 2.59% vs 3 x 30 sec = 65.30 ± 3.18%), together with an 
increase in the recovery of coronary flow (NonPostC = 81.52 ± 3.84% vs 3 x 30 sec = 
143.70 ± 18.71%) (figure 7). In the absence of aortic output recovery, it therefore seems 
plausible, that the observed CO recovery can be explained by the substantial increase in 
coronary flow.   
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 No significant decrease in infarct size was associated with any of the different postC 
protocols (shown in figure 8; NonPostC = 27.84 ± 2.36% vs 6 x 10 sec = 27.03 ± 2.27%; 4 
x 15 sec = 33.31 ± 4.26%; 3 x 30 sec = 25.28 ± 10.39%). In all four experimental groups 
area at risk size was similar (NonPostC = 48.65 ± 1.66%; 6 x 10 sec = 48.55 ± 3.00%; 4 x 
15 sec = 48.17 ± 2.72%; and 3 x 30 sec = 44.56 ± 1.13%). 
 
Despite the global application of the postC intervention (with its technical and thermal 
advantages), the postC protocols tested could not elicit any form of cardioprotection. This 
meant that another parameter, besides algorythm and method of application, had to be 
considered in the postC protocol. 
NonPostC 3 x 30 sec 
PostC 
*
*
AO
175
NonpostC: n = 22 
PostC: n = 3 
 
* P < 0.05 
** P < 0.0001 
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Figure 7: Histogram of percentage recovery of functional parameters of 3 x 30 
second globally applied postC vs NonPostC hearts. There is a significant increase in 
the coronary flow and cardiac output after 35 minutes regional ischaemia in the postC 
hearts. 
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Because of its predominance in the literature we decided to pursue the 6 x 10 second 
postC protocol. Because of practical considerations, we decided to try and implement this 
protocol by manipulating global flow to the hearts. As illustrated in figure 8, this protocol 
had not been showing any success up until now. We therefore slightly changed the original 
experimental protocol by increasing the temperature of the hearts during ischaemia and 
the first minutes of reperfusion (to approximately 36.5 °C – 37.3 °C). Special attention was 
given to maintaining this elevated temperature during the postC protocol itself. This 
change meant that a new control series, under the same thermal regulation, had to be 
included. There were no significant increases in functional recovery in the NonPostC (n = 
11; AO = 39.18 ± 2.91 ml/min; CO = 54.91 ± 3.07 ml/min) vs PostC (n = 13; AO = 40.38 ± 
1.97 ml/min; CO = 56.92 ± 2.50 ml/min) group. Post-ischaemic function and percentage 
recovery from baseline values are shown in table 6. 
NonPostC 6 x 10 sec 
PostC 
Figure 8: Infarct sizes associated with various postC protocols, applied via global flow 
regulation. There were no differences in infarct size between NonPostC, 6 x 10 second, 
4 x 15 second and 3 x 30 second postC groups. 
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Table 6: Post-ischaemic functional data and percentage recovery in NonPostC and 6 x 10 
sec postC, globally applied and under strenuous thermal regulation. This postC protocol 
could not elicit functional recovery. AO: aortic output; CO: cardiac output. 
 
Protocol 
Post-ischaemic 
AO (ml/min) 
AO recovery (%) 
Post-ischaemic 
CO (ml/min) 
CO recovery (%) 
NonPostC 4.91 ± 1.84 11.89 ± 4.39 19.55 ± 3.48 35.95 ± 5.97 
6 x 10 sec 2.65 ± 1.24 5.82 ± 2.58 20.03 ± 2.19 35.26 ± 3.72 
 
Despite the inability of the protocol to conserve post-ischaemic function, it did elicit an 
infarct sparing effect (figure 9; PostC = 17.74 ± 2.72% compared to NonPostC = 35.81 ± 
3.67%). Both groups had similar area at risk sizes (PostC = 52.24 ± 2.38 and NonPostC = 
48.08 ±2.96%).  
* P < 0.001 
Figure 9: Infarct size reduction with the application of a 6 x 10 sec global postC 
protocol, at a temperature of 36.5 °C – 37.3 °C. 
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In order to investigate the possible effect of temperature on postC efficacy the temperature 
of the hearts were measured regularly throughout ischaemia (every 5 minutes) and during 
the first 10 minutes of reperfusion (every 2 minutes).  The measured temperature profile is 
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depicted in figure 10. The “Unregulated” – group refers to hearts that were allowed to 
remain at cooler temperatures, while it was attempted to maintain the “Regulated” – group 
at an elevated temperature during ischaemia and especially reperfusion. 
 
Figure 10: Temperature profiling of NonPostC hearts, or hearts exposed to 6 x 10 sec 
global reperfusion / ischaemia at the onset of reperfusion. PostC hearts that showed a 
decrease in infarct size (the “Regulated” group) were in fact exposed to significantly 
higher temperatures than thermally “Unregulated” postC hearts. Especially the first 2 
minutes of reperfusion (postC time) was very  warm in the thermally regulated groups. 
Unfortunatley, no thermal data for the first 2 minutes of reperfusion was collected in the 
“Unregulated” hearts. 
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 3.3.2. The retrogradely perfused Langendorff model 
3.3.2.1. Global ischaemia 
In the retrogardely perfused (Langendorff) model two different ischaemic insults were 
utilised (fig. 11) : a 30 minute period of global ischaemia (with only functional recovery as 
end-point) and 35 minutes of global or regional ischaemia (with infarct size as an 
additional end-point). In this model, only the 6 x 10 second reperfusion / global ischaemia 
protocol was applied as a postC intervention. Temperature was maintained at 
approximately 37 °C throughout the whole duration of the experiment. As was the case in 
the working heart model, special attention was given to maintain temperature during the 
postC protocol. The same reperfusion temperatures were also maintained in the control 
(NonPostC) hearts.  
Global or regional ischaemia 30 minutes reperfusion30 minutes 
stabilisation 
6 x 10 
sec R/I 
General perfusion protocol 
In the retrogradely perfused (Langendorff) model 
28 minutes reperfusion
PostC 
Control 
(NonPostC) 
35 minutes regional ischaemia 
30 or 35 minutes global 
ischaemia 
Stabilisation 
30 minutes reperfusion35 minutes regional ischaemia 
30 or 35 minutes global 
ischaemia 
Stabilisation 
Figure 11: Experimental protocols applied in the retrogradely perfused Langendorff model. 
Functional recovery was evaluated after 30 and 35 minutes of global ischaemia. Infarct 
size and functional recovery was analyzed after 35 minutes regional ischaemia. Only one 
postC protocol was evaluated: 6 x 10 sec globally applied reperfusion and ischaemia. 
Temperature was maintained throughout at 37 °C. 
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Two different parameters, left ventricular developed pressure (LVDP) and rate pressure 
product (RPP; i.e. the product of the heart rate and the LVDP), were used to assess 
functional recovery in the presence or absence of postconditioning. Functional data in 
NonPostC and PostC hearts, before and after global ischaemia (30 minutes of 35 
minutes), are shown in table 7.  
 
Table 7: Functional data recorded in hearts exposed to a 6 x 10 sec postC intervention, as 
well as control (NonPostC) hearts, before and after 30 minutes and 35 minutes global 
ischaemia. LVDP: Left ventricular developed pressure; RPP: Rate Pressure Product; GI: 
global ischaemia. For 30 minutes GI: NonPostC: n=18; PostC: n=13. For 35 minutes GI: 
NonPostC: n=7; PostC: n=7. 
 * P < 0.01, NonPostC vs postC after 30 minutes global ischaemia. 
 
Baseline Post-ischaemic 
Intervention 
LVDP (mmHg) RPP LVDP (mmHg) RPP 
NonPostC 98.50 ± 3.30 33850 ± 1084 15.33 ± 3.32 4119 ± 911.8 30 min 
GI 6 x 10 sec 106.0 ± 3.67 35590 ± 1199 28.69 ± 2.42* 8646 ± 842.1* 
NonPostC 111.4 ± 8.09 38917 ± 3751 31.00 ± 7.42 12418 ± 3354 35 min 
GI 6 x 10 sec 98.71 ± 6.69 33924 ± 2875 48.14 ± 4.73 15870 ± 1469 
 
Hearts exposed to a 30 minute period of global ischaemia, followed by a 6 x 10 seconds 
postC protocol  showed a significant recovery in RPP (fig. 12), compared to NonPostC 
hearts (PostC = 24.61 ± 2.53% vs NonPostC = 12.27 ± 2.63%). It is noteworthy that there 
is also a striking (although not significant) increased LVDP recovery in postC vs NonPostC 
hearts (27.80 ± 2.96% vs 15.64 ± 3.31%). In absolute values, hearts exposed to a postC 
protocol after 30 minutes global ischaemia was associated with significantly elevated 
LVDP (NonPostC: 15.33 ± 3.32 mmHg vs postC: 28.69 ± 2.42 mmHg) and RPP 
(NonPostC: 4119 ± 911.8 vs postC: 8646 ± 842.1) values compared to NonPostC hearts 
(table 7). 
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Interestingly, in hearts exposed to 35 minutes global ischaemia (fig. 13), LVDP recovery 
was significantly higher in postC (48.49 ± 3.14%) than NonPostC (28.40 ± 7.02%) hearts, 
while the difference in RPP recovery, although noticeable, was not significant (PostC = 
47.64 ± 4.28% vs NonPostC = 31.35 ± 7.12%). Care was taken to maintain the 
temperatures of the hearts during ischaemia (NonPostC: 36.94 ± 0.05 °C; PostC: 37.00 ± 
0.04°C) and the first 10 minutes of reperfusion (NonPostC: 36.98 ± 0.05 °C; PostC: 36.74 
± 0.12 °C). 
 
 
 
 
 
 
 
 
* P < 0.05 
LVDP RPP
Figure 12: Functional recovery after 30 minutes global ischaemia, as expressed in 
terms of left ventricular developed pressure (LVDP) and rate pressure product (RPP) 
in Langendorff model hearts treated with a 6 x 10 second globally applied postC 
protocol. 
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 3.3.2.2. Regional ischaemia 
As was the case in the working heart model, we also decided to broaden our investigation 
in the Langendorff model to include infarct size analysis. We used our findings from the 
working heart model to guide our experimental approach in the Langendorff model. We 
therefore used the protocol which showed postC-mediated cardioprotection in the working 
heart model, in the Langendorff model. Hearts were subjected to 35 minutes regional 
ischaemia, followed by 30 minutes reperfusion. PostC entailed 6 x 10 seconds reperfusion 
/ ischaemia at the onset of reperfusion. Temperature was monitored and maintained at 
approximately 37 °C throughout ischaemia and reperfusion. 
 
This experimental protocol elicited a significant reduction infarct size in postC (27.81 ± 
2.49%) compared to NonPostC (47.99 ± 3.31%) hearts (fig.14). Both the postC and 
NonPostC groups presented with similar area at risk sizes (postC = 47.10 ± 1.92% and 
NonPostC = 47.85 ± 2.80%). 
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Figure 13: Functional recovery after 35 minutes of global ischaemia in hearts 
treated with postC (6 x 10 seconds) and nonPostC hearts, in the Langendorff 
model. Although there is a notable RPP recovery in postC hearts, it is only LVDP 
that shows significant recovery. 
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Figure 14: In the Langendorff model, a postC protocol of 6 x 10 seconds global 
reperfusion  / ischaemia was associated with a significant decrease in infarct size after 35 
minutes of regional ischaemia. 
Functional parameters measured in both groups are shown in table 8. As was obserevd in 
the working heart model, postC applied after a regional ischaemic insult was not 
associated with increased recovery of any of the functional parameters (NonPostC: LVDP 
= 78.76 ± 2.46%, RPP = 76.78 ± 1.86% compared to PostC: LVDP = 83.31 ± 2.66%, RPP 
= 83.41 ± 2.75%). 
 
Table 8: Functional parameters measured in NonPostC and PostC (6 x 10 sec global 
reperfusion / ischaemia cycles) hearts exposed to 35 minutes of regional ischaemia. PostC 
was not associated with a significant increase in post-ischaemic function. LVDP: Left 
ventricular developed pressure; RPP: Rate Pressure Product; RI: regional ischaemia. 
NonPostC: n=17; PostC: n=24. 
 
Baseline Post-ischaemic 
Intervention 
LVDP (mmHg) RPP LVDP (mmHg) RPP 
NonPostC 101.8 ± 3.54 33722 ± 1305 80.88 ± 2.70 26271 ± 1090 30 min 
RI 6 x 10 sec 99.21 ± 2.86 31174 ± 876.8 81.88 ± 2.59 25876 ± 998.3 
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 3.4. Discussion 
3.4.1. Working heart model 
3.4.1.1. Global ischaemia: Functional recovery 
In our initial attempts to develop a postC protocol that would elicit significant functional 
recovery in the working heart model, the same postC protocol was applied, but after 
different periods of global ischaemia (20 or 25 minutes). We chose a widely used postC 
protocol of 6 x 10 seconds reperfusion / ischaemia (Kin et al., 2004; Penna et al.; 2006; 
and Wang et al., 2007), which was applied by regulating the flow of perfusate to the heart 
as a whole. In both these experimental groups the postC intervention failed to elicit a 
significant recovery in function, as assessed by aortic output and cardiac output (figures 2 
and 3).  
 
At the time when this study was initiated, no other group had published data on 
postconditioning using the working heart model. Since then one group has used this 
particular model, but in a very unorthodox manner, compared to the postC experiments 
described in the retrogradely perfused Langendorff model. The model described by Sasaki 
et al. (2007) differ from ours in several respects: They perfused hearts at an afterload of 80 
cmH2O, while ours worked at a higher pressure of 100 cmH2O. Both models shared the 
same preload of 15 cmH2O. They applied 15 minutes of global ischaemia, while pacing 
their hearts at 330 beats per minute, which makes their model more applicable to study 
stunning, rather than irreversible myocardial damage. We chose 20 and 25 minutes of 
ischaemia, since previous work in our lab has shown that both these insults were 
associated with functional recovery in IPC hearts (Lochner et al., 2003). Perhaps the most 
important difference between our experimental setup and that of Sasaki et al. (2007) is the 
postC protocol itself: they applied a unique postconditioning protocol of 1 minute 
reperfusion, followed by 5 minutes of global ischaemia. Although this protocol could 
reduce reperfusion arrythmias, it was not associated with functional recovery or a 
decrease in creatine kinase (CK) release – all of which indicate the limited cardioprotective 
ability of this protocol. Thus, regardless of the differences in postC protocol, it would seem 
that functional recovery is not a reliable indicator of cardioprotection in postC. 
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3.4.1.2. Regional ischaemia: Infarct size and functional recovery 
In light of the failure of postC to elicit functional recovery after a global ischaemic insult in 
our working heart model, it was decided to focus on the reported infarct sparing effect of 
postconditioning. Since it has been widely reported that postconditioning does reduce 
infarct size, we pursued this end-point quite vigorously by testing various experimental 
conditions and postC protocols in our working heart model. Three parameters were taken 
into consideration: the method of postC intervention, the number of cycles applied and the 
temperature during this intervention. A period of 35 minutes regional ischaemia was used 
in all experiments. This ischaemic insult yields an infarct size of 30 – 60% of the area at 
risk (Lochner et al., 2003).  
 
¾ The method of postC intervention: This refers to how the reperfusion and ischaemia 
cycles were applied – either by manipulating the suture itself, and therefore the 
regional flow to the area at risk; or by manipulating the flow of perfusate to the whole 
heart. We applied three different postC protocols by manipulating the regional flow: 6 x 
10 sec, 3 x 20 sec and 3 x 30 sec. None of these postC protocols elicited either a 
decrease in infarct size (figures 5 & 6), or an increase in functional recovery. The 6 x 
10 sec protocol however did seem to show a trend toward a decrease in infarct size 
(PostC: 24.12 ± 5.22% vs NonPostC: 31.01 ± 3.26%), although the relatively wide 
distribution of postC data points precluded significant difference. 
Three protocols were also applied by manipulating global flow: 6 x 10 sec, 4 x 15 sec 
and 3 x 30 sec (fig. 8). None of these protocols were associated with a significant 
decrease in infarct size either. Admittedly, more hearts could have been done in the 3 x 
30 sec group, but since our previous results in this particular model (using regional 
manipulation) were not encouraging either, we decided to abandon this protocol. There 
was however, a significant increase in the cardiac output of postC hearts, in the 3 x 30 
sec group (fig. 7). This is probably not due to actual functional recovery, but rather to 
an increase in coronary flow.  Indeed, there was a significant increase in coronary flow 
in postC hearts, in the absence of aortic output recovery.  In our hands coronary flow 
regularly shows an increase after regional ischaemia (data not shown), due to physical 
tearing of the heart tissue by the suture.  
 
Although altering the mode of reperfusion / ischaemia induction failed to offer a 
protective postC protocol, we did learn that technically it was easier to apply a global 
reperfusion / ischaemia regime, than a regional one. There are primarily two reasons 
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for this: Firstly, repeated regional manipulation presents the risk that the heart or 
coronary artery might be damaged or torn during the postC protocol. Secondly, thermal 
regulation is much easier in the global model, since the heart is maintained in a buffer-
filled waterjacket cylinder. With regional manipulation the hearts are exposed to the 
ambient temperature for the duration of the postC intervention.  
¾ The number of cycles applied: Two protocols have been shown to be particularly 
successful in the rat heart: either a 6 x 10 second protocol (Kin et al., 2004; Wang et 
al., 2007; and Penna et al.; 2006), or a 3 x 30 second protocol (Bopassa et al., 2006; 
and Manintveld et al., 2007). We therefore focused our study on protocols within these 
limits, i.e. 6 x 10 sec, 4 x 15 sec, 3 x 20 sec and 3 x 30 sec. Another possibly important 
parameter to take into account is the total duration of the postC protocol (as speculated 
by Iliodromitis et al., 2006). In this regard out postC protocol also fell within the 
published limits of either 2 minutes or 3 minutes. Despite the fact that our experiments 
mimicked those described by others, we failed to repeat their results (placing us in the 
same company as Dow & Kloner, 2007; and Kaljusta et al., 2007). Despite the absence 
of functional recovery or reduction in infarct size associated with any of the protocols, it 
did seem as if the 6 x 10 sec protocol was the most promising. As already mentioned it 
decreased IFS when applied regionally (fig. 5), while it lead to a very wide distribution 
of infarct sizes in the global approach (fig. 8). 
¾ Temperature during ischaemia and reperfusion: In view of the above, we decided to 
focus our search for an infarct sparing postC protocol in the working heart model on the 
6 x 10 sec globally applied reperfusion / ischaemia protocol. Although this protocol had 
not been associated with a decrease in infarct size in our previous experiments (postC: 
27.03 ± 2.27% vs NonPostC: 27.84 ± 2.36%), we decided to test it again – but with a 
slight elevation in temperature during the postconditioning protocol (from approximately 
36.5 °C  to between 36.5 °C  and 37.3°C). This required a more strenuous regulation 
and monitoring of the temperature, than had been employed up until this point. 
Surprisingly, we now found that the postC protocol was associated with a significant 
reduction in infarct size (fig. 8; postC: 17.74 ± 2.72% vs NonPostC: 35.81 ± 3.67%). 
This decrease in infarct size was however still not associated with improved functional 
recovery. 
Analysis of the temperature data that was collected showed that in the cardioprotective 
postC protocol there was a significant increase in temperature, compared to the 
previous postC protocol, during ischaemia (36.32 ± 0.09 °C vs 35.45 ± 0.16 °C), as well 
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as the first 10 minutes  reperfusion (36.65 ± 0.1 °C vs 35.68 ± 0.07 °C).  The question 
is whether an increase of approximately 1 °C during ischaemia / reperfusion could 
really be responsible for the observed changes in infarct size? Work that has been 
done on the effect of temperature in ischaemia / reperfusion has focussed on much 
larger alterations in temperature, in the setting of the protective effect of hypothermia. 
For example, Riess et al. (2004) found that perfusion and ischaemia of guinea pig 
hearts at 17 °C was associated with a decrease in infarct size. Hypothermia (in the 
order of 29 °C), before and during hypoxia, was also associated with the preservation 
of myocardial function in rabbits (Ning et al., 2003). Another demonstration of the 
protection afforded by a slight decrease in temperature is given by Hale et al. (1997). 
They found that a reduction of 6 °C during ischaemia can elicit an infarct sparing effect, 
although such a degree of hypothermia 5 minutes before reperfusion had no 
cardioprotective effect. Schwartz et al. (1997) showed that even slight fluctuations in 
ischaemic epicardial temperature (35.5 – 41 °C) exerted a major effect on infarct size in 
canine hearts. These authors observed a positive correlation between infarct size and 
epicardial temperature. It is therefore clear that the myocardium is sensitive to 
fluctuations in temperature, but if it is sensitive to fluctuations of less than 1 °C seems 
to be unknown. All these studies also indicated a protective role for hypothermia, while 
in our hands upregulation of temperature during the postC protocol seemed to be a 
prerequisite for protection. We could only speculate that, if postC is an active process 
as suggested by Tsang et al. (2004) and Bopassa et al. (2006), the slight increase in 
temperature might favour increased protective enzymatic processes in the myocytes. It 
might also be possible that the answer lies in the temperature fluctuations during the 
ischaemia / reperfusion cycles. Recently Khaliulin et al. (2007) reported the existence 
of temperature preconditioning, in which three cycles of hypothermia (26 °C) prior to 
sustained ischaemia elicits a even more potent cardioprotective effect than ischaemic 
preconditioning.  
Further research is required to elucidate the role of temperature in postC efficacy. 
These studies could entail the comparison of the protective effects of postC at defined 
different temperatures. Further research would probably be dependent on 
computerized continuous temperature measurements throughout the experiments, as 
well as very stable temperature regulation. 
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Despite the absence of an adequate explanation, we had now for the first time, established 
a postC protocol that could elicit an infarct sparing effect in the working heart model.  
3.4.2. Retrogradely perfused Langendorff model 
3.4.2.1. Global ischaemia: functional recovery 
To further investigate the effect of postC on functional recovery, we decided to also 
investigate postC in the retrogradely perfused heart model. Previous work in our lab had 
shown the Langendorff model to be resilient enough to show functional recovery even after 
35 minutes global ischaemia, although elevated functional recovery in preconditioned 
hearts were only observed after 30 minutes global ischaemia (Lochner et al., 2003). In this 
model we tested the effects of the postC protocol, that we had found to be cardioprotective 
in the working heart model. As was the case in the working heart model, two different 
global ischaemic insults (30 and 35 minutes) were tested to determine the ability of our 
thermally regulated, globally applied  6 x 10 sec postC protocol to elicit functional recovery.  
 
In our study we found that postC was associated with a significant increase in functional 
recovery after both 30 and 35 minutes global ischaemia. Interestingly, after 30 minutes GI 
the RPP was significantly increased in postC hearts (fig. 12), while after 35 minutes GI 
only LVDP showed significant recovery (fig. 13) in the absence of a difference in heart rate 
recovery values (data not shown). Since RPP (the product of both heart rate and LVDP) 
could be considered more representative of functional performance, these differences 
might be due to the severity of the ischaemic insult. In fact, postC after 30 minutes global 
ischaemia was associated with a significant increase in heart rate recovery (NonPostC: 
54.19 ± 9.90% vs postC: 88.64 ± 3.32%), with post-ischaemic heart rate values within 
acceptable limits (in beats per minute: NonPostC: 187.2 ± 35.05 bpm; postC: 297.5 ± 
10.73 bpm). 
 
Although we demonstrated functional recovery after postconditioning in the Langendorff 
model, it should be noted that no functional recovery was observed in later experiments 
(data not shown) to determine the kinase profiles associated with postC (described in 
chapter 4). This emphasises the unreproducibility of the protective effects attributed to 
postC in the rat, specifically its ability to salvage function. It is noteworthy that in their 
review on postconditioning, Zhao & Vinten-Johansen (2006) did not even mention 
functional recovery as a possible end-point to investigate. However, several others 
assessed functional recovery associated with postconditioning, in the retrogradely 
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perfused Langendorff model, and showed improvement (Bopassa et al., 2006; Crisostoma 
et al., 2006; and Wang et al., 2007). In the study by Bopassa et al. (2006) they applied the 
unique protocol of 1 minute reflow followed by 3 x 30 sec ischaemia / reperfusion – which 
induced a significant recovery in function after 30 minutes of global ischaemia. Both 
Crisostoma et al. (2006) and Wang et al. (2007) found that a postC protocol similar to the 
one we applied, elicited an increase in functional recovery in rats after both 20 and 25 
minutes (in male rats, according to Crisostoma et al., 2006) and 30 minutes (Wang et al., 
2007) global ischaemia. Many researchers however did not attempt to use functional 
recovery as an end-point, while others were unable to demonstrate postC-related recovery 
in function. Couvreur et al. (2006) could not show that postC protected against stunning 
after 10 minutes ischaemia in both the in vivo canine and rabbit hearts. In the isolated 
rabbit heart Darling and coworkers (2005) could also not show postC – induced functional 
recovery.  
 
A question which does arise is why the same postC protocol could elicit functional 
recovery in the Langendorff model, but not in the working heart? Possible explanations are 
discussed in the comparative study between the two models in the setting of IPC (Lochner 
et al., 2003). Two very plausible explanations concern the oxygen utilisation in the working 
heart model. The working rat heart has to function against a preset preload and afterload; 
extra stress which the Langendorff model does not have to contend with. It could therefore 
be that the working heart’s oxygen demand exceeds its supply during reperfusion, 
undermining function. It has also been shown that the working heart generates significantly 
more free radicals during reperfusion than the Langendorff model – possibly due to an 
increase in oxygen consumption (Damerou et al., 1993). This increased oxidative stress 
could also influence post-ischaemic function. Despite these explanations it is still 
worrisome that postC could not increase post-ischaemic function in the working heart, in 
contrast to ischaemic preconditioning (Lochner et al., 2003). It could be that ischaemic 
preconditioning elicits a more potent cardioprotection effect than postconditioning, an 
observation also made by Kin et al. (2004). This was also reflected by the more outspoken 
reduction in infarct size induced by preconditioning (discussed in the next section). 
 
3.4.2.2. Regional ischaemia: infarct size and functional recovery 
In these experiments we did not test any variations in the postC protocol, rather we 
attempted to investigate the infarct-sparing effect of the postC protocol, that we had 
developed in the working heart model, in the Langendorff model. As described in the 
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Figure 15: Comparison 
between the infarct sizes 
generated in the working 
heart and Langendorff 
models. For a given 
intervention (NonPostC or 
PostC) the infarct sizes in 
the Langendorff model are 
significantly higher than in 
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working heart model, hearts were exposed to 35 minutes regional ischaemia, followed by 6 
x 10 second reperfusion / ischaemia cycles, applied globally. Temperature was monitored 
and regulated during ischaemia and reperfusion, at the same level as in the working heart 
setup. Results mimicked those found in the working heart model. The postC protocol 
exerted an infarct – sparing effect (fig. 14), without any significant functional recovery.  
 
Comparison of the infarct sparing effect of our postC protocol in the working heart model 
and the Langendorff model reveals two interesting differences. In the working heart model 
our postC protocol decreased infarct size by 50.46%, which is more than the 40.49% 
reduction in the Langendorff model. We also see a significantly higher IFS, for a given 
intervention, in the Langendorff compared to the working heart model (Langendorff postC: 
28.56 ± 2.50% vs work heart postC: 17.74 ± 2.72%, p < 0.05; and Langendorff NonPostC: 
47.99 ± 3.31% vs work NonPostC: 35.81 ± 3.67%, p < 0.05; also depicted in figure 15). 
 
 
 
These observed differences might be due to the intrinsic differences between the two 
models. As already discussed: the working heart model is exposed to different stressors 
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and energy demands than the Langendorff model. Nonetheless, our postC protocol was 
associated with a significant reduction in infarct size in both models. 
 
The first group to report on the infarct sparing effect of postC in the rat was Kin et al. 
(2004), who tested two postconditioning protocols, 3 and 6 cycles of 10 seconds 
reperfusion / ischaemia, both of which conferred the same degree of reduction in infarct 
size. Interestingly, these authors reported that although the decrease was significant 
compared to control hearts, the infarct sizes were still significantly greater than in the 
presence of ischaemic preconditioning. More specifically: both postconditioning protocols 
decreased infarct size from approximately 50% in control hearts to 40%, in contrast to IPC 
wich reduced infarct size to approximately 20% of the area at risk. Similiarly Tang and 
colleagues (2006), found that although postC could reduce infarct size significantly (6 x 10 
sec: 34% smaller than control; and 20 x 10 sec: 47% reduction), this protection was not as 
potent as that imparted by preconditioning (both in the early and late phases, which 
reduced IFS by 72% and 70% respectively). Using a 3 x 30 sec postC protocol, Manintveld 
and coworkers (2007) also reported that postC reduces IFS after 45 or 60 minutes of 
ischaemia, but by less than 50%. In contrast to these reports and maybe more similar to 
our results, Penna et al. (2006) found that a postC protocol similar to ours reduced infarct 
size from 65 ± 4% to 22 ± 4% (in constant-flow perfused hearts) and from 59 ± 5% to 46 ± 
2% (in constant-pressure perfused hearts). 
 In the light of the above discussed results by other groups, it seems as if postC protection, 
although present, is not very potent (especially compared to the protection associated with 
IPC). In fact, it seems that in our model, postC exerted quite a strong infarct sparing effect 
compared to other studies.  
 
This observed relatively potent infarct sparing effect in our postC model , however now 
raises another question: Why could we not demonstrate a stronger effect on functional 
recovery? In fact, in the working heart model which showed the greatest extent of infarct 
reduction, we did not find any functional recovery. This observed lack of the expected 
direct relationship between functional performance and infarct size has been made by 
other researchers as well (Cohen et al., 1999; and Lochner et al., 2003). Three possible 
explanations have been put forward to explain this dissociation. The phenomenon of 
stunning (discussed in chapter 1) following ischaemia would transiently suppress 
functional ability, even in the presence of a small infarct. The precise effect of postC on 
stunning has not yet definitively been determined - Couvreur et al. (2006) found that postC 
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could not protect against stunning, while Kin et al. (2005) concluded that it is protective. 
Interestingly Cohen et al. (1999) found that IPC could elicit functional recovery – but only 
after 3 days of reperfusion. But even this observed functional recovery was not 
proportional to measured IFS. These authors also speculate that it could be that the 
salvaged myocardium (in the cardioprotective setting of IPC) is not functionally normal. 
Functional recovery could also be determined by the physical site of necrosis / tissue 
damage in the heart. Cohen et al. (1999) speculate that damage to the subendocardial 
fibers might have a deleterious effect on overall fiber shortening, thus undermining cardiac 
function. 
3.4.3. Summary 
During the course of developing a cardioprotective postconditioning protocol in the isolated 
rat heart we tested different possible postconditioning algorithms, which we applied by 
manipulating either global or regional flow to the heart. Temperature (during ischaemia 
and especially the first ten minutes of reperfusion) appears to be very important in the 
efficacy of the protocol.  
 
We found that 6 cycles of 10 seconds reperfusion / ischaemia, applied by manipulating 
global flow to the heart, at the very onset of reperfusion and maintained at a target 
temperature of 36.6 °C  – 37.3 °C, conferred significant cardioprotection.  
 
This protocol was associated with a signifcant infarct sparing effect in both the working 
heart and retrogradely perfused models, after 35 minutes regional ischaemia. It could 
however not elicit functional recovery in the working heart model, although it was 
associated with functional recovery in the less strenuous Langendorff model. 
 
To our knowledge we are the first group to show that postconditioning can be used as a 
reperfusion intervention to decrease infarct size in the isolated working rat heart. Its failure 
to elicit functional recovery in this experimental model, is however disappointing. 
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Chapter 4: Postconditioning: role of signalling 
kinases 
 
“The most exciting phrase to hear in science, the 
one that heralds new discoveries, is not ‘Eureka!’ 
(I found it!) but ‘That’s funny…’” 
 
Isaac Asimov 
www.quotationspage.com 
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 Chapter 4: Postconditioning: role of the signalling 
kinases 
4.1. Background and motivation 
Several possible mechanisms have been implicated in the mechanism of postC. In the 
intact animal some of the proposed mechanisms involve blood borne factors, such as 
neutrophils (Zhao et al., 2003; Kin et al., 2004; Mykytenko et al., 2007). Postconditioning 
has however, also been demonstrated in the isolated heart system, implying a role for 
factors endogenous to myocardial tissue. Although various factors have been identified, 
the RISK (reperfusion injury salvage kinase) – pathway is especially noteworthy, since it 
seems this pathway is central in cardioprotection during reperfusion (particularly in IPC 
(Hausenloy et al., 2005), for a review on RISK in ischaemia / reperfusion see Hausenloy & 
Yellon; 2004).  
 
A number of researchers have shown that increased PI3-kinase activity is associated with 
postC cardioprotection (Yang et al., 2004; Fujita et al., 2007).  A notable exception is 
Darling et al. (2005), who could not show a functional role for PI3-kinase activity, nor 
increased PKB/Akt phosphorylation associated with postC. Despite this, Darling et al. 
(2005), and other authors (Yang et al., 2004; Fujita et al., 2007), have found that ERK 
p42/p44 also seems to be involved in postC. However, Zhu et al.(2006) reported that ERK 
p42/p44 activity was not increased in postC. Schwartz & Lagranha (2006) reported the 
intruiging results that although they found increased phosphorylation of PKB/Akt and ERK 
p42/p44 in postC hearts, this phosphorylation was not associated with cardioprotection. 
Thus, some uncertainty still exists as to the precise role of the RISK-pathway in the 
cardioprotective mechanism of postC. 
 
Another kinase of possible importance is p38 MAPK, since it has been shown to be 
involved in IPC (although its precise role is yet to be elucidated (Hausenloy & Yellon 
(2006)). Only one study by Sun and colleagues (2006) has shown a possible role for p38 
MAPK in postconditioning. They found it to be decreased in neonatal cardiomyocytes 
exposed to a postC protocol. 
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In view of the existing literature, it seems possible that either PKB/Akt or ERK p42/p44 (or 
probably both) are involved in postC protection, in our isolated rat heart models. We 
therefore decided to investigate the precise roles of PKB/Akt and ERK p42/p44 in our 
model of postconditioning. We also aimed to investigate the possible role of p38 MAPK in 
our postC model, since there seems to be virtually no information regarding this kinase in 
postC cardioprotection. 
4.2. Materials and methods 
Hearts from male Wistar rats were cannulated and perfused with oxygenated Krebs-
Henseleit buffer (see chapter 2). For this investigation we used both the working heart, as 
well as the retrogradely perfused Langendorff models. In view of our postC – development 
experiments (see chapter 3) we used the protocol which we had found was  best 
associated with postC-mediated cardioprotection (i.e. reduced infarct size and increased 
functional recovery). In brief: hearts were exposed to 30 minutes stabilisation, 35 minutes 
ischaemia (regional or global, depending on the perfusion model) and maximum 30 
minutes reperfusion. PostC was elicited by the application of 6 x 10 second global 
reperfusion / ischaemia cycles, at a temperature of between 36.5 and 37.3 °C. 
 
In order to assess the role of the kinases in postC, two different lines of investigation were 
pursued: 
1. In both perfusion models hearts were either exposed to a postC protocol, or 
conventional full and immediate reperfusion (NonPostC). Hearts were then freeze-
clamped at different time points during reperfusion, and later analyzed, using Western 
blotting.  
2. Following the above mentioned approach, the importance of the kinases that had been 
found to be phosphorylated in postC was further investigated by administering 
appropriate inhibitors during reperfusion. 
 
The protocols used will be described in detail in the “Results” section. All protein analyses 
also included control hearts, i.e. hearts that only received 30 minutes of retrograde 
perfusion. Densitometry data from these hearts were used as reference for the 
normalization and comparison of data from  the experimental groups (see chapter 2).  
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4.3. Results 
4.3.1. The kinase profile associated with postC 
This study was done in both working heart and Langendorff models. Hearts were exposed 
to 35 or 20 minutes of ischaemia (global or regional) and then freeze-clamped and plunged 
into liquid nitrogen at either 10 or 30 minutes reperfusion. The frozen tissue samples were 
then later analyzed using Western blotting techniques (as described previously), probing 
for p38 MAPK, ERK p42/p44 and PKB/Akt (in all cases antibodies were used for both total 
and phosphorylated protein). Data was analyzed as described in chapter 2. 
 
4.3.1.1. The working heart model 
The experimental protocols applied in the working heart model are shown in figure 16. 
PostC 
NonPostC 
30 minutes reperfusion35 minutes ischaemia 30 minutes 
stabilisation 
35 minutes regional ischaemia
20 minutes global ischaemia 
Stabilisation 
35 minutes regional ischaemia
20 minutes global ischaemia
Stabilisation 
General perfusion protocol 
Working heart model 
15 min 
15 min 
20 min
20 min
10 min 20 min
Working heart 
perfusion 
6 x 10 second cycles of global 
reperfusion / ischaemia 
Time point of freeze- 
clamping  
Figure 16: Perfusion protocols used to describe the expression and activation of p38 
MAPK, ERK p42/p44 and PKB/Akt associated with postC at 10 minutes and 30 minutes 
reperfusion, in the working heart.
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In order to investigate the kinase profile in the working heart model at 30 minutes 
reperfusion, hearts were initially exposed to 20 minutes global ischaemia only. Whole 
hearts were then freeze-clamped after 30 minutes reperfusion and stored in liquid 
nitrogen. 
 
In the PostC group 3 hearts were perfused (AO before ischaemia = 36.00 ± 2.31 ml/min; 
CO before ischaemia = 52.25 ± 3.62 ml/min).  Three hearts were also analyzed in the 
NonPostC group (AO = 40.67 ± 3.71 ml/min; CO = 56.67 ± 4.89 ml/min). Total and 
phosphorylated protein profiles of the kinases under investigation are shown in figure 17. It 
is noticeable that reperfusion per se increased the phosphorylation of all the kinases 
investigated: p38 MAPK (approximately 2 fold in NonPostC and PostC hearts), PKB/Akt 
(just more than 3 fold in both groups) and ERK p42/p44 (especially ERK p44 with a ~2.5 
fold increase, but also ERK p42 with a ~1.5 fold increase). At this stage in reperfusion 
there however seems to be no differences between the postC and NonPostC hearts, with 
regard to phosphorylated p38 MAPK, ERK p42/p44 and PKB/Akt. Similarly, the total 
protein content of each kinase evaluated did not differ between the two groups (fig. 17).  
 
In view of these negative results, it was decided to investigate the kinases at 10 minutes 
reperfusion, after exposure to 35 minutes regional ischaemia. After 10 minutes reperfusion 
(in the presence and absence of postC), just before freeze-clamping, the snare (used for 
the induction of ischaemia) was firmly tied around the coronary artery. The ischaemic zone 
of the ventricle distal to the suture was then quickly dissected from the rest of the heart 
and freeze clamped. The rest of the heart was also rapidly freeze-clamped after 
dissection. Thus, ischaemic, as well as non-ischaemic tissue samples, were harvested 
from each heart. This was done to investigate possible differences between the ischaemic 
and non-ischaemic samples, as well as to avoid a possible confounding influence of the 
non-ischaemic tissue on the ischaemic tissue. Functional baseline values for the hearts 
used in this investigation are shown in table 9. Since we found that slightly elevated 
temperatures during ischaemia and early in reperfusion are important in the infarct sparing 
effect of postC, care was taken to regulate the temperature of these hearts (NonPostC: RI 
temperature = 36.60 ± 0.03 °C; reperfusion temperature = 36.88 ± 0.04 °C, and PostC: RI 
temperature = 36.66 ± 0.02 °C; reperfusion temperature = 36.88 ± 0.05 °C). 
 - 107 -
  - 108 -
Total p38 MAPK Phospho p38 MAPK 
Total PKB/Akt Phospho PKB/Akt 
Total ERK p42/p44 Phospho ERK p42/p44 
NonPostC : n=3 
PostC : n=3 
Figure 17: Total and phosphorylated profiles of p38 MAPK (A), PKB/Akt (B) and ERK p42/p44(C) 
at 30 minutes reperfusion, after 20 minutes global ischaemia, in the working heart model. There 
were no significant differences in total protein levels or activity (as assessed by phosphorylation) 
between postC and NonPostC groups. Control: n=2. 
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Table 9: Baseline functional performance of hearts used to analyze the kinases at 10 
minutes reperfusion, in the presence or absence of postC, in the working heart model.  
PostC protocol N – value Aortic output (ml/min) Cardiac output (ml/min) 
NonPostC 6 48.33 ± 3.99   66.58 ± 5.55 
PostC (6x 10 sec) 6 48.08 ± 2.11 63.75 ± 3.16 
 
The total protein expression and the phosphorylation states of the kinases under 
investigation, in the non-ischaemic zone (i.e. the zone of tissue that was not exposed to 
ischaemia)  are shown in figure 18. Very interesting to note is that p38 MAPK shows a 
significant elevation in phosphorylation in postC compared to NonPostC hearts (postC: 
1.19 ± 0.08 AU vs NonPostC: 0.84 ± 0.11 AU, where AU refers to ‘arbitrary unit’). This is 
unexpected, since it is unlikely that postC exerts effects on tissue that was not exposed to 
ischaemia (and therefore not in need of protection). That was not the only unexpected 
finding in the non-ischaemic tissue: an increase in the total amount of PKB/Akt was  also 
observed in the postC vs NonPostC hearts. 
 
To ensure that the differences found in the expression of total PKB/Akt (NonPostC: 0.75 ± 
0.04 AU vs postC: 1.03 ± 0.07 AU) were not masking differences in the phosphorylation of 
the kinase, the ratio of phosphorylated to total protein was calculated. There were however 
still no differences in the phosphorylation levels between the postC and NonPostC groups, 
when expressed in terms of total PKB/Akt protein (fig. 19).  
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Figure 19: Comparison of the ratio 
of phosphorylated to total PKB/Akt. 
There is no difference between 
nonPostC and PostC – confirming 
that PKB/Akt phosphorylation is not 
influenced by postC. 
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PostC: n=5 
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Figure 18: Levels of total and phosphorylated p38 MAPK (A), PKB/Akt (B) and ERK p42/p44 (C) at 
10 minutes reperfusion in non-ischaemic tissue, after 35 minutes regional ischaemia, in the working 
heart model. PostC tissue was associated with a significant increase in the phosphorylation of p38 
MAPK, as well as a sigificant increase in total PKB/Akt. Control hearts; n=2. 
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The profile of total protein expression and phosphorylation in the myocardial tissue 
exposed to ischaemia showed even less difference between the postC and NonPostC 
groups, than in the non-ischaemic zone (fig. 20). These results are surprising as it is 
especially in the tissue that was exposed to ischaemia that one expects postC to exert its 
effects, if any. 
 
It is interesting to note that in the ischaemic tissue the same trend persists as noted in the 
tissue freeze-clamped after 30 minutes reperfusion, i.e. a noticeable increase in the 
phosphorylation of the kinases, in relation to control values, due to reperfusion itself. 
Phosphorylation of p38 MAPK increased approximately 4 fold in both postC and NonPostC 
groups, while phospho-PKB presented with an increase of about 6 fold. ERK p42/p44 also 
increased, but to a lesser degree: ERK p42 ~ 2.5 fold and ERK p44 ~ 1.5 fold. 
 - 111 -
 - 112 -
Total p38 MAPK Phospho p38 MAPK 
Phospho PKB/Akt 
Total ERK p42/p44 Phospho ERK p42/p44 
NonPostC : n=6 
PostC : n=6 
Figure 20: Total and phosphorylated levels of MAPK p38 (A), PKB/Akt (B) and ERK p42/p44(C) in 
tissue exposed to ischaemia, at 10 minutes reperfusion, after 35 minutes regional ischaemia, in the 
working heart model. There were no significant differences in protein levels or activity between 
postC and NonPostC groups. Control: n=2.
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4.3.1.2. The retrogradely perfused Langendorff model 
We previously observed that the retrogradely perfused heart (Langendorff model) survived 
a 35 minute global ischaemic insult better than the working heart (Lochner et al., 2003). It 
was therefore decided to apply a 35 minute global ischaemic insult to the retrogradely 
perfused hearts. Experimental protocols are depicted in figure 21. In the case of global 
ischaemia, the whole heart could be freeze-clamped – simplifying the protocol, as well as 
increasing the amount of tissue available for Western blotting.  
30 minutes reperfusion35 minutes ischaemia 30 minutes 
stabilisation 
General perfusion protocol 
Retrogradely perfused Langendorff model 
PostC 
NonPostC 
35 minutes global ischaemia Stabilisation 
35 minutes global ischaemia Stabilisation 
10 min 
20 min
6 x 10 second cycles of global 
reperfusion / ischaemia 
Time point of freeze 
clamping 
Figure 21: Perfusion protocols used to describe the expression and activation of MAPK p38, 
ERK 1/2 and PKB/Akt associated with postC, at 10 minutes and 30 minutes reperfusion. 
 
As in the case in the working heart model, no differences in the level of phosphorylation or 
total protein expression were found between the postC (n = 6; LVDP before ischaemia = 
97.17 ± 8.33 mmHg; RPP before ischaemia = 30966 ± 3667) and NonPostC (n = 6; LVDP 
= 96.83 ± 7.01 mmHg; RPP = 32774 ± 2461) hearts at 30 minutes reperfusion (figure 22). 
In NonPostC hearts temperatures measured during global ischaemia and the first 10 
minutes of reperfusion were 37.14 ± 0.14 °C and 36.96 ± 0.08 °C respectively. The same 
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magnitude of temperatures were also maintained in postC hearts (GI = 37.00 ± 0.04 °C; 
reperfusion = 36.73 ± 0.14 °C). 
 
The 10 minute reperfusion analysis in the Langendorff model differed from the working 
heart model, in that the hearts were exposed to a global ischaemic episode – which meant 
that whole hearts were freeze-clamped and analyzed. The kinase profiles of hearts which 
received the postC intervention (n = 4; LVDP = 97.25 ± 5.11 mmHg; RPP = 31320 ± 2436) 
or no reperfusion treatment (NonPostC: n = 6; LVDP = 99.67 ± 4.88 mmHg; RPP = 31520 
± 2706) are shown in figure 23. Temperatures during ischaemia and initial reperfusion 
were regulated and monitored as previously discussed (postC: GI = 36.88 ± 0.03 °C; 
reperfusion = 36.93 ± 0.05 °C, and NonPostC: GI = 37.02 ± 0.05 °C; reperfusion = 36.77 ± 
0.14 °C). 
 
At 10 minutes reperfusion in the Langendorff model there was a significant increase in the 
phosphorylation levels of both ERK p42 and PKB/Akt in the postC compared to NonPostC 
hearts (ERK p42: postC = 3.13 ± 0.19 AU vs NonPostC = 2.03 ± 0.20 AU, p < 0.01; and 
PKB/Akt: postC = 1.65 ± 0.06 AU vs NonPostC = 0.88 ± 0.23 AU, p < 0.05). It therefore 
seems likely that increased phosphorylation, and activation, of both ERK p42 and PKB/Akt 
might be involved in the cardioprotective pathways recruited by postconditioning. 
 
As observed in the working heart model, reperfusion on its own was associated with an 
increase in the phosphorylation of the kinases investigated, although this increase does 
seem to be less prominent in the in Langendorff model. After 30 minutes reperfusion 
PKB/Akt shows the most prominent increase: approximately 3 fold. At 10 minutes 
reperfusion the postC group presented with the most noticeable increases: ~ 2.5 fold in 
p38 MAPK, ~ 3 fold in ERK p42, ~ 2 fold in ERK p44 and in PKB ~ 1.5 fold. 
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Figure 22: Total expression and phosphorylation MAPK p38 (A), PKB/Akt (B) and ERK p42/p44 
(C) at 30 minutes reperfusion, after 35 minutes global ischaemia, in the Langendorff model. There 
are no significant differences between NonPostC and PostC treated hearts. Control hearts; n=1.
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Figure 23: Levels of total and phosphorylated p38 MAPK (A), PKB/Akt (B) and ERK p42/p44 (C) at 
10 minutes reperfusion, after 35 minutes global ischaemia, in the Langendorff model. PostC tissue 
was associated with a significant increase in the phosphorylation of PKB/Akt and ERK p42/p44. 
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In summary a number of interesting observations have been made thus far: 
I. Irrespective of the perfusion model used (Langendorff model or working heart), postC 
is not associated with a change in survival kinase and p38 MAPK expression or 
activation (as assessed by phosphorylation quantification) at 30 minutes reperfusion. 
II. Evaluation of kinase activation in regionally ischaemic tissue after 35 minutes 
regional ischaemia, also yielded disappointing results – even after 10 minutes 
reperfusion. 
III. We could however demonstrate an association between postC and marked 
activation of ERK p42 and PKB/Akt at 10 minutes reperfusion, after 35 minutes 
global ischaemia, in the retrogradely perfused Langendorff model. 
4.3.2. Investigating the functional importance of PKB/Akt and ERK p42 
In the above described phase of the study, using the retrogradely perfused rat heart as 
model, we found that at 10 minutes reperfusion, PKB/Akt and ERK p42 were significantly 
phosphorylated in postC. This follow-up study therefore focussed on the role of these two 
kinases, in the cardioprotection elicited by postC.  
 
The same basic perfusion protocol, as described previously, was followed (fig. 24). Briefly, 
hearts were mounted on the retrogradely perfused Langendorff system and allowed to 
stabilise. The hearts were exposed to a 35 minute period of regional ischaemia, followed 
by either 10 or 30 minutes of reperfusion. To investigate the functional importance of 
PKB/Akt and ERK p42/p44 in postC, hearts were perfused with either a specific PKB/Akt 
inhibitor, or an ERK p42/p44 inhibitor (Fig. 24). Both these inhibitors were administered for 
the final 5 minutes of regional ischaemia and the first 10 minutes of reperfusion, in the 
presence or absence of postC (6 x 10 second global reperfusion / ischaemia, at between 
36.5 and 37.3 °C). The effects of the inhibitors on the efficacy of the postC protocol was 
then determined in terms of infarct size reduction. Functional recovery during reperfusion 
was also monitored. 
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General perfusion protocol 
Retrogradely perfused Langendorff model 
PostC 
NonPostC 
35 minutes regional 
ischaemia 
Stabilisation 
35 minutes regional 
ischaemia 
Stabilisation 
10 min 
6 x 10 second cycles of global 
reperfusion / ischaemia 
Time point of freeze 
clamping 
PostC 
NonPostC 
35 minutes regional  
ischaemia 
Stabilisation 
35 minutes regional 
 ischaemia 
Stabilisation 
5 
min 10 min 
Administration of inhibitor 
(A6730 or PD098059) 
Infarct size 
Figure 24: Investigating the functional importance of PKB/Akt and ERK p42/p44 activation in 
the cardioprotective mechanism of postC. Inhibitors for both kinases were administered for the 
final 5 minutes of ischaemia and the  first 10 minutes of reperfusion. Hearts were then either 
freeze-clamped or reperfused for another 20 minutes, before determination of infarct size.
30 minutes 
stabilisation 
35 minutes ischaemia 30 minutes reperfusion
 
4.3.2.1. Effects of ERK p42/p44 inhibition
To inhibit ERK p42/p44 the inhibitor PD098059 (Sigma-Aldrich) was administered at a 
concentration of 10 μM, dissolved in 0.053% DMSO (Merck).  
 
To verify that the inhibitor was effectively inhibiting ERK p42/p44 phosphorylation, as well 
as to investigate possible effects of PD098059 on the other kinases of interest, hearts 
were perfused with the inhibitor, either in the presence (postC: n = 4; LVDP = 100 ± 0.19 
mmHg; RPP = 36041 ± 2216) or absence (NonPostC: n = 4; LVDP = 94.00 ± 5.96 mmHg; 
RPP = 30834 ± 3020) of postC, and then freeze-clamped at 10 minutes reperfusion to be 
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later analyzed using Western blotting (as described in fig. 24). Although regional 
ischaemia was applied, the whole hearts were freeze-clamped for analysis (contrary to the 
method of separating the ischaemic and non-ischaemic zones described previously), since 
the effects of the inhibitor on the hearts per se were investigated. As explained earlier, 
freeze-clamping the whole heart, gives us the luxury of more tissue for Western blotting 
analysis. Western blotting analysis of the tissue samples included a postC group, not 
treated with the inhibitor, which served as a positive control (PostC (+)). As in all other 
Western blotting experiments, a control group was included that only received 30 minutes 
perfusion, with no intervention (Control). Data is shown in figures 25 and 26.  
 
The inhibitor was not associated with a significant decrease in the phosphorylation of ERK 
p44, although there is a strong trend (PostC (+): 4.04 ± 0.17 AU vs PostC+PD: 1.06 ± 0.16 
AU). Concerning ERK p42, the inhibitor was associated with a significant reduction in 
phosphorylation in postC hearts (PostC (+): 4.49 ± 1.28 AU vs PostC+PD: 1.52 ± 0.24 AU, 
p < 0.05). Since it inhibited pERK 42 in postC hearts, it was  the right tool to investigate the 
role of ERK p42 in the mechanism of postconditioning. 
 
Interestingly, PD098059 seemed to inhibit p38 MAPK as well – both in the presence and 
absence of postC (PostC (+): 2.19 ± 0.64 AU; vs NonPostC+PD: 1.08 ± 0.05 AU, p < 0.05; 
and PostC+PD: 0.74 ± 0.02 AU, p < 0.01). As expected, the inhibitor did not show any 
effect on the total protein levels (figures 25 and 26), when compared with control hearts 
and postC hearts which did not receive the inhibitor. 
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Figure 25: Effect of PD098059 treatment, in the final 5 minutes of ischaemia and the first 10 
minutes reperfusion, on levels of total and phosphorylated p38 MAPK (A) and PKB/Akt (B). 
Tissue was collected at 10 minutes reperfusion, after 35 minutes regional ischaemia, in the 
Langendorff model.  Control hearts: n=2; Positive control (PostC (+)): n=2. 
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PostC (+) PostC 
Figure 26: Effect of PD098059 treatment, in the final 5 minutes of ischaemia and the first 10 
minutes reperfusion, on levels of total and phosphorylated ERK p42/p44 (A) and phosphorylated 
ERK p42/p44 (B). Tissue was collected at 10 minutes reperfusion, after 35 minutes regional 
ischaemia, in the Langendorff model.  Control hearts: n=2; Positive control (PostC (+)): n=2. 
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Concerning the effect of MEK1/2 – ERKp42/p44 inhibition on infarct size, data is shown in 
figure 27. In all four groups depicted in figure 27, similar area at risk values were 
measured (NonPostC: 45.96 ± 3.62%; PostC: 43.14 ± 3.24%; NonPostC+PD: 43.81 ± 
4.48%; and PostC+PD: 48.33 ± 3.29%). Another series of postC and NonPostC hearts 
were perfused, without PD098059 administration (PostC: n = 13, and NonPostC: n = 9). 
Just as previously shown, infarct size was significantly lower in the postC than NonPostC 
hearts (postC: 27.32 ± 2.14% vs NonPostC: 43.26 ± 3.9%; p = 0.001). There was however 
no significant recovery of any functional parameters in the postC hearts (table 10).  
 
Table 10: Functional parameters in hearts exposed to 35 minutes regional ischaemia, in 
the presence and absence of postC, as well as the presence and absence of the ERK 
p42/p44 inhibitor PD098059. PostC was not associated with significant changes in 
functional recovery, irrespective of ERK p42/p44 inhibition. 
 
Baseline Post-ischaemic Recovery (%) 
Intervention LVDP 
(mmHg) 
RPP 
LVDP 
(mmHg) 
RPP LVDP RPP 
NonPostC 99.56±5.53 31627±1766 80.89±4.03 25360±1776 82.49±4.64 80.43±3.83 Without 
PD098059 PostC 100.40±4.39 30828±1645 76.38±4.25 22288±1365 77.67±5.50 73.74±5.08 
NonPostC 101.3±5.42 34310±1796 83.57±6.19 27473±2089 84.47±8.01 81.49±6.97 With 
 
PD098059 PostC 103.2±3.95 34101±913 63.33±9.96 20807±3490 63.36±10.98 61.49±10.74
Administration of PD098059 together with NonPostC (n = 7) and postC (n = 9) hearts did 
not alter the infarct sparing effect of postC. PostC together with PD098059 still significantly 
reduced IFS, compared to NonPostC hearts, in the presence and absence of the ERK 
p42/p44 inhibitor (PostC+PD: 23.56 ± 2.82% vs NonPostC+PD: 39.41 ± 3.36%, p < 0.01; 
and NonPostC: 43.26 ± 3.91%, p < 0.001). Just as was the case in the absence of 
PD098059, there were no functional recovery differences between postC and NonPostC 
hearts (table 10). Postconditioning could therefore not elicit any functional recovery, 
irrespective of the administration of the MEK1/2 – ERKp42/p44 inhibitor. Temperature 
during ischaemia (NonPostC: 37.12 ± 0.05 °C; PostC: 37.06 ± 0.05 °C; NonPostC+PD: 
36.85 ± 0.17 °C; PostC+PD: 37.04 ± 0.07 °C) and reperfusion (NonPostC: 36.94 ± 0.03 
°C; PostC: 36.90 ± 0.04 °C; NonPostC+PD: 37.00 ± 0.17 °C; PostC+PD: 36.94 ± 0.11 °C) 
was closely monitored and regulated, as previously described. 
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Figure 27: Infarct sizes in  postC and nonPostC hearts, either in the presence or 
absence of PD098059. The inhibition of MEK1/2 – ERK p42/p44 did not affect the 
cardioprotective effects of postconditioning.  
 
4.3.2.2. Effects of PKB/Akt inhibition 
The specific PKB/Akt inhibitor, A6730 (Sigma-Aldrich), was used to investigate the 
importance of PKB/Akt in the cardioprotection associated with postC. To confirm that the 
inhibitor (at the administered concentration of 2.5 µM, dissolved in 0.025% dimethyl 
sulfoxide (DMSO)) was inhibiting the phosphorylation of PKB/Akt, hearts were perfused  
and freeze-clamped at 10 minutes reperfusion, as described in figure 24. As explained 
earlier, since the effect of the inhibitor on the myocardium per se was of interest, whole 
hearts were harvested for analysis. These hearts received the inhibitor, together with 
standard uncontrolled reperfusion (NonPostC: n = 4; LVDP = 93.00 ± 5.12 mmHg; RPP = 
31351 ± 3339) or the postC intervention (n = 5; LVDP = 85.60 ± 4.50; RPP = 29219 ± 
2592). Western blotting analysis of these samples was done together with a positive 
control (postC (+); n = 2), as well as a control group which received only 30 minutes 
perfusion (Control). The effect of the inhibitor on the phosphorylation, as well as the total 
levels, of the kinases under investigation are shown in figures 28 and 29. 
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Figure 28: Effect of the PKB/Akt inhibitor, A6730,  treatment, in the final 5 minutes of 
ischaemia and the first 10 minutes reperfusion, on levels of total and phosphorylated p38 
MAPK (A) and PKB/Akt (B). The inhibitor clearly caused a significant decrease in the 
phosphorylation of PKB/Akt. Control hearts: n=2; Positive control (PostC (+)): n=2. 
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A: Total ERK 
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Figure 29: Effect of A6730 treatment, on total ERK p42/p44 (A) and phosphorylated ERK 
p42/p44 (B) profiles. Tissue was collected at 10 minutes reperfusion, after 35 minutes 
regional ischaemia, in the Langendorff model.  The significant increase in phosphorylated 
ERK p42 in PostC compared to  NonPostC hearts is probably due to the postC intervention, 
and not related to the inhibitor. Control hearts: n=2; Positive control (PostC (+)): n=2. 
NonPostC: n=4 
PostC: n=5 
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The efficacy of the inhibitor is clearly demonstrated in the dramatically reduced levels of 
phosphorylation of PKB/Akt (fig. 28), in both NonPostC and postC hearts (PostC(+): 1.73 ± 
0.07 AU vs NonPostC+A6730: 0.31 ± 0.06 AU and postC+A6730: 0.22 ± 0.04 AU, p < 
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0.05). This reduction in phosphorylated PKB/Akt occurred while, no differences were 
observed in the amount of total protein. 
 
The only other significant difference in phosphorylation levels was found in ERK p42 (fig. 
29): postC was associated with elevated phosphorylation (PostC: 1.45 ± 0.16 AU vs 
NonPostC: 0.85 ± 0.08 AU, p < 0.05). This is probably not linked to the inhibitor, rather it is 
likely due to postC itself. This then is a confirmation of our initial findings, that ERK p42 
phosphorylation increases with postconditioning. No significant differences were found in 
the total ERK p42/p44 expression (fig. 29). It is therefore clear that A6730 acted as an 
effective and specific PKB/Akt inhibitor in our experimental setup. 
 
To evaluate the importance of PKB/Akt in postC, hearts were reperfused in the presence 
of the PKB/Akt inhibitor, A6730, either in the presence (postC: n=9) or absence of the  
postC (NonPostC: n=9) intervention. Baseline, as well as post-ischaemic functional values 
are shown in table 11. As in all postC experiments, temperature was closely regulated 
(postC: RI = 36.97 ± 0.06 °C; reperfusion = 36.91 ± 0.09 °C, and NonPostC: RI  = 37.23 ± 
0.11 °C; 36.88 ± 0.10 °C). The same series of inhibitor-free NonPostC and postC hearts, 
as described in the ERK p42/p44 inhibitor experiments, were used. The effect of the 
inhibition of PKB/Akt on the infarct sparing effect of postC is shown in figure 30.  
 
There was no significant difference in the area at risk between the drug treated groups 
(NonPostC: 49.13 ± 3.15% and PostC: 53.00 ± 3.05%). In contrast to ERK p42/p44, 
inhibition of PKB/Akt was associated with a loss in the infarct sparing effect of postC 
(NonPostC+A6730: 38.07 ± 4.34% vs PostC+A6730: 35.27 ± 4.42%). It is important to 
note though, that administration of A6730 was also associated with changes in functional 
recovery – as depicted in table 11 and figure 31.  
 
 
 
 - 126 -
Table 11: Baseline and post-ischaemic functional performance of hearts exposed to 35 
minutes regional ischaemia and combinations of NonPostC, PostC, and the presence and 
absence of the PKB/Akt inhibitor A6730. A6730 dramatically decreased functional 
recovery, regardless of the presence or absence of postC. * p < 0.001 vs corresponding 
drug free hearts. 
  
 
Baseline Post-ischaemic Recovery (%) 
Intervention LVDP 
(mmHg) 
RPP 
LVDP 
(mmHg) 
RPP LVDP RPP 
NonPostC 99.56±5.53 31627±1766 80.89±4.03 25360±1776 82.49±4.64 80.43±3.83 Without 
A6730 PostC 100.40±4.39 30828±1645 76.38±4.25 22288±1365 77.67±5.50 73.74±5.08 
NonPostC 95.67±6.24 30267±1713 22.11±2.35 7195±804 24.32±3.05* 24.36±2.91* With 
A6730 PostC 87.44±6.08 27307±1513 27.22±5.07 6638±1066 30.36±5.08* 24.49±4.36* 
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Figure 30: The effect of PKB/Akt inhibition on the infarct sparing effect of postC. In 
the absence of the inhibitor postC can reduce infarct size, however with 
administration of A6730 the postC intervention is no longer cardioprotective. 
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 Inhibition of PKB/Akt with A6730, at a concentration of 2.5 µM, significantly reduced 
functional recovery, compared to hearts that did not receive the inhibitor – irrespective of 
the administration of a postC intervention.  
 
4.3.2.3. Vehicle controls 
For the administration of both PD098059, as well as A6370, DMSO was used as drug 
solvent. To ascertain whether the concentration DMSO administered to the hearts could 
exert a confounding effect on the kinase profiles, hearts were perfused with either 54 µl 
DMSO / 100 ml Krebs-Henseleit buffer (n = 4; corresponding to PD098059 experiments) or 
25 µl DMSO / 100 ml buffer (n = 4; as administered with A6730) in the final 5 minutes of 
regional ischaemia and the first 10 minutes of reperfusion, whereafter hearts were 
immediately freeze-clamped for Western blot analysis.  
 
The kinase profiles of hearts exposed to only DMSO were compared to hearts that did not 
receive any DMSO in reperfusion (n = 4). Analysis of all kinases under investigation (as 
desribed in chapter 2) showed no confounding effect, associated with the DMSO 
concentrations used, on the phosphorylation of the kinases (data not shown). The 
NonPostC NonPostC PostCPostC
RPP recovery LVDP recovery 
Figure 31: Treatment of hearts with the PKB/Akt inhibitor, A6730, in reperfusion, 
leads to a significant decrease in functional recovery, irrespective of the presence 
or absence of postC. 
0
10
20
30
40
50
60
70
80
90
NonPostC
PostC
NonPostC+A6730
PostC+A6730
* * * *
Pe
rc
en
ta
ge
 re
co
ve
ry
* P < 0.001 
 - 128 -
observed effects of the inhibitors on the kinases are therefore solely due to the inhibitors, 
and not associated with the drug solvent. 
 
4.4. Discussion
Studies on the mechanism of protection associated with ischaemic preconditioning (IPC) 
have shown a definite role for the survival kinases ERK p42/p44 and PKB/Akt, in the 
transduction of pro-survival / protective signals, which eventually lead to the recruitment of 
protective end-effectors (for reviews on the role of the kinases in IPC see Hausenloy & 
Yellon, 2004; and for a broader review on the mechanisms of IPC see Yellon & Downey, 
2003). The advent of postconditioning as a cardioprotective intervention, therefore also 
prompted intensive research into the role of the kinases, especially the so-called 
reperfusion injury salvage kinases (RISK). However, consensus concerning the precise 
role of the kinases in reperfusion and postC-protection has still not been reached (as 
discussed in chapter 1). In our study we investigated the phosphorylation of PKB/Akt, ERK 
p42/p44 (i.e. the RISK – pathway) and p38 MAPK associated with postconditioning, in two 
different experimental models, at two different time-points during reperfusion. 
4.4.1. At 30 minutes reperfusion 
Initial evaluation of kinase activity, associated with postC, was done after 30 minutes of 
reperfusion. This was done, since a longer period of reperfusion also offered the 
opportunity to record functional recovery data. However, at 30 minutes reperfusion we 
could not demonstrate differences in the phosphorylation of the kinases under 
investigation, in either the working heart model, or the Langendorff model. This is not too 
surprising, since all other studies done on the activation of ERK p42/p44 and PKB/Akt 
focussed their investigation on much earlier time-points in reperfusion, namely from 5 to 15 
minutes reperfusion (for example Darling et al., 2005; Tsang et al., 2004 and Zhu et al., 
2006). It is therefore clear that the activation of the kinases in postC cardioprotection is 
transient and limited to the early moments of reperfusion. This early recruitement of the 
signalling pathways, is in agreement with the the observations made by Kin and co-
workers (2004) and Downey & Cohen (2005), that the postC-intervention must be applied 
either very early in reperfusion, or immediately at the very onset of reperfusion.  
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4.4.2. At 10 minutes reperfusion 
In view of the failure to detect changes in survival kinase activation at 30 minutes 
reperfusion, the reperfusion time was shortened to 10 minutes. As expected, the effect of 
the postC – intervention on the signalling kinases is evident at 10 minutes reperfusion. 
Interestingly, in the regionally ischaemic working heart model we could not demonstrate 
any differences in the phosphorylation of any of the kinases of interest, in the ischaemic 
zone. This was contrary to what we found in the Langendorff model, where a significant 
increase in the phosphorylation of both ERK p42 and PKB/Akt was observed in the postC 
group. This difference in kinase activity between the two models might be due to the 
inherent differences between the perfusion models. It must be remembered that, to our 
knowledge, we are the first to apply postconditioning in the working heart model. Possible 
differences between the experimental setups, in this context, therefore still need to be 
explored. This explanation however, does seem unlikely, since the working heart model 
has been used to show elevated phosphorylation of p38 and PKB/Akt associated with the 
cardioprotection conferred by red palm oil, in the setting of global ischaemia (Engelbrecht 
et al., 2006).  
 
Another, more plausible, explanation for the differences in observed kinase profiles, 
pertains to the samples used for analysis. In the retrogradely perfused Langendorff model 
whole hearts were exposed to sustained ischaemia, and then snap frozen and later 
analyzed. This “global” approach has the primary advantages that more tissue is available 
for analysis, as well as that the damage is more homogeneous than in regional ischaemia. 
Any differences in protein phosphorylation due to an intervention is therefore “amplified” 
and easier to detect. This is contrary to the regional ischaemia working heart experiments, 
in which the heart tissue had to be divided into ischaemic and non- ischaemic samples. 
Despite the fact that extreme care was exercised in separating the areas, it is possible that 
the so-called ischaemic area contained undamaged tissue – the result being a lack of 
detectable differences in kinase phosphorylation. 
 
Intriguingly, there was one unexpected observation in the working heart model. At ten 
minutes reperfusion there was, in fact, a significant increase in the phosphorylation of p38 
MAPK in the non-ischaemic tissue. The precise role and importance of p38 MAPK in 
cardioprotection is still a matter of debate, while various isoforms complicate matters even 
further. In IPC both protective and deleterious roles for p38 MAPK have been suggested. 
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In our laboratory it has been found that p38 MAPK transiently increases during the 
preconditioning protocol itself, but then it is attenuated during sustained ischaemia and 
reperfusion, which is associated with protection (Marais et al., 2001 and 2005). Saurin and 
colleagues (2000) reports that the deleterious effect of increased p38 MAPK during 
ischaemia might be attributable to activation of the α-isoform. On the other hand, 
increased phosphorylation of p38 MAPK has also been implicated in IPC (Nagy et al., 
2007).  Increased phosphorylation of p38 MAPK in reperfusion has also been linked to 
other cardioprotective treatments, such as dietery supplementation with red palm oil 
(Engelbrecht et al., 2006; and Van Rooyen et al., 2007), as well as insulin administration in 
ischaemia / reperfusion (Tiron et al., 2006). For a review on p38 MAPK in the setting of 
ischaemia / reperfusion and preconditioning, see Steenbergen (2002). 
 
Only two studies evaluated p38 MAPK activation in postconditioning. Sun et al. (2006) 
found postC to be associated with a reduction in p38 MAPK activity, while Feng and 
colleagues (2006) found p38 MAPK to be unimportant in a isoflurane postC model. In our 
study, p38 MAPK is clearly not involved in the effect of postC on the ischaemic tissue 
itself, since it was not significantly phosphorylated at any time point in tissue exposed to 
ischaemia, in both experimental setups (it should be remembered that global ischaemia 
was applied in the Langendorff model (fig. 16)). In addition, it seems as if the MEK1/2 – 
ERK p42/p44 inhibitor, PD098059, also significantly inhibited the phosphorylation of p38 
MAPK (fig. 25) in both NonPostC and PostC hearts. Despite this, PD098059 did not 
abrogate the cardioprotection of postC – indicating that p38 MAPK is indeed not involved. 
 
However, as described above, p38 MAPK has been implicated in cardioprotection. It could 
be speculated that increased activation of p38 MAPK in neighbouring non-ischaemic 
tissue might somehow contribute to overall cardioprotection via a paracrine interaction with 
the ischaemic tissue. It could also be that the postC protocol itself is stimulating an 
increase in p38 MAPK phosphorylation – as is the case in the IPC protocol (Marais et al., 
2001) – without this effect actually being of importance in the eventual cardioprotection. It 
would be interesting to run a series of postC-intervention “controls”, in which a postC 
protocol is applied in the absence of sustained ischaemia / reperfusion. This could then 
shed light on the possible effect of the intervention per se on p38 MAPK phosphorylation.  
 
Another interesting finding at 10 minutes reperfusion, is the significant elevation of total 
PKB/Akt levels in the non-ischaemic tissue of postC working hearts. Two possible 
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mechanisms could be involved, namely: either an increase in protein expression, or a 
change in the degradation of proteins. It is however unlikely that either of these 
mechanisms could come into play after just 10 minutes reperfusion. This significant 
increase was not noted at 30 minutes reperfusion, or in the ischaemic tissue and not at all 
in the Langendorff model. Furthermore, the ratio of phospho – PKB/Akt to total PKB/Akt 
also did not differ between the postC and NonPostC groups, indicating that, as shown in 
the phosphorylation profile of PKB/Akt, there was indeed no significant postC-related 
phosphorylation of PKB/Akt at 10 minutes reperfusion in the non-ischaemic tissue, in the 
working heart model. Whatever the cause, the increase in total PKB/Akt does not appear 
to be significant. 
 
As previously mentioned, at 10 minutes reperfusion, after 35 minutes global ischaemia in 
the Langendorff model, we did observe significant increases in the phosphorylation of both 
ERK p42 and PKB/Akt in the postC group, compared to a NonPostC group. This is in 
accord with several other studies. Many researchers have shown a link between PI3-
kinase – PKB/Akt activity, early in reperfusion (between 7 and 15 minutes reperfusion), 
and the cardioprotection conferred by postconditioning (in rats: Tsang et al., 2004; Zhu et 
al., 2006; Bopassa et al., 2006; as well as in canine hearts: Fujita et al., 2006), as well as 
pharmacological postconditioning with isoflurane administered in reperfusion (Feng et al., 
2006). This activation of PKB/Akt was also shown in diseased hearts, i.e. infarct – 
remodeled (Feng et al., 2006) and hypertrophied (Zhu et al., 2006) hearts. Darling et al. 
(2005), intriguingly found that PI3-kinase is unimportant in postC, and suggested that it is 
rather ERK p42/p44 that is of importance. Increased phosphorylation and activation of 
ERK p42/p44 has indeed been implicated in postconditioning (Fujita et al., 2006; Yang et 
al., 2004). Interestingly, Zhu et al. (2006) found this ERK p42/p44 phosphorylation to be 
dependent on PI3-kinase activity, in agreement with Yang et al. (2004) who speculated 
that PKB/Akt could be upstream from ERK p42/p44 in a form of pharmacological 
postconditioning (bradykinin or an A1/A2 adenosine agonist, NECA, applied at reperfusion). 
Postconditioning with isoflurane however, does not seem to lead to the increased 
phosphorylation of ERK p42/p44 (Feng et al., 2006).  
 
To further investigate the functional importance of the observed increase in 
phosphorylation of PKB/Akt and ERK p42/p44, we utilised inhibitors co-aministered with 
the postC intervention.  
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4.4.3. Inhibition of PKB/Akt using A6730 in reperfusion: effect on 
cardioprotection   
Despite discrepancies in the literature, it generally seems as if especially PKB/Akt, but also 
ERK p42/p44, are involved in the mechanism of postconditioning. The phosphorylation 
profiles that we observed at 10 minutes reperfusion in the Langendorff model, therefore fits 
into the work that has already been done. We however, wanted to establish the 
involvement of these kinases in cardioprotection, by investigating the effect of 
pharmacological inhibition on the infarct sparing effect of  postconditioning.  
 
For inhibition of PKB/Akt, the inhibitor A6730 (Sigma-Aldrich) was used. This compound is 
also known as Akt-I-1/2 and has been shown to be a specific inhibitor of the PKB/Akt 
isoforms Akt1 and Akt2 (Barnett et al., 2005). In cells it has been shown to block the 
phosphorylation of Akt Thr308 and Ser473, affecting downstream components. To our 
knowledge, this is the first study that utilised this inhibitor in the isolated rat heart. All other 
studies done on the role of PKB/Akt in postC utilised either Wortmannin or LY-294002, 
both of which are PI3-kinase inhibitors (Yang et al., 2004; Fujita et al., 2007). This then, is 
the first study to specifically focus on PKB/Akt, not involving upstream PI3-kinase.  
 
As expected, the inhibition of PKB/Akt using the inhibitor A6730 at reperfusion, did 
abrogate the infarct sparing effect of the postC-intervention (fig. 30), indicating PKB/Akt as 
a necessary role player in the postC cardioprotection mechanism.  
 
Interestingly, Barnett and co-workers (2005) reported that this inhibitor has an IC50 value of 
2.7 µM for Akt1 and 21 µM for Akt2. We however demonstrated a significant decrease in 
phosphorylation of PKB/Akt (ser473), compared to positive postC controls, at a 
concentration of 2.5 µM inhibitor (fig. 28). In fact, it could even be argued that the 
concentration we used might have been too much, since it significantly compromised 
functional recovery after sustained ischaemia, in both NonPostC and postC hearts (table 
11 and figure 31). This decrease in functional recovery after the administration of A6730 
further confirms inhibition of PKB/Akt, since PKB/Akt has been implicated in cardiac 
contraction and relaxation (Matsui et al., 2001; Condorelli et al., 2002; and Kim et al., 
2003). In this regard, Matsui and coworkers (2001) found in rats tranfected with a 
constitutively active PKB/Akt mutant, that PKB/Akt exerts a protective effect in the setting 
of ischaemia / reperfusion by decreasing cell death and increasing the functional 
 - 133 -
performance of viable cells. The inotropic effect of PKB/Akt is due to amongst others, 
increased sensitivity of the myofilaments to Ca2+ (Cittadini et al., 2006), as well as 
optimisation of Ca2+ handling (Kim et al., 2003; and Cittadini et al., 2006). The latter has 
been linked to increased Ca2+-current through the L-type Ca2+ channel (Kim et al., 2003), 
as well as post-translational upregulation of SERCA2 (Kim et al., 2003; and Cittadani et 
al., 2006). The wide variety of cellular activities regulated by PKB/Akt complicates 
investigation into its precise role in cardioprotective mechanisms, such as postC. 
Regardless, use of this inhibitor at the concentration we administered, did demonstrate the 
importance of PKB/Akt in the cardioprotective mechanism of postC. 
4.4.4. Inhibition of ERK p42/p44 using PD098059 in reperfusion 
Contrary to expectations, inhibition of ERK p42/p44 using PD098059 in reperfusion, did 
not diminish the infarct sparing effect of postC (fig. 27), which suggests that ERK p42/p44 
is not important in the mechanism of postC, in our model. Others have also shown  that 
ERK p42/p44 is not involved in postC. For example, Feng et al. (2006) did not find 
elevated phosphorylation of ERK p42/p44 in response to isoflurane postconditioning in 
infarct-remodeled rat hearts. Our findings fit in with the phenomenon where increased 
phosphorylation of a kinase does not necessarily imply an increase in enzyme activity or 
functional importance of the kinase. This observation has been made in the setting of IPC: 
In 2000 Behrends et al. reported that MAPK phosphorylation does not correlate with the 
decrease in infarct size elicited by IPC. Bell and colleagues (2007) found that both ERK 
p42/p44 and PKB/Akt activity is of importance in angiotensin II preconditioning, both in the 
early and late phases of protection. However, at 6 hours reperfusion (between the two 
phases), increased phosphorylation of both kinases were observed in the absence of 
cardioprotection. In the case of postconditioning: Schwartz & Lagranha (2006) could not 
elicit a significant decrease in infarct size in swine hearts, although they could demonstrate 
an increase in the phosphorylation of both ERK p42/p44 and PKB/Akt (to the same extent 
as was measured in a cardioprotective preconditioning protocol). Although Zhu et al. 
(2006) demonstrated a cardioprotective effect for postC in remodeled rat hearts, 
associated with an increased phosphorylation of PKB/Akt and ERK p42/p44, only PKB/Akt 
showed increased activity in postC hearts, using in vitro kinase activity assays. ERK 
p42/p44 however, was not activated following the postC intervention, leading them to 
conclude that ERK p42/p44 is not primarily involved in postC protection. It is therefore 
possible that in our model, postC is associated with an increased phosphorylation of ERK 
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p42, without it actually being part of the cardioprotective mechanism – as suggested by the 
results obtained with PD098059.  
 
Another possible confounder that might have had an effect on our results relates to the 
inhibitor, PD098059. This inhibitor was first described in 1995 by Dudley et al. as a specific 
inhibitor of the Mitogen Activated Protein Kinases (MAPKs), specifically ERK, by inhibiting 
the MAPK activating enzyme, MEK. In this original report, it was stated that PD098059 
does not inhibit the MAPK homologues JNK and p38. Interestingly, later in 1995 Alessi 
and colleagues demonstrated that PD098059 does not inhibit the already phosphorylated 
form of MAPK kinase 1 (MAPKK1, more specifically MEK), but prevents the activation and 
phosphorylation of MAPKK1. Since these first descriptions of PD098059, it has been used 
as the main ERK p42/p44 inhibitor in studies to dissect signalling pathways. Another 
inhibitor which is commonly used is U0126. Just like PD, this inhibitor acts as a 
noncompetitive inhibitor of MEK, with a high specificity and affinity for MEK. In fact, its 
affinity seems to be higher than that of PD (Favata et al., 1998). In our study, Western blot 
analysis of hearts treated with PD098059 in reperfusion showed three interesting effects of 
the drug in our model (figures 25 and 26).  
 
First, in both postC and NonPostC groups treated with the drug there was a significant 
decrease in phosphorylated MAPK p38, compared to positive controls (postC without 
inhibitor). In fact, this decrease was more evident than the inhibition of ERK 
phosphorylation. This anomaly might be due to nonspecific inhibtion of p38, which is after 
all a MAPK analogue. Should this be the case, PD098059 administration also eliminated 
p38 MAPK as a functional role player in postC protection. However, in the light of the initial 
descriptions of PD (in which the specificity of the drug was highlighted), this explanation is 
unlikely.  
 
The second and third surprises concern the phosphorylation of ERK p42/p44. 
Simultaneous statistical comparison of the NonPostC+PD, postC+PD and positive control 
(i.e. only postC) hearts (using ANOVA analysis) failed to indicate significant inhibition of 
ERK p44 by the inhibitor (fig. 26). This might be due to the small number of hearts in the 
positive control group (although this author thinks it is unlikely).  It must be noted that 
leaving the NonPostC ERK p44 group out of statistical analysis (i.e. using an unpaired T 
test to  compare phosphorylation levels of only the positive control and postC ERK p44 
 - 135 -
hearts) reveals a statistical difference between the positive control and postC ERK p44 
groups (4.04 ± 0.17 AU vs 1.06 ± 0.16 AU; p < 0.01).  
 
This observation highlights the third surprise, namely the absence of a significant reduction 
in ERK p42/p44 phosphorylation in the NonPostC group. In fact, NonPostC phospho-
ERK44 was almost equal to the positive control (4.11 ± 1.28 AU and 4.04 ± 0.17 AU 
respectively). This unexpected observation might be due to the fact that PD098059 
actually inhibits MEK 1/2, which is directly upstream of ERK p42/p44. The failure of PD to 
inhibit already activated MEK 1/2 (Alessi et al., 1995) might also be a confounding effect. 
As described earlier, PD098059 has been used in various studies – including 
investigations to elucidate the signalling cascades involved in  PostC. Darling et al. (2005) 
infused 10 µM of PD098059 for 30 minutes into rabbit hearts. In a study by Yang and 
colleagues (2004) they also administered 10 µM PD, for 20 minutes. This is the same 
concentration we utilised. In fact, it is the same concentration reported by Dudley et al. 
(1995), as the IC50 value of PD for the inhibition of either basal of partially activated MEK. It 
is therefore unlikely that the concentration we used was at fault. Currently we have no 
explanation for the failure of PD to inhibit ERK p42/p44 in NonPostC hearts. 
  
A possible future route of investigation would be to use U0126 as an alternative inhibitor, 
and then compare it with our PD098059 data. Despite the unexpected observation that 
PD098059 did not inhibit ERK p42/p44 phosphorylation in NonPostC hearts, the inhibitor 
did inhibit the activation of ERK p42/p44 in postC hearts, i.e. the group of interest. For the 
purpose of this study, the dose and timing of PD administration was therefore adequate. 
4.4.5. Summary 
Two different timepoints in reperfusion (10 and 30 minutes), in both the working heart and 
Langendorff models, were investigated to assess the involvement of the RISK pathway 
(PKB/Akt and ERK p42/p44) and p38 MAPK in postC. We could only demonstrate a 
postC-associated increase in the phosphorylation of ERK p42 and PKB/Akt at 10 minutes 
reperfusion, in the retrogradely perfused Langendorff model. Inhibition studies revealed 
that it is only the increase in PKB/Akt phosphorylation that contributes to the infarct sparing 
effect of postC. Possible downstream components of the PI3-kinase – PKB/Akt pathway 
have been identified, in the setting of postC, as the mPTP (Bopassa et al., 2006; 
Manintveld et al., 2007), via GSK-3ß (Zhu et al., 2006). Increased NO production has also 
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been implicated downstream of PKB/Akt, in PostC (Tsang et al., 2004; Zhu et al., 2006; 
Manintveld et al., 2007). 
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Chapter 5: The effect of phosphatase 
inhibition in postconditioning and reperfusion 
 
“The phosphorylation state of a protein is a 
dynamic process controlled by both protein 
kinases and protein phosphatases.” 
 
Wera S & Hemmings BA 
Biochem J 1995; 311:17-29. 
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Chapter 5: The effect of phosphatase inhibition in 
postconditioning and reperfusion 
5.1. Background and motivation 
Not much is known about the roles of the different phosphatases in the setting of 
ischaemia / reperfusion. The few studies that have been done, in general, demonstrate a 
pro-injury role for the phosphatases (Xiuhua et al., 1997; Weinbrenner et al., 1998; 
Armstrong et al., 1998). This conclusion has been based on results obtained using 
pharmacological inhibition of some of the phosphatases, which caused protection against 
injury.  
 
The precise mechanism of protection elicited by phosphatase inhibition is not known, but it 
seems obvious that it should be due to an increase in the phosphorylation state of proteins 
involved in protection. These proteins could be ion-channels and transporters (Carr et al., 
2002; Neumann et al.,1995), structural proteins (Fernandez et al., 1990) or proteins 
involved in established protective pathways such as PKC or the mK+ATP – channel 
(Weinbrenner et al., 1998; Armstrong et al., 1997) or the reperfusion injury survival kinases 
(RISK). 
 
It was therefore decided to investigate the possible role of the phosphatases in the 
mechanism of postC, by administering cantharidin, an inhibitor of  protein phosphatase 
type 1 (PP1) and protein phosphatase type 2A (PP2A), in conjunction with our postC 
protocol. In view of the above, we hypothesise that inhibition of the phosphatases would 
be beneficial to the survival of ischaemic cardiac tissue, maybe even increasing the 
protective effects of postC. If indeed protein phosphatase inhibition were cardioprotective, 
the next question would be if it could be exerting its beneficial effects by increasing the 
activity of the protective reperfusion injury survival kinases that have been implicated in 
postC and IPC (i.e. PKB/Akt and ERK 1/2)? 
5.2. Materials and methods 
To investigate the possible role of the protein phosphatases in the settings of ischaemia / 
reperfusion and postC, cantharidin, a PP1 and PP2A inhibitor was administered at 
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different time points in the perfusion protocol. A stock solution of cantharidin was prepared 
by dissolving 5 mg of the inhibitor in 25 ml pure ethanol (AnalaR grade; Merck chemicals) 
to give a stock concentration of 102 μM. From this solution, 0.5 ml was diluted in 100 ml 
Krebs-Henseleit buffer to give a final concentration of 5 μM, with which the hearts were 
perfused. 
30 minutes reperfusion35 minutes ischaemia 30 minutes 
stabilisation 
General perfusion protocol 
 Working heart model 
PostC 
Control 
(NonPostC) 
PostC 
Control 
(NonPostC) 
10 min
5 
min 
2 min 
35 minutes regional 
ischaemia
Stabilisation 
35 minutes regional 
ischaemia
Stabilisation 
6 x 10 second cycles of global 
reperfusion / ischaemia 
Infarct size 
35 minutes regional 
ischaemia
Stabilisation 
35 minutes regional 
ischaemia
Stabilisation 
15 min 20 min
15 min 20 min
Infarct size 
15 min 20 min
15 min 20 min
Working heart    
perfusion 
Cantharidin 
administration 
Figure 32: The study design used to investigate the effect of cantharidin on the infarct sparing 
effect of postC. Two different time points of cantharidin administration were investigated: either for 
a duration of 10 minutes directly before ischaemia, or during the final 5 minutes of ischaemia and 
the first 2 minutes of reperfusion; in each instance in the presence or absence of postC. Infarct 
size was used as the end-point of investigation. 
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The same basic experimental protocol was followed, as previously described. Hearts were 
perfused in the working mode, with Cantharidin administered for a period of 10 minutes 
directly before sustained ischaemia (35 minutes regional ischaemia), or during the final 5 
minutes of ischaemia and the first 2 minutes of reperfusion. This was done either in the 
presence or absence of the postC intervention (fig. 32). The postC intervention entailed 6 x 
10 second cycles of global reperfusion / ischaemia, under strict thermal regulation during 
ischaemia (36.66 ± 0.11 °C) and the first 10 minutes of reperfusion (36.35 ± 0.09 °C). 
Infarct size (after 30 minutes reperfusion) was used as end-point. All other procedures are 
as described in chapter 2. 
 
5.3. Results 
5.3.1. Pre-treatment with cantharidin 
For the investigation on the effect of Cantharidin pre-treatment (PreCanth) on infarct size, 
data from the NonPostC group that had been perfused at random with the postC group 
were pooled with data from a NonPostC group that had 10 minutes extra stabilisation 
(therefore directly comparable to the pre-treatment protocol). The end result was a 
NonPostC control group that comprised 17 hearts with a baseline AO of 40.29 ± 2.70 
ml/min and a mean CO before ischaemia of 55.18 ± 2.70 ml/min, maintained during 
regional ischaemia at 36.65 ± 0.03 °C and during initial reperfusion at 36.62 ± 0.07 °C. The 
same postC-only group (n = 11; baseline AO = 40.00 ± 2.27 ml/min; baseline CO = 56.68 
± 2.87 ml/min) was used in the evaluation of the effects of cantharidin administration, both 
before ischaemia as well as in reperfusion. The effect of canthiridin pre-treatment on 
infarct size in the presence (PreCanth-postC: n = 7; AO = 45.14 ± 2.26 ml/min; CO = 63.86 
± 1.13 ml/min) and absence (PreCanth-NonPostC: n = 7; AO = 46.86 ± 2.13 ml/min; CO = 
62.43 ± 2.26 ml/min) of postC is shown in figure 33. 
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 The significant reduction in infarct size elicited by postC (17.74 ± 2.72% vs NonPostC: 
30.81 ± 2.90%, p < 0.01) has been described previously. Administration of cantharidin 
before sustained ischaemia also elicited the same degree of infarct size reduction 
(PreCanth-NonPostC: 15.42 ± 1.80% and PreCanth-postC: 13.30 ± 3.46%),  irrespective 
of the presence or absence of postC. The total area at risk, in relation to the total cardiac 
surface area, could be a confounding factor in infarct size determination. The “area at risk” 
for the different groups are shown in figure 34. 
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Figure 33: The effects of 10 minutes administration of a PP1 and PP2A inhibitor, 
cantharidin, immediately before sustained ischaemia on infarct size – in the presence 
and absence of a postC intervention. 
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The area at risk in the postC group was found to be significantly higher than that of the 
postC group pre-treated with cantharidin (52.24 ± 2.38% vs 39.41 ± 2.21%). Since the 
infarct size of both these groups were similarly low (in comparison to NonPostC), it is 
unlikely that in this case, the measured area at risk is exerting a confounding effect. This 
was confirmed by the lack of significant correlation between the area at risk values and the 
infarct size data in both the postC and PreCanth-PostC groups (PostC: r-value = -0.31, p = 
0.4133; PreCanth-PostC: r-value = -0.49, p = 0.3126).  
 
Despite these significant reductions in infarct size associated with cantharidin pre-
treatment and the postC intervention, these interventions could not induce a significant 
increase in functional recovery. Functional recovery of parameters after 30 minutes 
reperfusion, in the various experimental groups, are shown in table 12. Despite the lack of 
significant differences between the four groups (calculated using ANOVA), it does seem as 
if the PreCanth-NonPostC group tended to show weaker recovery. In fact, comparison of 
* P < 0.05  
No 
Cantharidin 
Cantharidin pre-
treatment  
Figure 34: Area at risk (IFS + AR) in relation to the total area in the different treatment 
groups. There is a significant difference in the area at risk between the postC and 
cantharidin treated postC group. (NonPostC: n = 16; PostC: n = 9; PreCanth-NonPostC: 
n = 7; PreCanth-postC: n = 7). 
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only the pre-treated groups revealed a significant difference in aortic output recovery 
(PreCanth-NonPostC: 19.35±2.99% vs PreCanth-postC: 32.12±4.00%). 
 
Table 12: Recovery of functional parameters after 35 minutes regional ischaemia, in 
hearts exposed to combinations of postC, NonPostC and cantharidin pre-treatment. 
Although it seems as if hearts pre-treated with cantharidin, in the absence of postC, 
showed less recovery, it was not significant in an analysis taking all four groups into 
account.  
 
Post-ischaemic function Recovery (%) 
Intervention 
AO (ml/min) CO (ml/min) AO (ml/min) CO (ml/min) 
NonPostC 5.42±1.60 20.04±2.67 9.11±2.97 37.11±4.49 
PostC 2.40±1.36 20.90±2.36 5.30±2.80 37.06±4.04 
PreCanth-
NonPostC 
1.00±1.00 12.07±1.88 2.27±2.27 19.35±2.99 
PreCanth-
PostC 
5.57±2.53 20.71±2.90 11.36±5.09 32.12±4.00 
 
 
As mentioned earlier, at certain concentrations cantharidin has been reported to elicit an 
inotropic effect. Neumann et al. (1995) reported that cantharidin increases the force of 
contraction of guinea-pig papillary muscles in a concentration dependent manner, reaching 
a maximum effect at 10 μM – although Boknik et al. (2001) found that 100 μM elevated 
force of contraction even further. To investigate the possibilty that the concentration of 
cantharidin we were using might induce vasoconstriction of the coronary arteries, coronary 
flow measurements were made at the end of Langendorff stabilisation, just before 
cantharidin administration, at the end of cantharidin perfusion and at the end of 
Langendorff reperfusion (i.e. after 10 minutes reperfusion; note that only measurements 
made during Langendorff perfusion were used). All hearts (both NonPostC and PostC) that 
received pre-treatment were included in this investigation, since the focus was on the 
period of cantharidin treatment, before the postC intervention. The effect of Cantharidin on 
coronary flow is shown in figure 35. 
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Results show that a gradual increase in coronary flow occurs during the experimental 
protocol: at the end of Langendorff reperfusion the coronary flow rate is significantly higher 
than at the end of stabilisation (stabilisation: 8.33 ± 0.32 ml/min vs reperfusion: 10.93 ± 
0.70 ml/min, p < 0.01). The same change in coronary flow rate was also observed in 
hearts which did not receive any canthadirin, but was also exposed to regional ischaemia 
and reperfusion (stabilisation: 8.50 ± 0.30 ml/min vs reperfusion: 10.00 ± 0.34 ml/min, p < 
0.01) – ruling out a possible effect of canthadirin on the observed increase in coronary 
flow. This increase in coronary flow after ischaemia can probably be attributed to physical 
damage to the hearts, due to the tightening of the suture (i.e. the hearts tear slightly and 
therefore become more “leaky”). These results indicate that the cardioprotective effects  
we found to be associated with cantharidin, are not due to vasoconstriction. 
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Figure 35: The effect of cantharidin administration on coronary flow. Measurements were 
taken at the end of Langendorff stabilisation, just before cantharidin pre-treatment, just after 
cantharidin administration and at the end of Langendorff reperfusion. This was done to 
investigate if cantharidin might have an effect of coronary artery tone. Coronary flow rates at 
the end of stabilisation and reperfusion, in hearts not treated with cantharidin, are also 
shown. 
* P < 0.05 
n = 15 - 21 
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5.3.2. Cantharidin treatment in reperfusion 
In these studies administration of cantharidin (during the final 5 minutes of ischaemia and 
the first 2 minutes of reperfusion) was done in the presence (PostCanth-PostC: n = 13; 
baseline AO = 44.54 ± 2.27 ml/min; baseline CO = 61.77 ± 2.87 ml/min) or absence of 
postC (PostCanth-NonPostC: n = 10; baseline AO = 46.60 ± 2.58 ml/min; baseline CO = 
64.75 ± 3.43 ml/min). Temperatures during ischaemia and the first 10 minutes of 
reperfusion were closely monitored and regulated in both groups, as described in chapter 
3 (PostCanth-PostC: RI = 36.35 ± 0.15 °C; reperfusion = 36.24 ± 0.21 °C, and PostCanth-
NonPostC: RI = 36.54 ± 0.12 °C; reperfusion = 36.44 ± 0.26 °C). Since these protocols did 
not employ an extra 10 minutes before ischaemia (contrary to the pre-treatment groups), 
the NonPostC hearts which were perfused with an extra 10 minutes stabilisation were 
excluded from the NonPostC goup – leaving 10 hearts with a baseline AO of 36.70 ± 4.22 
ml/min and CO of 51.15 ± 4.62 ml/min. The same postC group as described in the above 
section (n = 11; baseline AO = 40.00 ± 2.27 ml/min; baseline CO = 56.68 ± 2.87 ml/min), 
was included as an experimental group. 
 
As was the case with cantharidin pre-treatment, administration of the drug during 
reperfusion was associated with a decrease in infarct size in NonPostC hearts (NonPostC: 
35.81 ± 3.67% vs PostCanth-NonPostC: 21.60 ± 2.79%, p < 0.01). Administration of 
cantharidin to postC hearts did not further reduce infarct size (postC: 17.74 ± 2.72% vs 
PostCanth-PostC: 15.39 ± 2.67%). Unlike the above described pre-treatment experiments, 
there were no significant differences between the area at risk values for the four groups. 
The area at risk values in the different groups are as follows: NonPostC: n = 9, 48.08 ± 
2.96%; PostC: n = 9, 52.24 ± 2.38%; PostCanth-NonPostC: n = 10, 58.98 ± 1.50% and 
PostCanth-PostC: n = 13, 51.59 ± 3.31%. Infarct size data is shown in figure 36. 
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Just as observed in the pre-treatment groups, there was no significant increase in 
functional recovery in any of the treated hearts or in the postC group itself (table 13).  
 
Table 13: Functional recovery in hearts exposed to 35 minutes regional ischaemia and 30 
minutes reperfusion. Hearts were treated with cantharidin in reperfusion in the presence 
and absence of postC. No significant differences are present between the groups. 
 
Post-ischaemic function Recovery (%) 
Intervention 
AO (ml/min) CO (ml/min) AO (ml/min) CO (ml/min) 
NonPostC 4.60±2.00 17.65±3.13 10.86±4.71 36.29±5.84 
PostC 2.40±1.36 20.90±2.36 5.30±2.80 37.06±4.04 
PostCanth-
NonPostC 
4.05±1.76 22.80±3.97 8.41±3.48 34.87±5.09 
PostCanth-
PostC 
5.52±2.16 25.05±2.42 11.67±4.25 40.78±3.32 
* P < 0.05 
NonPostC PostC  
Figure 36: The effect of cantharidin administration during the final 5 minutes of ischaemia 
and the first 2 minutes of reperfusion, either with or without the application of a postC 
intervention, on infarct size. Cantharidin treatment reduced infarct size to the same extent 
as postconditioning. 
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After 30 minutes reperfusion, the aortic output in the NonPostC group averaged 4.6 ± 2.00 
ml/min, compared to 2.4 ± 1.36 ml/min in the the postC group. In hearts which received 
cantharidin in reperfusion, aortic output was 4.05 ± 1.76 ml/min in the NonPostC group 
and 5.52 ± 2.16 ml/min in the postC group. Cardiac output also declined to the same 
degree in all four groups: NonPostC = 17.65 ± 3.13 ml/min; postC = 20.90 ± 2.36 ml/min; 
PostCanth-NonPostC = 22.80 ± 3.97 ml/min and PostCanth-PostC = 25.05 ± 2.42 ml/min. 
The infarct sparing effect of cantharidin in our model, does therefore not seem to be 
associated with improved functional recovery during reperfusion. 
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 5.3.3. Kinases and the infarct sparing effect of Cantharidin 
In order to investigate the mechanism of cantharidin action in ischaemia / reperfusion, the 
drug was administered in the working heart model at the same time points as described 
above. Hearts were then freeze-clamped after 5 or 10 minutes of reperfusion. Western 
blotting (as described in chapter 2) was used to investigate the total and phosphorylated 
levels of p38 MAPK, ERK p42/p44 and PKB/Akt. Two different perfusion protocols were 
followed (fig. 37):  
Cantharidin 
administration 
10 min
Figure 37: Investigating the possible role of some of the signalling kinases in the mechanism 
of cantharidin cardioprotection. Cantharidin was administered either before ischaemia 
(PreCanth), or in the initial stage of reperfusion (PostCanth). Control hearts  did not receive 
cantharidin (NonCanth). At this stage the postC protocol was not included in the 
experiments. 
Working heart 
perfusion 
2 min 5 
min
10 min 
5 min 
Working heart model 
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Control 
(NonCanth) 
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ischaemia
Stabilisation 
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 5.3.3.1. Pre-treatment with Cantharidin 
Two perfusion protocols were employed to investigate the effect of cantharidin 
administration before sustained ischaemia on the kinases of interest:  In the PreCanth 
group (n = 5), cantharidin was administered for a period of 10 minutes directly before 20 
minutes sustained global ischaemia and hearts were freeze-clamped after 5 minutes 
reperfusion. The NonCanth group (n = 5) followed the same protocol, but in the absence of 
any cantharidin (40 minutes stabilisation followed by 20 minutes global ischaemia and 5 
minutes reperfusion) (fig. 37).  Since we found thermal regulation during ischaemia and 
the first 10 minutes of reperfusion to be of importance in postC (see chapter 3), these 
hearts were also subjected to similar thermal regulation, i.e. approximately 36.5 – 37.3 °C 
during ischaemia / reperfusion. We were particularly interested in the effects on the kinase 
activities, it was therefore decided to use a global ischaemic model, which yields 
homogeneous tissue for analysis. It is important to note that, since the focus of this part of 
the investigation was solely on the activity of cantharidin, the postC-intervention was not 
applied in any experimental protocol. Baseline functional values of the two experimental 
groups are shown in table 14. 
 
Table 14: Baseline functional 
values of hearts used for the 
investigation into the effect of 
cantharidin pre-treatment on 
the kinase profiles.Hearts 
were either treated with cantharidin before sustained ischaemia (PreCanth; n = 5) or 
perfused without intervention (NonCanth; n = 5). 
Baseline values 
Intervention 
AO (ml/min) CO (ml/min) 
NonCanth 46.40 ± 2.23 61.90 ± 2.68 
PreCanth 51.20 ± 1.02 67.10 ± 1.56 
 
Total protein and phosphorylation profiles associated with Cantharidin pre-treatment  are 
shown in figure 38. No differences in total protein levels were observed, concerning any of 
the kinases of interest. This was not the case with the phosphorylation profiles. 
Interestingly Cantharidin pre-treatment was associated with a significant increase in the 
phosphorylation of p38 MAPK (PreCanth: 2.49 ± 0.17 AU vs NonCanth: 1.52 ± 0.26 AU, p 
< 0.05). Increased phosphorylation of ERK p42/p44 and PKB/Akt, in these experiments, 
were not recruited in the cardioprotection imparted by the administration of Cantharidin 
before sustained ischaemia. 
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Total PKB/Akt Phospho PKB/Akt
Total ERK p42/p44 Phospho ERK p42/p44 
Figure 38: Levels of total and phosphorylated p38 MAPK (A), PKB/Akt (B) and ERK p42/p44 (C) 
after treatment with Cantharidin, prior to a 20 minute global ischaemic insult in the working heart 
model. Hearts were freeze-clamped at 5 minutes reperfusion. Cantharidin pre-treatment was not 
associated with any changes in the kinase profiles, except for a significant increase in 
phosphorylated p38 MAPK. Control hearts; n=2.
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5.3.3.2. Cantharidin treatment in reperfusion 
To investigate cantharidin administered in reperfusion (Post-Canth), the same protocol 
was followed as was used in the investigation into the roles of the kinases in postC. 
Basically, hearts were stabilised and then subjected to 35 minutes of regional ischaemia, 
followed by 10 minutes of reperfusion. Two experimental groups were perfused: In the 
PostCanth-group (n = 6) cantharidin was administered in the final 5 minutes of ischaemia 
and the first 2 minutes of reperfusion, without the postC-intervention being co-
administered. The second group served as a control group in which hearts did not receive 
any cantharidin (NonCanth, n = 6). Hearts were then freeze-clamped at 10 minutes 
reperfusion, since our study on the kinases in postC showed this time point to be 
important. All hearts were subjected to the same thermal regulation as described in 
chapter 3. Baseline functional data of the hearts used in these experimental groups are 
shown in table 15. It was decided, that in these experiments the ischaemic and non-
ischaemic zones of the heart would be freeze-clamped separately. Since, our interest lay 
primarily with the ischaemic tissue, only these samples were analyzed using Western 
blotting (as described in chapter 2).  
 
Table 15: Pre-ischaemic 
functional parameters as 
measured in the two 
experimental groups, i.e. 
either in the presence (PostCanth) or absence (NonCanth) of cantharidin during the final 5 
minutes of ischaemia and the first 2 minutes of reperfusion. None of the experimental 
groups included a postC intervention. 
Baseline values 
Intervention 
AO (ml/min) CO (ml/min) 
NonCanth 48.00 ± 3.39 64.00 ± 3.22 
PostCanth 39.67 ± 0.92 65.92 ± 0.91 
 
Results of the Western blotting analysis are shown in figure 39. As was the case with pre-
treatment, cantharidin given during the final 5 minutes of regional ischaemia and the first 2 
minutes of reperfusion did not alter the total levels of any of the kinases under 
investigation. Cantharidin administered in reperfusion did however exert an effect on the 
phosphorylation of some of the kinases (fig. 39). Similar to the effect of pre-treatment on 
p38 MAPK, cantharidin given in reperfusion was also associated with a significant increase 
in the phosphorylation of p38 MAPK (NonCanth: 5.64 ± 1.17 AU vs Post-Canth: 10.69 ± 
1.29 AU, P < 0.05). In addition, administration of cantharidin in reperfusion was associated 
with a significant increase in the phosphorylated form of ERK p42 (NonCanth: 2.24 ± 0.21 
AU vs Post-Canth: 3.34 ± 0.37 AU, p < 0.05), which was not the case with pre-treatment. 
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Figure 39: Total and phosphorylated p38 MAPK (A), PKB/Akt (B) and ERK p42/p44 (C) profiles at 10 
minutes reperfusion, after 35 minutes regional ischaemia, in the presence or absence of Cantharidin 
during reperfusion. Cantharidin administration was associated with a significant increase in 
phosphorylated p38 MAPK and ERK p42. Control hearts; n=2. 
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5.3.4. Vehicle controls 
To assess the possible influence of the solvent used in the administration of cantharidin, 
hearts were treated with only 500 µL pure ethanol / 100 ml Krebs-Henseleit buffer, instead 
of cantharidin, in a pre-treatment protocol and a reperfusion protocol (as described for 
canthadirin in figure 37).  
 
Ethanol administered for a duration of 10 minutes directly before 20 minutes global 
ischaemia, did not exert any effect on the phosphorylation of the kinases under 
investigation (n = 5), in comparison to hearts subjected to a similar protocol, but with no 
ethanol or drug administration (n = 5) (data not shown). 
 
In the reperfusion protocol ethanol was administered for the final 5 minutes of regional 
ischaemia and the first 2 minutes of reperfusion. After 10 minutes reperfusion hearts were 
divided into ischaemic and non-ischaemic zones and both these segments freeze-
clamped. As described in the cantharidin experiments, the tissue exposed to ischaemia 
was analysed using Western blotting. Hearts treated with ethanol (PostEtOH: n = 5, 
baseline AO = 48.80 ± 2.33 ml/min, baseline CO = 66.10 ± 2.86 ml/min) were compared to 
hearts exposed to a similar protocol, but in the absence of ethanol administration 
(NonEtOH: n = 4, AO = 46.50 ± 4.65 ml/min, CO = 62.13 ± 5.11 ml/min). Ethanol 
administered in reperfusion did not exert an effect on ERK p42/p44 (data not shown). 
There was however an association between ethanol reperfusion and a significant increase 
in the phosphorylation of p38 MAPK (NonEtOH: 0.31 ± 0.05 AU vs PostEtOH: 0.60 ± 0.07 
AU; p < 0.05) and PKB/Akt (NonEtOH: 1.81 ± 0.24 AU vs PostEtOH: 2.88 ± 0.24 AU; p < 
0.05) (figure 40). 
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Figure 40: The effect of ethanol administered in the final 5 minutes of ischaemia and the 
first 2 minutes of reperfusion on p38 MAPK and PKB/Akt in tissue exposed to ischaemia. 
Ethanol was associated with a significant increase in the phosphorylation of both these 
kinases,  without exerting an effect of the total protein content. 
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5.4. Discussion 
5.4.1. Effect of cantharidin treatment on infarct size 
Treatment with Cantharidin, either directly before ischaemia or in reperfusion, was 
associated with a decrease in infarct size (figures 33 and 36). This cantharidin-induced 
decrease in infarct size was observed in the presence, as well as the absence of the 
postC-intervention. Just as was the case with our initial studies on postC in the working 
heart model, we could not elicit any improvement in functional recovery in either the postC 
hearts, or hearts treated with cantharidin (again in the presence and absence of postC, 
given as a pre-treatment or in reperfusion). These results confirm the conclusions made in 
chapter 3, namely that a reduction in infarct size fails to show a relationship with an 
improvement in functional recovery in the ex vivo working heart model, and that eliciting 
functional recovery in the postconditioned working heart is quite a challenge. 
 
The finding of a protective effect due to phosphatase inhibition, in the context of ischaemia 
/ reperfusion is not a new one, and has been reported in the literature by several workers. 
Similar to our pre-treatment experiments: In 1997 Armstrong and co-workers reported that 
administration of a protein phosphatase inhibitor, fostriecin, for a period of 10 minutes 
directly before sustained ischaemia, protected isolated cardiomyocytes. These authors in 
fact suggested that it mimicked preconditioning. Xiuhua et al. (1997) similarly reported 
that, in vascular smooth muscle cells, 10 minutes incubation with okadaic acid (a protein 
phosphatase inhibitor) before a hypoxic preconditioning protocol, followed by hypoxia and 
reoxygenation, elicited a protective preconditioning-like effect. Armstrong et al. (1998) 
found that the administration of the protein phosphatase inhibitors, calyculin A and 
fostriecin, 75 minutes into ischaemia still protected rabbit cardiomyocytes – even to the 
same degree as pre-incubation before ischaemia. They speculated that this protection 
might be due to the increased phosphorylation of structural proteins (which then maintain 
cellular structural intergrity) and proteases (favouring inhibition of these enzymes).  
 
Cardioprotection associated with phosphatase inhibition in reperfusion has been reported 
by Fenton et al. (2005), who investigated the effect of phosphatase inhibition on 
preconditioning in the aged rat heart. In agreement with our results, they reported that 
okadaic acid administered in reperfusion, in young rat hearts, was associated with a 
significant reduction in infarct size (31%). Interestingly, in this same model, when they 
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administered okadaic acid for 25 minutes before ischaemia, they did not observe a 
significant reduction in infarct size – contrary to our pre-treatment results. Contrary to our 
results and Fenton et al. (2005), Hausenloy and co-workers (2002) reported that 
administration of FK508 (an inhibitor of the phosphatase calcineurin) in reperfusion 
exerted no infarct sparing effect in the isolated rat heart.  
 
Except for this latter study, it seems clear that phosphatase inhibition is associated with 
protection. The precise mechanisms by which phosphatase inhibition however protects 
cells, still have to be determined. 
 
There was no additive cardioprotective effect observed with the combination of postC and 
cantharidin (either as a pre-treatment or administered in reperfusion). In fact the decrease 
in infarct size elicited by postC, cantharidin pre-treatment and postC combined with 
cantharidin were all of the same magnitude, with no significant differences between these 
groups (percentage decreases in infarct size are shown in table 4). This lack in additive 
infarct sparing effect might be due to a maximum degree of protection elicted by each of 
these treatment strategies. It could also be that these two strategies share the same 
mechanism, in which case postC protects by inhibiting phosphatases – this however 
seems unlikely, as will be discussed later in the text. 
 
Table 4: Percentage decreases in infarct size compared to the NonPostC group used in 
the cantharidin pre-treatment experiments (with an infarct size of 30.81 ± 2.90%). 
Decreases induced by postC and cantharidin treatment, either on its own or in combination 
with postC, are of the same magnitude. There does not seem to be a cumulative infarct 
sparing effect when Cantharidin is administered together with a postC intervention. 
 
 
 NonCanthadirin (%) 
Cantharidin pre-
treatment (%) 
Cantharidin in 
reperfusion (%) 
NonPostC   49.95  29.90  
PostC  42.42  56.83  50.05 
After the initial description of postconditioning, the possible additive protection that might 
be elicited by a combination of ischaemic preconditioning and postconditioning was 
investigated. Contradictory results were reported. Halkos et al. (2004) could not 
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demonstrate an additive effect when both these interventions were applied in their canine 
model. Both IPC and postC however elicited a comparable degree of protection (both IPC 
and postC in their model elicited an approximate 50% decrease in infarct size). Similar 
results were also reported by Tsang et al. (2004) in isolated perfused rat hearts. On the 
other hand, Yang and colleagues (2004) reported that IPC and postC both reduced IFS 
from 62% to between 35% and 40% in their rabbit model. However, co-administration of 
these interventions significantly reduced IFS even further to 22%, demonstrating an 
additive effect which argues against the possibility that postC on its own elicits a maximum 
degree of protection. More comparable to our work is a study done by Chiari et al. (2005). 
They found that co-administration of a non-protective postC intervention (3 x 10 seconds), 
together with a non-protective level of isoflurane in reperfusion (0.5 MAC administered 
three minutes before and two minutes after reperfusion) induced a decrease in infarct size 
from 41% to 17%, equal to a protective postC protocol (3 x 20 seconds, IFS: 20%) or a 
higher protective dose of isoflurane (1.0 MAC, IFS: 21%). Similarly, Weihrauch and 
coworkers (2005) found that the combination of non-protective concentrations of morphine 
and isoflurane during reperfusion (final 3 minutes of ischaemia and the first 2 minutes of 
reperfusion) elicited an infarct sparing effect equal to the effect exerted by any one of the 
two drugs, at double the concentration. In both these cases it could be argued that the 
drugs administered at the higher concentration in fact elicited a maximum degree of 
protection, with the co-administration of sub-protective interventions showing an additive 
effect – until the maximum protection was reached. In 2006 Tessier-Vetzel et al. reported 
that co-administration of isoflurane with an ischaemic postC protocol (4 x 30 seconds) 
enhanced the infarct sparing effects of the postC intervention. This was true with 2% 
isoflurane administered throughout their experiments, as well as only in reperfusion. 
Studies on the combination of a drug (a p53 inhibitor) and anesthetic postconditioning 
(Venkatapuram et al., 2006), as well as combination of anesthetic preconditioning and 
anesthetic postcondtitioning (Obal et al., 2005) all report enhancement of protection. 
However, Deyhimy et al. (2007) reported no additive effect with a combination of 
sevoflurane preconditioning and postconditioning.  
 
It therefore seems possible that, in principle, an additive degree of protection can be be 
elicited when postC is combined with other interventions, although a maximum degree of 
protection can be reached. The relevant question therefore seems to be when is the 
applied postC protocol already eliciting a maximum degree of protection? Another closely 
related question would be whether the additional treatment acts via the same 
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cardioprotective mechanism as postC. If so, it makes even more sense that a maximum 
degree of protection can be reached, when all the components of the relevant mechanism 
have been maximally recruited. Since we saw a comparable degree of infarct size 
reduction between cantharidin treatment and postC, without an additive effect when the 
two are co-administered, we decided to investigate if cantharidin was indeed recruiting the 
same kinases as postC in its protection mechanism. 
5.4.2. Cantharidin pre-treatment: effect on kinase profiles 
The effect of cantharidin, administered directly before the onset of ischaemia, on the 
kinase profiles are shown in figure 38. Although there might have been enough time for 
protein synthesis (35 minutes, of which 20 minutes was global ischaemia) between the 
initiation of drug administration and eventual freeze-clamping, no differences in total 
protein levels were observed. This was not unexpected, since in all likelihood, cantharidin  
is conferring its cardioprotective effect through the modulation of existing proteins and 
kinases.  
 
Interestingly, pre-treatment was associated with a significant increase in the 
phosphorylation of p38 MAPK. Again we are confronted with the problem whether p38 
MAPK activation is protective. Interestingly, although PP2A has been implicated in p38 
MAPK regulation (Doza et al., 1995), it seems that this kinase is especially regulated by 
PP2C (Millward et al., 1999). The observation that phosphatase inhibitors are associated 
with an increase in phosphorylated p38 MAPK is however not new. Armstrong et al. (1998) 
reported that administration of calyculin A before the onset of ischaemia increased the 
level of phosphorylated p38 MAPK during ischaemia. In a later paper they speculated 
(Armstrong et al., 1999) that the protection associated with phosphatase inhibition might in 
fact be due to the increase in phosphorylated p38 MAPK, which then recruits the 
protective heat shock protein, HSP27 (they found that a p38 MAPK inhibitor, SB203580, 
was associated with an accelerated ischaemic dephosphorylation of HSP27 and 
development of injury in cardiomyocytes). On the other hand, Mackay & Mochly-Rosen 
(2000) found that administration of vanadate (a tyrosine phosphatase inhibitor) increased 
the phosphorylation of p38 MAPK during ischaemia, which then favoured an increase in 
cell damage. Inhibiting p38 MAPK (using SB203580) decreased cell damage, even in the 
presence of vanadate. These controversial observations, however, could be due to 
species differences (rabbits vs rats, respectively). 
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The question is therefore whether the increased p38 MAPK phosphorylation observed in 
our rat heart model, is of any significance in the increased cardioprotection induced by pre-
treatment with cantharidin. Depending on the dominantly activated p38 MAPK isoform, this 
increase in phosphorylation might be protective. Saurin and co-workers (2000) however 
speculate that it might be the detrimental α-isoform which increases during ischaemia. This 
corresponds to the observation that protective ischaemic preconditioning is associated 
with an attenuated increase in phosphorylated p38 MAPK during ischaemia and 
reperfusion (Marais et al., 2005). In fact, Moolman and colleagues (2006) report that the 
administration of a p38 MAPK inhibitor (SB203580) 10 minutes directly before ischaemia 
conferred protection against both infarct size development and apoptosis. This then leaves 
us with two options: either the increased phosphorylation due to phosphatase inhibition 
favours a protective isoform of p38 MAPK, or the observed increase is a cellular response 
associated with cantharidin which does not affect the cardioprotection elicited by the drug. 
Clearly, further investigation is required. 
5.4.3. Cantharidin in reperfusion: effect on kinase profiles 
As expected after a time lapse of just 8 minutes (between cantharidin administration and 
freeze-clamping), no significant differences in total protein levels were observed (fig. 39). 
These results indicate that, as with cantharidin pre-treatment, cantharidin in reperfusion is 
eliciting its cardioprotective effect through the modulation of existing proteins 
 
The question is therefore: which proteins / kinases are being modulated by cantharidin in 
reperfusion? In our model we found that cantharidin administration in reperfusion was 
associated with significant increases in the phosphorylation of both p38 MAPK and ERK 
p42 (fig. 39).  
 
As discussed in the pre-treatment group, the increase in p38 MAPK phosphorylation is 
probably due to the inhibitory effects of cantharidin on PP1 and PP2A activity, causing  
maintainance of phosphorylated p38 MAPK, which was generated during ischaemia and 
reperfusion. The question however remains whether this observed significant activation is 
actively contributing to protection, or not? As discussed above, it seems unlikely that 
increased p38 MAPK phosphorylation is cardioprotective in the rat heart. 
  
Activation of ERK p42/p44 during reperfusion has been implicated in cardioprotection – 
both in ischaemic preconditioning (Hausenloy et al., 2005) and postconditioning (Darling et 
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al., 2005; Yang et al., 2004). In our experiments we found a slight increase in ERK 
p42/p44 phosphorylation in the first 10 minutes of reperfusion, compared to control hearts 
which were freeze-clamped directly after stabilisation (in ERK p42: NonCanth = 10611 ± 
1006 total pixels vs control = 4750 ± 30.34 total pixels; and ERK p44: NonCanth = 4139 ± 
659.2 total pixels vs control = 1577 ± 467.8 total pixels). It is therefore conceivable that this 
slight ischaemia / reperfusion-induced increase in phosphorylation is further enhanced and 
sustained in the presence of cantharidin during reperfusion. The phosphorylation of ERK 
p42/p44 is known to be regulated by amonst others PP2A (Anderson et al., 1990; Sontag 
et al., 1997; and Millward et al., 1999), it is therefore not surprising that a PP2A inhibitor 
favours ERK p42/p44 phosphorylation. 
 
Interestingly, cantharidin did not enhance PKB/Akt activation during reperfusion. PKB/Akt 
also presented with an increase in activation in the presence of only reperfusion 
(approximately a 5 fold increase in phospho-PKB/Akt in NonCanth hearts, compared to 
control hearts exposed to only 30 minutes perfusion). This absence of increased 
phosphorylation is difficult to explain, as cantharidin is an inhibitor of PP1 / PP2A and 
PP2A plays a role in the the regulation  and dephosphorylation of PKB/Akt (Andjelkovic M 
et al., 1996; Millward et al., 1999; and Ugi et al., 2004). We can only speculate  that there 
might be other factors, beside the protein phosphatases, that are dephosphorylating 
PKB/Akt in our experimental setup. In this regard, PTEN (a protein tyrosine phosphatase) 
has also been identified as a negative regulator of the PI3-kinase – PKB/Akt pathway 
(Stambolic et al., 1998). It must be remembered that the phosphorylation status of the 
kinases is the result of the balance between phosphorylating and dephosphorylating 
factors. Inclusion of cantharidin in our model definitely favours phosphorylation, but it could 
be, that for some proteins the equilibrium still remains shifted in the direction of 
dephosphorylation during reperfusion. Identifying all the factors involved in the 
determination of this balance is still an ongoing scientific pursuit.  
 
5.4.4. Vehicle controls 
Ethanol administered for a period of 10 minutes immediately before 20 minutes global 
ischaemia did not influence the expression or phosphorylation of any of the kinases under 
investigation. This confirms that the increased phosphorylation of p38 MAPK, associated 
with cantharidin pre-treatment, is indeed due to the action of the phosphatase inhibitor. 
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Administration of ethanol during reperfusion was however associated with signficant 
increases in the phosphorylation of both p38 MAPK and PKB/Akt (fig. 40). Not much work 
has been done on the effect of ethanol on the kinases in cardiac tissue. Studies that have 
been done on the effects of ethanol in other tissues have reported contradictory results: in 
the rat hippocampus ethanol increased the activation of MAPK p38 and ERK p42/p44 (Ku 
et al., 2007); in rat testes (Koh et al., 2007) and brain (Han et al., 2006) ethanol was found 
to reduce the activation of PKB/Akt and ERK p42/p44, while Zhang et al. (2005) found that 
ethanol decreased phospho-ERK p42/p44 and exerted no effect on p38 MAPK in murine 
cardiomyocytes. Differences in ethanol administration and dosage, as well as model used 
and tissue studied, makes it virtually impossible to compare our results to those reported 
by others. The possible effects of ethanol in cardiomyocytes also fall outside the scope of 
this text.  
 
Although it could be argued that the increase in phosphorylated p38 MAPK, associated 
with cantaridin administration during reperfusion, is actually due to the ethanol solvent 
present, it is also very likely that cantharidin at least contributed to this increase. Especially 
since we observed an ethanol-independent increase in p38 MAPK phosphorylation 
associated with cantharidin pre-treatment, confirming this stimulatory effect of 
phosphatase inhibition in our model. 
 
The absence of increased PKB/Akt phosphorylation associated with cantharidin 
administration is even more surprising in view of the observed stimulatory effect of ethanol. 
Cantharidin has been associated with the increased phosphorylation of various proteins 
(Neumann et al., 1995). It could therefore be speculated that cantharidin somehow 
interferes with the signalling cascade triggered by ethanol. At this stage, we are however 
unable to explain the absence of increased PKB/Akt phosphorylation in the presence of 
both ethanol and cantharidin (since both are expected to increase PKB/Akt 
phosphorylation). 
 
It has been reported that transient exposure to ethanol before a period of sustained 
ischaemia, confers protection in both the intact heart, as well as cardiomyocytes (Chen et 
al., 1999). For a review on the acute effects of ethanol administration, in the setting of 
ischaemia / reperfusion, see Krenz et al. (2004). Interestingly, Krenz et al. (2001) found 
that ethanol blocks its own protective effect, when it remains present during the sustained 
ischaemia. Although we did not investigate the effect of only ethanol on IFS, it is unlikely to 
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be a confounding factor in our model. In our pre-treatment experiments ethanol was still 
present during ischaemia, since there was no wash-out period between drug 
administration and ischaemia. Theoretically, the ethanol present would therefore not exert 
a protective effect. Other workers have reported the protective effects of phosphatase 
inhibition, confirming our results. In our lab phosphatase inhibition using okadaic acid, 
dissolved in DMSO, elicited the same protective profile as cantharidin. Although further 
investigation could be done on the effects of ethanol in reperfusion, we are confident that 
the infarct-sparing effects observed is attributable to cantharidin. 
 
Despite the unexpected effects of the solvent on the kinase profiles, it seems reasonable 
to still conclude that cantharidin administered during reperfusion increases the 
phosphorylation of ERK p42 and p38 MAPK (fig. 39). The infarct sparing effect of 
cantharidin administered in reperfusion (fig. 36) remains independent of PKB/Akt 
activation. 
5.4.5. Summary 
In summary, we are now left with two interesting questions and one noteworthy 
observation. We found that p38 MAPK is significantly activated in reperfusion, in 
cantharidin treated hearts (pre-treatment, as well as in reperfusion). Cantharidin is also 
cardioprotecive and decreases infarct size. The question that therefore still needs to be 
adressed is whether p38 MAPK is important in this protection. To further investigate this 
problem infarct size could be monitored in the presence of a p38 MAPK inhibitor (such as 
SB203580), administered together with cantharidin – as a pre-treatment, but especially in 
reperfusion. 
 
The same question can also be asked concerning the role of the upregulation of 
phosphorylated ERK p42 in the cardioprotection, observed with the administration of 
cantharidin in reperfusion. As with p38 MAPK, this question can possibly be answered by 
the administration of an ERK p42/p44 inhibitor such as PD098059 or U0126, together with 
cantharidin, during reperfusion. 
 
Despite the above mentioned uncertainties and questions still to be investigated, we did 
observe an unexpected and definite lack of PKB/Akt activation in the presence of 
cantharidin. This is contrary to our observation in postconditioned hearts, in which we 
found a definite important role for the activation of PKB/Akt, during reperfusion, in the 
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cardioprotective mechanism of postconditioning. We can therefore conclude that 
cantharidin seems to elicit its cardioprotective effect through a different mechanism than 
postconditioning. However, despite these differences in protective mechanisms recruited, 
co-treatment of hearts with both a postC-intervention and cantharidin do not elicit a greater 
infarct sparing effect, than each on its own. Should it be the case that cantharidin is 
exerting its protective effect through a different mechanism than postC, it becomes even 
more difficult to explain why cantharidin and postC do not have additive protective effects. 
Another explanation for the lack of additive protection, despite separate signalling / 
mediator pathways, might be that both interventions recruit the same protection end-
effector(s). However, in my view, it is most likely that each intervention on its own elicited a 
maximum degree of protection, which can not be increased further. 
 
Another possibility to be considered is that cantharidin is eliciting its cardioprotective effect 
primarily through mechanisms that do not include the signalling kinases (discussed in 
chapter 1). Other possible cardioprotective candidates, that have been implicated in 
phosphatase inhibition, include an increased phosphorylation and stabilisation of structural 
proteins (Fernandez et al., 1990) or more optimal handling of intracellular calcium 
(Neumann et al., 1995; and Carr et al., 2002) and sodium (Chen et al., 1995).  
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Chapter 6: Conclusion 
 
“A cheerful heart is good medicine…” 
 
Proverbs 17:22 
The Bible 
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Chapter 6: Conclusion 
6.1. Developing a postconditioning protocol 
In this study we endeavoured to develop a cardioprotective postconditioning protocol in the 
isolated perfused rat heart, using the retrogradely perfused Langendorff model, as well as 
the working heart model. The purpose of establishing these postC protocols was to 
characterise the kinases involved in postC cardioprotection, as well as to investigate the 
possible role of the protein phosphatases in the mechanism of postC. 
 
In an effort to optimise postC protection, we focussed our attention on four different 
parameters: 
I. The number of cycles of reperfusion and ischaemia: we applied 3, 4 and 6 cycles in 
different protocols. 
II. The duration of each cycle: we experimented with 10, 15, 20 and 30 second cycles. 
III. The mode of postC application: this refers to either manipulating the flow of 
perfusate to the heart as a whole, or manipulating flow to only the tissue exposed 
to the sustained ischaemic insult (by opening and closing the coronary artery 
ligature). 
IV. The temperature of the hearts during ischaemia and early reperfusion, especially 
during the postC intervention itself. 
 
We found that a 6 x 10 second global reperfusion / ischaemia protocol, applied at a 
temperature of approximately 37 °C, conferred an infarct sparing effect in both the working 
heart, as well as Langendorff models. We could however only demonstrate functional 
recovery in the Langendorff model. Our results suggest that although postC can confer 
cardioprotection, it is an intervention that is very sensitive to experimental conditions and it 
is not as robust in exerting protection as ischaemic preconditioning. It might be that the 
animal model we used (the rat) is particularly less sensitive to the cardioprotection 
conferred by postC. In the first postC experiments done in rats, it was noted that postC did 
not impart such a potent degree of protection, as observed in the dog and rabbit (Kin et al., 
2004). It is however a fact that postC protection has been reported to be subject to 
experimental variation in all laboratory animal species tested (Vinten-Johansen et al., 
2007). Nevertheless, it is encouraging that postC could limit infarct size in the energy 
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demanding working heart model. Although Sasaki et al. (2007) has also investigated postC 
in a working heart model, this study is the first to demonstrate the infarct sparing effect of a 
postC protocol in the working heart, similar to the protocols that have been successfully 
used in the Langendorff model. We could therefore show that postC can limit infarct size, 
even under conditions of hightened energy metabolism, as occurs in the working heart. 
6.2. Signalling kinases involved in postconditioning 
Characterisation of the kinase profiles (specifically PKB/Akt, p38 MAPK and ERK p42/p44) 
in our postC intervention in both ex vivo models, at 10 and 30 minutes reperfusion, yielded 
disappointing results: only at 10 minutes reperfusion in the Langendorff model an increase 
in phosphorylated ERK p42 and PKB/Akt, associated with postC, could be observed. This 
indicated that the kinase signalling cascase component of the postC mechanism is active 
only in the early minutes of reperfusion. Using pharmacological inhibition studies, we could 
demonstrate a functional role, in postC cardioprotection, for PKB/Akt, but not for ERK 
p42/p44. In our model, postconditioning is therefore associated with an increase in the 
phosphorylation of ERK p42 and PKB/Akt early in reperfusion, although only PKB/Akt is 
necessary in the mediation of the cardioprotective effect. 
6.3. The role of protein phosphatases in postconditioning 
For the investigation into the possible role of PP1 and PP2A in postC, an inhibitor of both 
(cantharidin) was administered. Inhibition of these serine / threonine phosphatases 
immediately before sustained ischaemia, as well as in reperfusion conferred an infarct 
sparing effect independent of postC, suggesting an alternative cardioprotective 
mechanism. Further investigation in the working heart revealed that cantharidin 
administration was associated with an increase in the phosphorylation of p38 MAPK and, 
when administered in reperfusion, also ERK p42. Although we did not determine the 
functional importance of these kinases in cantharidin protection, the difference in kinase 
activation profile indicates that cantharidin protects the hearts through a different signalling 
pathway, than postC. It therefore seems unlikely that postC is dependent on phosphatase 
inhibition in its mechanism.  
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6.4. Limitations and future directions 
Although we found an elevated temperature to be important in eliciting postconditioning, it 
is a confounding factor which we only identified, but did not further investigate. It would be 
interesting and of experimental value to characterise the precise impact of temperature on 
postC efficacy. This could be done by systematically applying different temperatures 
during postconditioning. Such experimentation would however require even more strict 
thermal control and accurate temperature measurements than is currently the accepted 
standard. 
 
The lack of phosphorylation of the kinases investigated in association with postC, 
observed in the working heart, might be due to the fact that tissue samples had to be 
divided into non-ischaemic and ischaemic zones. In the experimental setup we used this 
was a necessity. This procedure can however be avoided using a global ischaemia 
protocol. This would entail the development of a postC protocol in the working heart model 
that confers functional protection after global ischaemia – a feat we could not accomplish, 
or else measurement of infarct size in the globally ischaemic heart. The latter procedure 
has been found to be problematic, due to patchy necrosis which is difficult to quantify (data 
not shown). 
 
Although we could not demonstrate functional importance for the postC-associated 
upregulation of ERK p42, this might be due to the inhibitor used. It would therefore be 
worthwhile to investigate the effect of another ERK p42/p44 inhibitor, U0126, on the infarct 
sparing effect of postC. 
 
We found an increase in the phosphorylation of p38 MAPK associated with postC after 10 
minutes reperfusion in tissue not exposed to prior sustained ischaemia, in the working 
heart model. This unexpected phenomenon could be addressed by investigating the effect 
of the postC protocol itself on healthy heart tissue per se.  This would entail application of 
the brief postC cycles in hearts not exposed to a prior ischaemic insult, followed by freeze-
clamping and analysis of the signalling kinases. It would be interesting to identify 
intracellular changes initiated by the protocol itself, independent of cells being damaged or 
exposed to stress.  
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The observation that postC and cantharidin cardioprotection is associated with different 
kinase profiles in reperfusion leaves us with two questions:  
I. Is cantharidin mediating its protection through the observed increase in 
phosphorylated p38 MAPK and ERK p42? To investigate this, inhibitors of these 
kinases (SB203580 against p38 MAPK and PD098059 and / or U1026 against 
ERK p42/p44) could be co-administered with cantharidin, or immediately after 
cantharidin treatment. 
II. If cantharidin and postC are indeed working through different mechanisms, why do 
the combination of these two interventions not shown an additive effect? It should 
however be ascertained if they are truly working through different pathways. We 
found that they recruit different signalling pathways, but end-effectors of 
importance in both interventions should also be identified. Especially the mPTP 
could be of importance. It has received a lot of attention in postC literature but less 
has been done in the context of phosphatase inhibition.  
 
Another limitation of this study was that we only characterised the kinase profile 
associated with cantharidin in one experimental model, namely the working heart. Since 
we only observed  kinase participation in the postC mechanism in the Langendorff model, 
it would be interesting to also characterise cantharidin in the Langendorff model.  
 
We unexpectedly found that the solvent we used in our cantharidin experiments (ethanol) 
exerted an effect on the kinases, when administered during reperfusion. Although, it 
seems unlikely that this effect is a confounding factor in this study, it would be advisable to 
use a different vehicle in future studies with cantharidin. In this regard, Knapp et al. (1998) 
reported that they used DMSO in their cantharidin studies. DMSO was shown not to affect 
the kinase profile in our experimental setup. 
 
It should be noted that one of the difficulties in investigating the phosphatases is the lack 
of truly specific inhibitors. Cantharidin is no exception, although it only inhibits PP1 and 
PP2A, it influences various intracellular proteins (Neumann et al., 1995). A more specific 
inhibitor could therefore also be used, such as okadaic acid, which primarily inhibits PP2A 
at a concentration of 1 nM. Another approach to avoid the broad spectrum effects of the 
phosphatase inhibitors could be to investigate phosphatase activity localisation. This could 
be done by investigating only certain cellular fractions (for example Schaffer & Punna, 
1993, who only focused on the sarcolemmal fraction of rat cardiomyocytes). It could be 
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possible that postC does recruit phosphatase inhibition, but only in certain cellular 
compartments – such as possibly the mitochondrial membrane or sarcolemma. 
6.5. Summary 
We confirmed that the application of brief cycles of reperfusion / ischaemia, directly at the 
onset of reperfusion, can reduce the infarct size associated with a sustained ischaemic 
episode, in the retrogradely perfused isolated rat heart. We also demonstrated that this 
phenomenon of postC can also be elicited in the more rigoruous working heart model. The 
cardioprotective effect of postC is mediated by the early reperfusion activation of PKB/Akt. 
We could not find evidence that postC recruits phosphatase inhibition in the signalling 
component of its cardioprotective mechanism. The inhibition of the protein phosphatases 
PP1 and PP2A however, does confer a powerful infarct sparing effect.  
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